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Imaging and therapy in multiple sclerosis 
James William Lyle Brown 
Abstract 
Multiple sclerosis (MS) is a common, debilitating autoimmune disorder of the central nervous 
system (CNS). The most visible element of MS pathology is white matter (WM) lesions.  However, 
extra-lesional abnormalities are recognised and appear most marked at the outer (subpial) brain 
surfaces at post-mortem. Magnetisation transfer ratio (MTR) is a non-conventional MRI 
sequence that correlates with myelin density and axonal count, and has recently uncovered 
reductions in the innermost (periventricular) layers and outermost (cortical) layers of patients 
with longstanding MS. These abnormalities are termed “outside-in” changes. The cause, extent, 
evolution and treatment-responsiveness of these outside-in gradients is unknown. 
Most patients present with relapsing-remitting (RR) MS for which numerous immunomodulatory 
disease-modifying therapies (DMTs) are licensed. However, after approximately 20 years most 
convert to secondary progressive (SP) MS where immunomodulatory therapies have little if any 
effect. Whether DMTs delay or prevent this transition remains unclear. 
During this PhD I examined whether outside-in MTR gradients occur in different disease stages, 
their clinical associations and predictive capabilities, and (for periventricular gradients) their 
response to a potent immunomodulatory DMT. In a separate project, I used real-world data to 
explore whether DMT use is associated with a lower risk of conversion to SPMS. 
 
Outside-in MTR gradients of tissue damage were seen in periventricular and cortical regions at 
all stages of relapse-onset MS and primary-progressive MS. The periventricular MTR gradient was 
reversed by peripheral immunomodulation and independently predicted subsequent relapse 
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activity on and off DMTs. The underlying process(es) remain unknown but appear at least 
partially distinct from those underlying lesion formation; a CSF-mediated process – secondary to 
meningeal inflammation or primarily degenerative – might explain both periventricular and 
cortical gradients.  
Among patients with RRMS, initial treatment with fingolimod, natalizumab or alemtuzumab was 
associated with a lower risk of conversion to SPMS compared to initial treatment with glatiramer 
acetate or interferon beta over a median 5.8 years of follow-up.  A lower risk of conversion was 
also associated with early (versus late) commencement of glatiramer acetate or interferon beta; 
and with early escalation from these therapies to fingolimod, natalizumab or alemtuzumab 
compared to late escalation. These findings, considered along with these therapies’ risks, may 
help inform decisions about DMT selection.  
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Foreword 
I am interested in multiple sclerosis (MS). I use magnetic resonance imaging (MRI) to explore MS 
disease effects, particularly their differential regional variability, and – within the limitations of 
the tool – potential reasons behind this. More recently, I have become interested in using large-
scale real-world data to examine associations between clinical outcomes and exposures, 
particularly disease-modifying therapies. 
As an introduction, I will briefly examine our current understanding of the aetiology and 
pathogenesis of MS, and then discuss disease classification, diagnosis and therapeutic strategies. 
Next, the role of MRI and its contributions to disease understanding will be explored, with special 
emphasis placed on regional variation and potential explanations. This will lead into the key 
objectives for the thesis. The methods and results of each project will be presented in turn. The 
discussion incorporates separate sections for each project. However, as Projects 1-3 explore 
different facets of the same topic (regional variability in disease effects on MRI), the biological 
interpretation – and advances in the field contemporaneous to this PhD - have been apportioned 
an additional section of the Discussion. The fourth project explores a very different research 
question using a different tool. It does not seamlessly link to the previous projects but I felt it 
sufficiently important to include. 
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Chapter 1. Introduction 
The aetiology and pathology of multiple sclerosis 
 
The precise aetiology of MS is unknown, though it appears to be triggered by environmental 
factors in genetically susceptible individuals. Genetic variation accounts for about one third of 
the overall disease risk (Harkiolaki et al., 2009; International Multiple Sclerosis Genetics et al., 
2013), yet identified loci account for only a quarter of this heritability - a further quarter is likely 
to reflect undiscovered risk alleles (Zuk et al., 2012), and the remaining half from hitherto-
undefined interactions between risk factors (International Multiple Sclerosis Genetics et al., 
2010). 
 
The immunopathogenesis of multiple sclerosis 
Immune system dysregulation outside the central nervous system 
In health, the majority of autoreactive T cells are removed within the thymus as part of central 
tolerance. Some escape into the periphery, but peripheral tolerance mechanisms keep these cells 
at bay. In MS, reduced regulatory T-cell (Treg) activity or effector T/B-cell resistance to suppressive 
mechanisms, causes peripheral autoreactive T cells to trigger CNS-directed autoreactive T/B cells 
to become aggressive effector cells (CD8+ T cells, differentiated CD4+ T helper (TH1 and TH17 
cells), B cells and innate immune cells), which in turn infiltrate the CNS (Viglietta et al., 2004).  
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Immune system dysregulation within the central nervous system 
Peripheral lymphocytes and monocytes access the CNS through the blood-brain barrier (BBB) or 
blood-CSF barrier. The identification of veins/venules within MS plaques - first described by 
Charcot (1880), and shortly afterwards attributed to vascular inflammation by Babinski (1885) – 
can now be observed in vivo with clinical-grade MRI scanners (for example (Samaraweera et al., 
2017)). Plaques comprise perivascular inflammation dominated by CD8+ cell infiltrates, and 
cluster around the lateral ventricles, juxtacortical tissues, the infratentorial region, spinal cord 
and optic nerves. Inflammatory demyelination and neurodegeneration appear to result from 
multiple mechanisms: direct cytotoxicity of CD8-positive T cells directed against an antigen 
expressed on oligodendrocytes (Saxena et al., 2008); activation of microglia by cytokines secreted 
from CD4 cells and subsequent microglial attack of the oligodendrocyte-myelin unit (for example 
(Zajicek et al., 1992; Felts et al., 2005)); and demyelinating antibody production (Linington et al., 
1988). Axonal injury within lesions is seen from the earliest clinical stage of the disease and 
correlates with the extent of T-cell and microglial infiltration (Ferguson et al., 1997; Trapp et al., 
1998; Kuhlmann et al., 2002). There is also evidence of inflammation, demyelination and 
neuroaxonal loss in the normal—appearing white matter (NAWM) and grey matter (NAGM) 
(Kutzelnigg et al., 2005), including early in the disease course (Lucchinetti et al., 2011). 
 
The pathology of progressive multiple sclerosis 
Inflammation and neurodegeneration are both present throughout the disease course. However, 
the inflammatory demyelinating processes that dominate the early disease course gradually yield 
to more neurodegenerative mechanisms and diffuse changes in later disease (Frischer et al., 
2009). Potential mechanisms underlying neuronal death in progressive disease - chronic 
oxidative injury, axonal mitochondrial damage, microglial activation and age-related iron-
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accumulation – will be sequentially discussed, though the precise cascade and their interrelations 
remain unclear.  
The most prominent pathological feature of progressive disease is brain atrophy (Bermel and 
Bakshi, 2006), although this is seen at the very earliest stages of the disease (Chard et al., 2002). 
Atrophy reflects irreversible axonal and neuronal loss and occurs in both lesions and normal-
appearing tissue (for example (Evangelou et al., 2005)).  
Degeneration of chronically demyelinated axons within lesions leads to shrinkage of lesions (even 
those with a border of advancing myelin and axonal destruction decrease in relative size 
(Kutzelnigg et al., 2005)).  The degree of axonal loss is clinically relevant: in the most disabled 
patients, chronic WM lesions have lost up to 70% of their axons (Bjartmar et al., 2000). Mouse 
models suggest a degree of compensatory reserve: loss of less than 38% of spinal axons was not 
associated with permanent disability (Wujek et al., 2002). Exhaustion of this axonal functional 
reserve – in combination with the below mechanisms - may represent a pathological tipping point 
culminating in the neurodegenerative cascade underlying progressive disease. 
There is increasing evidence of abnormality in the NAWM and grey matter which worsen with 
disease duration. Cortical demyelination and diffuse NAWM axonal injury are predominantly 
seen in progressive disease and are accompanied by pronounced microglial activation (Kutzelnigg 
et al., 2005). These appear at least partially distinct from the processes underlying lesion genesis: 
WM lesion load does not correlate with the extent of cortical demyelination, diffuse NAWM 
axonal injury nor cortical volume (De Stefano et al., 2003; Kutzelnigg et al., 2005). In the spinal 
cord - where atrophy has been reported in the absence of white matter plaques (Evangelou et 
al., 2005) - the degree of axonal loss appears influenced by T-cell infiltration from the meninges 
(Androdias et al., 2010). Taken together, these data point to one or more processes distinct from 
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lesion genesis causing clinically relevant tissue damage throughout the central nervous system. 
Potential processes are explored later. 
While the overall extent of inflammation is clearly lower in progressive disease (Frischer et al., 
2009), there is increasing evidence of its presence and importance. For example, in progressive 
MS, neurodegeneration is only seen in patients with pronounced inflammation (quantified by 
levels of B-cells, T-cells, plasma-cells, HLA-D positive macrophages and microglia); while in very 
late progressive disease (where the degree of brain T-cell / B-cell infiltration matches age-
matched controls) the rate of neurodegeneration in patients matches that seen in controls 
(Frischer et al., 2009). The marked reduction (or absence) of contrast-enhancing lesions on MRI 
(indicating BBB breakdown) in progressive MS should also not be construed as a lack of 
inflammation: parenchymal and perivascular inflammation are still seen despite absent protein 
leakage from blood vessels (Hochmeister et al., 2006), implying a ‘trapped’ inflammatory 
process, no longer reliant on peripheral inflammation, no longer indicated by contrast-
enhancement on MRI and no-longer accessible to disease-modifying therapies that cannot cross 
the BBB (Mahad et al., 2015).  
Such compartmentalised inflammation is also seen in the meninges. Meningeal inflammation is 
reported in all stages of relapse-onset (Magliozzi et al., 2010; Howell et al., 2011; Lucchinetti et 
al., 2011) and primary progressive (Choi et al., 2012) MS, with the most severe form – lymph 
follicle-like structures – reported in a subset of SPMS patients with early-onset disease, rapid 
progression and early death (Magliozzi et al., 2007). In PPMS (Choi et al., 2012) and SPMS (Howell 
et al., 2011), the degree of demyelination and neurodegeneration in cortical lesions directly 
correlates with the degree of meningeal inflammation. In fact, a gradient of cortical axonal loss 
was seen in the NAGM surrounding meningeal aggregates in the ~40% of SPMS patients found 
to have lymph follicle-like aggregates (Magliozzi et al., 2010). This is discussed further on p. 51. 
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While the mechanisms underlying active demyelination and neuronal degeneration are varied in 
early disease (Lucchinetti et al., 2000), they are invariably associated with microglial activation in 
progressive disease (Prineas et al., 2001; Fischer et al., 2013). However, as inflammation is a 
physiological process, microglial activation may simply reflect the inflammatory response to 
tissue damage (clearing up myelin debris for example), rather than an inflammatory driver itself 
resulting in oligodendrocyte or neuronal death.   While disentangling these microglial functions 
is difficult, their presence in NAWM, WM lesions and normal appearing grey matter (NAGM) – 
where they express molecules involved in reactive oxygen species production – imply at least 
some destructive role (Prineas et al., 2001; Gray et al., 2008; Fischer et al., 2012).  
There is also growing interest in the role of mitochondria in MS progression, abnormalities of 
which have been found in progressive disease in the absence of meningeal inflammation 
(Campbell et al., 2011). For multiple reasons – not the least difficulties in mitochondrial 
distribution resulting from the elongated shape of the neuron-axon unit – axons are highly 
susceptible to mitochondrial dysfunction. A cascade of events leading from mitochondrial 
dysfunction to axonal degeneration has been hypothesized: during the relapsing phase of MS, 
mitochondrial injury occurs through inflammation-induced dysfunction of cytochrome c oxidase-
1 and mitochondrial DNA deletions in both WM and GM, culminating in energy deficiency. With 
increasing age and disease duration abnormal mitochondria in cell bodies of neurones are 
amplified and, when distributed around the axon, result in further energy deficiency and further 
production of reactive oxygen species which amplify oxidative injury (Mahad et al., 2015). The 
resultant state of reduced oxygen consumption and energy failure despite normal blood and 
oxygen supply (known as histotoxic hypoxia) couple with the increased oxygen demands posed 
by perivascular inflammation such that – if this occurs in areas of lower blood flow (for example 
the boundary zones between cerebral arteries (watershed areas)) – the oxygen tension might 
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drop below a critical threshold (Davies et al., 2013). This in turn may account for the increased 
density of WM lesions, demyelination and neurodegeneration in the watershed areas in 
progressive MS (Brownell and Hughes, 1962; Holland et al., 2012; Haider et al., 2016).  
Iron builds up in the human brain with age and is stored (as the non-toxic Fe3+ form) in myelin, 
oligodendrocytes and microglia (Hallgren and Sourander, 1958). However, following their 
damage, iron is converted to the divalent – and highly toxic – Fe2+ form, which convert hydrogen 
peroxide into highly reactive hydroxyl molecules resulting in intensified oxidative injury 
(Hametner et al., 2013). 
The final major pathological change seen in progressive MS is failure of endogenous 
remyelination. Following inflammatory demyelination, lesions undergo varying degrees of 
endogenous remyelination (Schmierer et al., 2004; Patrikios et al., 2006; Patani et al., 2007). This 
process has two principal benefits. First, it re-enables saltatory conduction (Smith et al., 1979) 
facilitating improvement in symptoms and function after a relapse (Jeffery and Blakemore, 1997). 
Second, and arguably more importantly, remyelination protects the underlying axon, thereby 
reducing axonal loss. This assumption reflects an increasing body of evidence showing that 
myelin directly supports the underlying axon: myelinating glia sequester ineffective axonal 
organelles (Spencer and Thomas, 1974) and transfer trophic factors to the axon (Novotny, 1984; 
Kramer-Albers et al., 2007); oligodendrocytes release growth factors for neurons in-vitro (Wilkins 
et al., 2003); fast axonal transport is focally impaired beneath biochemically deficient myelin in a 
mouse model (Edgar et al., 2004); and oligodendrocytes may exert a metabolic role through 
conveying glycolytic products to fuel oxidative phosphorylation (Nave, 2010) and even increase 
axonal calibre (Witt and Brady, 2000).  
Endogenous remyelination does not seem to arise from existing oligodendrocytes; instead 
oligodendrocyte precursor cells (OPCs) divide, migrate and differentiate into myelinating 
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oligodendrocytes that ensheath the axons with new myelin (Franklin and Ffrench-Constant, 
2008). Much effort has been channelled into identifying why endogenous remyelination fails in 
the hope that therapeutic manipulation might enhance remyelination and in so doing prevent 
axonal loss (De Stefano et al., 1998; Franklin, 2002; Franklin et al., 2012).  
At post-mortem, OPCs are found within the majority of demyelinated lesions (Wolswijk, 1998; 
Chang et al., 2002) suggesting that – in a large proportion of patients - the limiting step in 
endogenous remyelination is OPC differentiation (Franklin et al., 2012). Much work has focused 
on the pathways regulating OPC differentiation into myelinating oligodendrocytes. These have 
been recently reviewed elsewhere (Kremer et al., 2015)  but include two negative regulators of 
OPC differentiation (LINGO-1(Mi et al., 2005) and the Wnt signaling pathway (Fancy et al., 2009)), 
inhibition of which have both been shown to promote remyelination in animal models of MS (Mi 
et al., 2007; Preisner et al., 2015). The retinoid acid receptor RXR-γ is a positive regulator of 
endogenous OPC differentiation, which, when stimulated, increased axonal remyelination in 
animal models (Huang et al., 2011).  
In a far smaller proportion of patients, endogenous remyelination failure reflects inadequate OPC 
recruitment to lesions (Niehaus et al., 2000); in such situations the therapeutic promotion of 
endogenous OPC differentiation would be fruitless (Franklin, 2002), and exogenous therapy – 
transplantation of oligodendrocytes or OPCs – would ostensibly be more helpful. Distinguishing 
patients who would benefit from each therapeutic approach is a major unmet need, fore mostly 
necessitating the development and validation of in-vivo imaging markers of OPCs.  
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The aetiology of multiple sclerosis 
Genetic predisposition 
Numerous genome-wide association studies (GWAS) have uncovered more than 200 different 
loci associated with multiple sclerosis. These variants almost invariably implicate genes 
associated with immunological processes, are predominantly found in regulatory (non-coding) 
regions and often colocalise with gene enhancers or repressors in immune cells (International 
Multiple Sclerosis Genetics et al., 2011; Farh et al., 2015). Thirty-seven percent either influence 
the risk of other autoimmune diseases or are in linkage disequilibrium with other autoimmune-
disease-associated variants (International Multiple Sclerosis Genetics et al., 2011). The functional 
implications for most identified loci however remain unknown. We know most about HLA-
DRB1*15:01 (the main risk allele for multiple sclerosis, odds ratio (OR) 3.10), the protective allele 
HLA-A*02:01 and the genes encoding IL-2Ra and IL-7Ra (Gregersen et al., 2006; Gregory et al., 
2007; Friese et al., 2008; International Multiple Sclerosis Genetics et al., 2011; Hartmann et al., 
2014). 
Despite this progress, MS genetics must be interpreted carefully. The HLA-DRB1*15:01 allele, for 
example, is present in 13.3% of the UK population (International Multiple Sclerosis Genetics et 
al., 2011), yet less than 0.3% of people carrying it develop MS; and a significant number of 
patients without the allele will develop the disease. Further, genetic factors only account for a 
third of the overall disease risk (International Multiple Sclerosis Genetics et al., 2013). Genetic 
risk factors should therefore be viewed as insufficient alone to cause multiple sclerosis but 
definitively contribute to the risk of its development. 
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Environmental factors 
Numerous environmental and lifestyle factors increase the risk of MS including tobacco smoke 
exposure, Epstein-Barr virus (EBV) infection, low vitamin D levels, adolescent obesity and organic 
solvents. All environmental risk factors for MS can, like MS risk alleles, influence adaptive and / 
or innate immunity.  
One of the most convincing arguments for the environment’s role in MS centre around the 
latitude gradient. A recent meta-analysis of 321 peer-reviewed studies (Simpson et al., 2011), 
found a positive association between latitude and the prevalence of MS (change in prevalence 
per degree 1.04, p <0.001), which persisted after adjusting for HLA-DRB1 allele frequency. 
Perhaps most compellingly, individuals migrating from low to high risk areas before adolescence 
acquire the same high risk as those who are born and grow up in the high-risk area (Gale and 
Martyn, 1995).  
The commonly reported risk factors are discussed below. 
 
Smoking and organic solvents 
Smoking tobacco results in a dose-dependent increase in the risk of (i) developing MS (Hernan et 
al., 2001); (ii) developing neutralising antibodies against two of the most frequently used DMTs 
(natalizumab (Hedstrom et al., 2014a) and interferon-beta (Hedstrom et al., 2014c)); and (iii) a 
worse disease course (for example (Manouchehrinia et al., 2013)), though this may be 
ameliorated through smoking cessation (for example, patients that quit smoking converted to 
SPMS 8 years later than in those that continued (Ramanujam et al., 2015)).  
 
	 	 30	
EBV  
Clinically-overt infectious mononucleosis carries more than a two-fold increase in the risk of 
developing MS (Martyn et al., 1993), though this only appears the case with infection during 
adolescence, not childhood (Makhani et al., 2016). The vast majority of patients with infectious 
mononucleosis do not, however, go on to develop MS. Markedly higher levels of antibodies 
against EBV nuclear antigen 1 (EBNA1) are found in patients with MS, and almost all EBNA1-
negative individuals serologically convert to being EBNA1 positive prior to MS onset (Levin et al., 
2010). Infectious mononucleosis may act in synergy with HLA DRB1*15:01 to increase the risk of 
MS (Nielsen et al., 2009); while the precise mechanisms are debated, molecular mimicry appears 
a prominent candidate.  
 
Ultraviolet radiation and vitamin D 
Both ultraviolet radiation exposure and vitamin D levels inversely correlate with the risk of MS 
(Lucas et al., 2015). Production of the active metabolite of vitamin D requires ultraviolet 
radiation, so distinguishing the protective effect of each is challenging. Even so, both animal work 
and human studies appear to show that ultraviolet radiation confers a protective effect 
independent of vitamin D levels (Becklund et al., 2010; Baarnhielm et al., 2012). The mechanism 
however remains elusive. Animal models have shown reduced inflammation in the periphery 
(Rana et al., 2011) and CNS (Becklund et al., 2010) following ultraviolet radiation which appear 
to be mediated through increased Treg activation. 
Low vitamin D levels are associated with (i) a greater risk of developing MS (particularly low levels 
in childhood and adolescence (Munger et al., 2006)); (ii) higher subsequent rates of relapses, new 
lesion accrual, lesion growth and disability accumulation when measured after a clinically 
isolated syndrome (Ascherio et al., 2014); and (iii) increased neurofilament light chain levels in 
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the CSF, indicating greater axonal damage (Sandberg et al., 2016). However, despite a reduction 
in lesion accrual on MRI (Soilu-Hanninen et al., 2012) and increased oligodendrocyte production 
in vitro (de la Fuente et al., 2015), vitamin D supplementation has thus far not led to improved 
clinical outcomes in small (n<100) clinical trials (Kampman et al., 2012; Soilu-Hanninen et al., 
2012)), and larger studies (e.g. NCT01490502) are eagerly awaited. How vitamin D influences the 
development and activity of MS is not clear; however numerous effects that follow 
supplementation in humans – Treg stimulation, for example (Muris et al., 2016) – broadly point to 
improved immunomodulation. 
 
Obesity 
Adolescent obesity carries an adjusted two-fold risk of subsequently developing MS compared 
to a normal adolescent body mass index, though obesity at the time of onset has no influence 
(Hedstrom et al., 2014b). The higher risk may reflect an interaction with HLA variants (particularly 
HLA-DRB1*15:01 and A*02 (Hedstrom et al., 2014b)), release of pro-inflammatory mediators 
from the low-grade inflammation found in obesity (Lumeng et al., 2007), elevated levels of the 
proinflammatory mediator leptin (Matarese et al., 2005) and or decreased vitamin D 
bioavailability (Wortsman et al., 2000). 
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Types of MS 
About 85% of people with MS initially have relapsing-remitting (RR) disease (Confavreux et al., 
2000) characterised by acute or subacute episodes of neurological dysfunction (relapses) 
followed by at least partial resolution (remissions). The first such episode is termed a clinically 
isolated syndrome (CIS), and 63% of patients with a CIS will experience a further episode over 20 
years (Fisniku et al., 2008), thus realising the diagnosis clinically definite multiple sclerosis 
(CDMS). Eventually, most people with MS develop progressive disease: ~80% of people with 
CDMS will eventually accrue progressive neurological deficits (SPMS) and ~15% develop 
progressive impairments without ever having had relapses (known as primary progressive (PP) 
MS (Weinshenker et al., 1989; Confavreux et al., 2000; Kremenchutzky et al., 2006). While 
incomplete recovery from relapses causes persistent neurological deficits, most disability 
accumulates in people with progressive disease (Confavreux et al., 2000; Confavreux et al., 2003). 
Once progression has started, its rate does not appear to be strongly influenced by previous 
relapses (Confavreux et al., 2003).  
Most literature on progressive MS reports on findings from people with SPMS. There is on-going 
debate about whether PPMS and SPMS are essentially the same disease or fundamentally 
different. For example the age at onset and rate of progression is similar in both (Gayou et al., 
1997; Confavreux et al., 2000) but lesions appear to be less extensive and less inflammatory in 
PPMS compared with SPMS (Revesz et al., 1994; Lucchinetti et al., 2011). It should therefore not 
be assumed that findings in PPMS and SPMS are interchangeable. 
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Diagnosis and prognostication 
Diagnosing and predicting RRMS 
Attaining the diagnosis of RRMS requires evidence of dissemination in time and space (DIT and 
DIS), traditionally requiring, after the first episode, a further clinical episode reflecting an 
anatomically distinct region of the CNS (CDMS). Numerous revisions to diagnostic criteria have 
enabled earlier, more sensitive and more specific diagnosis (Brownlee et al., 2017) through the 
use of paraclinical tests, particularly MRI. The 2010 revisions enable multiple sclerosis to be 
diagnosed after a single attack in the presence of radiological evidence of dissemination in time 
(simultaneous asymptomatic gadolinium-enhancing and unenhancing lesions on the same scan; 
or new T2 lesions on a follow-up scan) and dissemination in space (>1 T2 lesion in at least 2 MS-
typical regions: periventricular, juxtacortical, infratentorial or spinal cord) (Polman et al., 2011). 
Dissemination in space may also be achieved by examination findings suggesting a lesion in a 
region distinct to that of the CIS. In the most recent 2017 McDonald Criteria, dissemination in 
time may also be attained through the presence of CSF-specific oligoclonal bands; and cortical 
lesions may be used to demonstrate dissemination in space (Thompson et al., 2017).  
An MRI scan acquired soon after a CIS also provides significant prognostic information: the 
presence of asymptomatic WM lesions is associated with an ~80% risk of developing CDMS over 
the following 20 years, while in their absence the risk is ~20% (Fisniku et al., 2008). It also has a 
well-defined role in clinical trials. In RRMS, WM lesion measures are now an accepted outcome 
measure in early phase immunomodulatory treatment trials (Sormani and Bruzzi, 2013), while in 
SPMS brain atrophy measures are increasingly used (for example (Kapoor et al., 2010)). 
 
	 	 34	
Diagnosing and predicting SPMS 
While the definition of SPMS is clear - “a history of gradual worsening after an initial relapsing 
disease course, with or without acute exacerbations” (Lublin et al., 2014) - making the diagnosis 
is challenging. Clinical manifestations occur slowly, often requiring years of gradual deterioration 
for confident recognition by neurologists (Sand et al., 2014). Relapses further complicate the 
situation in SPMS, and it can be very difficult to distinguish the residual effects of relapses from 
underlying symptom progression. Relapses are not unusual in people with SPMS: for example, in 
one recent treatment trial in SPMS about half those in the placebo arm had a relapse over the 
two years of the study (Hayton et al., 2012). In contrast to PPMS, for which the current  McDonald 
criteria require at least one year of disease progression (Thompson et al., 2017), the guidelines 
contain no agreed criteria on the duration of disease progression necessary before a diagnosis of 
SPMS can be made. One study found that on average three years elapsed after the possibility of 
progressive disease was first raised before a confident diagnosis of SPMS was made (Sand et al., 
2014), and some recent SPMS treatment trials have required at least two years of progression as 
an inclusion criterion (Kapoor et al., 2010; Chataway et al., 2014). This uncertainty in clinical 
diagnosis means that studies looking for markers predicting the onset of SPMS, or recognizing it 
once it has begun, need to be sufficiently long-term for the diagnosis to be certain in the majority 
of cases. Fortunately, recent work has compared the performance of more than 500 potential 
definitions of SPMS, concluding that the best performing definition required an expanded 
disability status scale (EDSS) increase (if the EDSS score was 5.5 or less, an increase of 1 point was 
required; if the EDSS score was over 5.5 an increase of 0.5 points was required), in the absence of 
a relapse, achieving a minimum EDSS score of 4, with confirmation of EDSS progression at least 3 
months later (Lorscheider et al., 2016).  
 
	 	 35	
Given the difficulty in identifying the onset of SPMS, it is perhaps unsurprising that predicting the 
onset of SPMS is also challenging. The strongest clinical predictor for developing SPMS is the total 
disease duration - more than half of those with RRMS will have developed SPMS 15 years after 
symptom onset (Vukusic and Confavreux, 2003; Scalfari et al., 2014) - but, this is impractical for 
short-term predictive purposes as there is a modest effect per year (odds ratio 1.07 for each 
additional year, p<0.001 (Scalfari et al., 2014)). Males are also at greater risk of developing 
secondary progression (hazard ratio 1.41, p<0.001 (Scalfari et al., 2014)), as are smokers (hazard 
ratio 1.49 (95% CI 1.18-1.86 (Manouchehrinia et al., 2013))), although again these features do 
not allow reliable prediction of SPMS onset on an individual basis. The advent of an evidence-
based, validated SPMS definition (Lorscheider et al., 2016) might finally facilitate the robust 
examination of risk factors for conversion; and help answer the controversial question as to 
whether immunosuppressive drugs influence conversion to SPMS (Signori et al., 2016). 
 
Notwithstanding this, clinical measures are the standard against which any predictive measures 
(for example MRI) are compared. The most commonly used outcome measure is the EDSS, which 
ranges from 0 (normal neurological examination) to 10 (death due to MS) in 0.5 point increments 
(Kurtzke, 1983). However it has several significant limitations (Hobart et al., 2000). First, while 
MS commonly affects motor, sensory and cognitive functions (Compston and Coles, 2002), EDSS 
scores above 3.5 are almost entirely determined by the person’s walking ability. MRI measures 
that correlate with non-ambulatory functions may therefore be undervalued based on their 
association with EDSS scores (Meyer-Moock et al., 2014). Secondly, the reproducibility of EDSS 
scores between assessors and over time is limited when compared with MRI measures such as 
brain atrophy (Noseworthy et al., 1990) particularly at lower EDSS scores (Goodkin et al., 1992), 
and this limits the maximum correlation possible between MRI measures and EDSS scores. This 
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might lead us to erroneously underestimate how clinically relevant an MRI measure is. Thirdly, 
the EDSS score is neither cardinal nor linear: a person with MS will tend to traverse some parts 
of the scale more rapidly than others (Weinshenker et al., 1991). This means that correlations 
between EDSS scores and MRI measures may vary along the EDSS. 
 
Other MS clinical measures have been developed to address these limitations, including the MS 
functional composite (MSFC) score (Fischer et al., 1999). Rather than relying on the distance a 
person can walk, the MSFC combines measures of walking speed, arm function and cognitive 
performance, and scores are calculated relative to normative values. The MSFC may be more 
reproducible and sensitive to change than the EDSS (Cutter et al., 1999; Meyer-Moock et al., 
2014), but by combining functions that may be unrelated within a single score, associations 
between specific clinical and MRI measures may be diluted. The MSFC is also vulnerable to 
learning effects, i.e. improved scores with practice (Meyer-Moock et al., 2014). As such there is 
increasing interest in using multiple separate clinical outcome measures rather than composite 
functional scores. 
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The management of multiple sclerosis 
Patients with MS should be managed in multi-disciplinary teams. The pharmacological 
management presently comprises three facets: (i) management of a relapse (for patients with 
relapse-onset disease); (ii) disease-modifying treatments; and (iii) symptomatic therapies. 
 
Management of a relapse 
In patients with RRMS or SPMS, a relapse may be indicated by the acute or subacute onset of 
new neurological symptoms or worsening or pre-existing symptoms. The clinician’s first priority 
– particularly in the latter scenario – is to exclude a systemic illness that might mimic a relapse 
(termed a “pseudo-relapse”), for example fever from a urinary tract infection resulting in 
Uhthoff’s phenomena. Then, if the symptoms are particularly disabling or unpleasant, a short 
course of corticosteroids (typically 0.5-1g oral or intravenous methylprednisolone for 3-5 days) 
is offered. Corticosteroids reduce the relapse duration but have no bearing on the extent of 
symptomatic improvement following a relapse nor future disease course (Miller et al., 2000). Up 
to 42% of steroid-resistant relapses may improve with plasma exchange administered within 1 
month of relapse onset, though this too has no bearing on future disease activity (Weinshenker 
et al., 1999). 
 
Disease modifying treatments (DMTs) 
At the time of writing, 13 DMTs were licensed for patients with RRMS or a CIS internationally 
(Table 1). Comparisons of drug efficacy between trials is precluded by markedly different trial 
inclusion criteria and methodologies, particularly whether the comparator was placebo or an 
injectable therapy (interferon or glatiramer acetate). Many drug comparisons therefore rely on 
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meta-analyses, observational cohort studies and independent clinical trials. For example, 
rigorous examination of real-world data has identified similar effects on relapses between 
alemtuzumab and natalizumab, which both appear superior to fingolimod (Kalincik et al., 2017a); 
and cladribine has shown similar efficacy to fingolimod but inferior efficacy to natalizumab 
(Kalincik et al., 2017b). There is insufficient evidence to know whether DMT prescription should 
follow an escalation strategy (beginning with a moderate efficacy therapy with better safety 
profile then escalating to more effective (and toxic) therapies if required) or an induction strategy 
(beginning with a highly-effective therapy such as natalizumab). Comparisons of disability data 
are even more challenging due to multiple disability scales, differing definitions of worsening or 
improvement, variable durations of disability change required between studies and short trial 
durations (Brown and Chard, 2016). Perhaps more relevant than disability ‘event’-driven 
outcomes is whether DMTs in RRMS have any bearing on (i) the timing of conversion to SPMS 
(where most disability accumulates); and (ii) the rate of disability accumulation after conversion 
to SPMS.  
 
Generic name Mechanism of action Reduction in 
relapse rate* 
Side effects 
Interferon-ß-1a  
(5 preparations) 
Reduced antigen 
presentation and T cell 
proliferation, alters cytokine 
expression, restores 
suppressor function 
30-34% (vs 
placebo) 
Common: Influenza-like symptoms, 
injection site reactions and 
deranged liver function tests (LFTs) 
Less common: Liver toxicity 
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Glatiramer 
acetate 
Alters T-cell differentiation 
which induces proliferation of 
anti-inflammatory 
lymphocytes 
29% (vs 
placebo) 
Common: Injection-site reactions, 
lipoatrophy, post-injection general 
reaction. 
 
Dimethyl 
fumarate 
Reduces release of 
inflammatory cytokines and 
activates antioxidant 
pathways 
51% (vs 
placebo) 
Common: Flushing, gastrointestinal 
symptoms, lymphopenia 
Less common: Progressive 
multifocal leukoencephalopathy 
(PML) (1:50,000) 
Teriflunomide Inhibits proliferation of 
autoreactive B and T cells and 
induces shift to anti-
inflammatory profile 
31% (vs 
placebo) 
Common: Nausea, diarrhea, hair-
thinning, rash. 
Less common: Teratogenicity. 
 
Fingolimod Syphingosine-1-phosphate 
receptor antagonist, thereby 
inhibiting the egress of 
lymphocytes from lymph 
nodes and their recirculation 
45% (vs 
interferon) 
Common: Bradycardia, heart block, 
infections, lymphopenia, liver 
dysfunction 
Less common: PML (1:12,000), 
macular oedema, varicella zoster 
virus infection, herpes encephalitis 
Natalizumab Humanised monoclonal 
antibody which blocks α-4 
integrin, preventing 
68% (vs 
placebo) 
Common: Dizziness, nausea, itchy 
skin, rash, shivering, increased risk 
infection. 
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lymphocyte entry to CNS 
across the BBB 
Less common: PML (4-19/1,000), 
hypersensitivity reactions 
Cladribine Deoxyadenosine analogue 
which depletes B & T 
lymphocytes 
58%  (vs 
placebo) 
Common: Lymphopenia, increased 
risk of infection, headache. 
Less common: Possibly teratogenic, 
pulmonary TB, PML (in hairy cell 
leukaemia at a different dose), 
malignancy 
Alemtuzumab Anti-CD52 humanised 
monoclonal antibody, leading 
to profound B and T cell 
lymphopenia 
52% (vs 
interferon) 
Common: Infusion reactions, viral 
infection, thyroid disease 
(especially hyperthyroid) in up to 
40% of patients.  
Less common: idiopathic 
thrombocytopenic purpura, 
Goodpasture’s, listeria meningitis. 
Ocrelizumab Anti-CD20 (B-cells) 
humanised monoclonal 
antibody 
47% (vs 
interferon) 
Common: Infusion reactions, chest 
infections, herpes infection 
Less common: Six cases of PML (5 
post natalizumab, 1 post 
fingolimod), possible increased risk 
of malignancy (particularly breast) 
though longer follow-up needed 
Table 1: Licensed disease-modifying therapies in RRMS. *Comparison between trials precluded by 
markedly different trial inclusion criteria and methodologies, particularly whether the comparator was 
placebo or an injectable therapy (interferon or glatiramer acetate). 
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These therapies principally target inflammation, though some may have modest indirect effects 
on neurodegeneration. Ocrelizumab is the only drug shown to slow progression in PPMS, 
although subgroup analyses demonstrated the greatest benefit in those with enhancing T1 
lesions on MRI (Montalban et al., 2017).  
 
Remyelination trials 
Clinical trial results have been mixed. The RENEW study compared the LINGO1 antagonist 
opicinumab with placebo in patients with a clinically-isolated optic neuritis, using visual-evoked 
potentials (VEPs) as the primary outcome measure. While a (pre-specified) subpopulation 
analysis showed an improvement in VEPs favouring opicinumab (53% normalisation in the 
opicinumab group versus 26% normalisation in controls), the primary outcome and clinical 
measures were negative (Cadavid et al., 2017). The SYNERGY study also found no clinically-
significant improvements between the same molecule and placebo in patients with RRMS and 
SPMS (Cadavid et al., 2019). The ReBUILD study compared the anticholinergic agent clemastine 
with placebo in patients with chronic demyelinating optic neuropathy from RRMS (Green et al., 
2017). Although no significant improvements in clinical outcomes were seen, the study did 
identify a statistically significant reduction in the primary outcome measure (mean reduction in 
the P100 latency by 1.7ms/eye on VEP), and thus the first positive trial of a putatively 
remyelinating agent. A phase IIa trial of the RXR-agonist bexarotene will report shortly. 
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MRI in multiple sclerosis 
Field strength 
Nearly all current clinical and research MRI scanners operate at 1.5 or 3 Tesla (T), although higher 
fields strengths (for example 7T) are available in specialised research centres. With increasing 
field strength comes a greater signal to noise ratio, and so potentially higher resolution. This is 
well illustrated with GM lesion detection. In people with long-standing SPMS, GM lesions are at 
least as extensive as those in WM (Calabrese et al., 2010) and most GM lesions occur adjacent to 
the outer (subpial) surface of the brain (Mainero et al., 2009). However, GM lesions are difficult 
to detect using 3T MRI systems even with sequences that have been tuned for this (see below). 
At 7T, not only are significantly more GM lesions seen, but subpial lesions - which are very rarely 
seen in 3T MRI scans - can be detected (Mainero et al., 2009). At present few in vivo studies have 
assessed the associations between GM lesions and clinical outcomes in MS, despite this being a 
substantial component of MS pathology. Increasing sensitivity to lesions with higher magnetic 
field strengths may reflect both the higher resolution and differences in the contrast between 
normal and abnormal tissues (Kreidstein et al., 1997; Kollia et al., 2009). With higher field 
strengths more energy can be deposited in tissues, which itself can lead to heating, limiting the 
clinical utility. As such, scanning methods developed at 1.5T or 3T may need to be significantly 
modified before running at higher field strengths, and so reduce the potential signal to noise 
gains. In addition, with higher field strengths it becomes increasingly difficult to achieve an even 
magnetic field throughout the brain or spinal cord, leading to noticeable changes in tissue 
intensity towards the edge of MRI scans. However, the main field strength is not the only factor 
that affects image quality. For example, the design of the coils that send and receive the radio-
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frequency signals used by MRI can significantly effect signal to noise, and the strength and 
accuracy of a scanner's magnetic gradients also effects scan quality. 
 
MRI methods 
The MRI toolkit can be broadly divided into techniques assessing macrostructure, microstructure, 
metabolism and neural function. Macrostructural techniques are the best established and 
include measures of WM and GM lesion counts and volumes, and brain and spinal cord atrophy. 
Microstructural techniques, such as magnetisation transfer imaging (MTI) and diffusion tensor 
imaging (DTI), can provide some information about neuronal and axonal damage, and 
demyelination. Of the metabolic MRI methods, to date proton spectroscopy has been the most 
used technique, and can provide relatively cell specific information. 
 
White matter lesions 
White matter lesions are the most visible abnormality on MRI in people with MS. They are usually 
identified on T2-weighted, T1-weighted and fluid-attenuated inversion recovery (FLAIR) scans 
(Figure 1). At 1.5T, about 60% of histopathologically confirmed WM lesions are seen on T2-
weighted scans, and 70% on FLAIR (Geurts et al., 2005a). Lesions seen on T2-weighted scans are 
not pathologically specific, and may exhibit different degrees of inflammation, axonal loss, 
demyelination (Miller et al., 1998) and remyelination (Barkhof et al., 2003). A subset of lesions 
seen on T2-weighted and FLAIR scans are also seen on T1-weighted scans (Figure 2), termed 
‘black holes’ due to their hypointensity relative to surrounding WM, and these are thought to 
represent more destructive lesions with greater myelin (Bitsch et al., 2001) and axonal loss (van 
Walderveen et al., 1998; Bitsch et al., 2001). The BBB is normally impermeable, but during acute 
inflammation this is breached, and acute WM lesions may be seen to enhance when gadolinium-
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based MRI contrast agents are given intravenously. On average new WM lesions enhance for 
about four weeks (Silver et al., 1999). The additional information gained through contrast 
administration must be weighed against the potential risks. Contrast-induced nephrogenic 
systemic fibrosis (NSF) has been largely eradicated through pre-administration screening for 
renal disease and avoidance of agents with a higher risk of NSF, but dose-dependent retention 
of gadolinium-based contrast agents within the brain is seen on T1 scans (Kanda et al., 2014) and 
at post-mortem (McDonald et al., 2015). The consequences remain unclear and no pathologic 
nor clinical sequelae have been confirmed. 
 
Figure 1: Axial MRI scan showing lesions in the same slice from the same patient with relapsing-remitting 
multiple sclerosis. FLAIR: fluid attenuated inversion recovery. PD: proton density. PSIR: phase sensitive 
inversion recovery. Figure from (Brown and Chard, 2016) 
 
 
Figure 2: 3D T1-weighted MRI scan from a patient with relapsing remitting multiple sclerosis (same slice, 
time point and patient as Figure 1). Periventricular T1 hypointense lesions (‘black holes’) evident on source 
image. Remaining images show automated segmentation of the 3DT1 scan into grey matter (red), white 
matter (yellow) and cerebrospinal fluid (blue). Figure from (Brown and Chard, 2016) 
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Grey matter lesions 
In long-standing MS, lesions account for 26% of cortical GM compared to 6% of the WM (Bo et 
al., 2003). GM lesions are seen in the spinal cord (Fog, 1950); deep GM (where they occur most 
frequently in the inner layers closest to the ventricles (Haider et al., 2014)); and cortical GM 
(where they occur most frequently in the outermost (subpial) layer (Kutzelnigg et al., 2005)). 
Subpial lesions are evident early (Calabrese et al., 2007; Lucchinetti et al., 2011) but become 
more prevalent in progressive disease (Kutzelnigg et al., 2005) where they account for two thirds 
of all cortical lesions (Bo et al., 2003). Subpial lesions are not perivenous. If active, subpial lesions 
are found close to focal areas of meningeal inflammation (Howell et al., 2011) which 
predominantly occur in cortical sulci (Magliozzi et al., 2007; Haider et al., 2016), suggesting that 
these lesions might arise from a soluble factor released by meningeal inflammation, which 
diffuses across the CSF and causes tissue damage (perhaps via microglial activation) (Kutzelnigg 
et al., 2005; Howell et al., 2011). 
When compared with WM, GM lesion detection using MRI is poor: at 1.5T only ~5% of GM lesions 
confined to the cortex (intracortical GM lesions), ~40% of mixed cortical GM-WM lesions, and 
~40% of deep GM lesions are identified, (Geurts et al., 2005a)) so sequences tuned to detect 
them have been developed. Double inversion recovery (DIR) more than doubles the detection of 
intracortical GM lesions when compared with FLAIR (Geurts et al., 2005b). Another sequence, 
phase sensitive inversion recovery (PSIR) may improve on this further, and when compared in 
vivo with DIR, two to three times more cortical GM lesions are seen (Sethi et al., 2013). However, 
even at 7T, no more than 35% of cortical lesions are seen with any sequence (while at 7T T2 and 
FLAIR detect 75% and 88% of histopathologically-confirmed WM lesions respectively) (Kilsdonk 
et al., 2016). Defining NAGM using MRI is therefore less robust as apparent extralesional 
abnormalities could reflect occult lesions.  
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Atrophy 
Brain and spinal cord atrophy are thought to reflect irreversible neuronal and axonal loss 
(Evangelou et al., 2005); brain atrophy is evident from the CIS stage (Chard et al., 2002). In the 
brain, atrophy appears to occur more in GM than WM (Dalton et al., 2004; Fisher et al., 2008; 
Perez-Miralles et al., 2013) and accelerates as a person transits from RRMS to SPMS (Dalton et 
al., 2006; Fisher et al., 2008). Brain atrophy is most often assessed using high-resolution (usually 
1x1x1mm) T1-weighted scans, and can be measured using a variety of automated or semi-
automated methods, for example SIENA/SIENAX (Smith et al., 2002), FreeSurfer (Dale et al., 
1999) and SPM [SPM; Wellcome Trust Centre for Neuroimaging, London, UK; 
www.fil.ion.ucl.ac.uk/]. When measuring brain atrophy on T1-weighted scans, a complicating 
issue in MS is the presence of lesions. WM lesions can have similar signal intensities to GM on a 
T1-weighted scan, and so may erroneously be counted as part of the GM. It is now increasingly 
usual to account for this either by filling WM lesions with simulated normal-appearing WM 
(NAWM) before segmentation (for example (Chard et al., 2010)) or by correcting segmentations 
before measuring tissue volumes. 
 
Spinal cord atrophy is usually measured in the upper cervical spine, as a mean cross-sectional 
area or volume over a fixed length of the cord. It can be measured on T2-weighted sequences 
(Horsfield et al., 2010), T1-weighted sequences (including those acquired for brain atrophy 
measures (Liu et al., 2014)), and more recently PSIR scans (Kearney et al., 2014). Semi-automated 
methods that require minimal operator input are now most commonly used for these 
measurements (Horsfield et al., 2010). 
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Diffusion-tensor imaging (DTI) 
DTI assesses the movement of water molecules in tissues, providing information about tissue 
microstructure. In MS, it has mostly been used to assess WM rather than GM. Fractional 
anisotropy (FA) is a measure of the directionality of water movement, i.e. whether it occurs 
evenly in all directions (low anisotropy) or mostly in one direction (high anisotropy), and is usually 
high in WM and lower in GM (Basser and Pierpaoli, 1996). Mean diffusivity (MD) measures the 
mean distance water travels in any direction, and is usually low in WM and higher in GM (Basser 
and Pierpaoli, 1996). Combined MRI and histopathology studies have shown that both of these 
measures are affected by myelin content and, to a lesser degree, axonal count in post mortem 
WM brain tissue (Table 2) (Schmierer et al., 2007b). 
 
Magnetization transfer imaging 
Conventional MRI techniques are largely based on signals derived from protons in water, so 
protons bound to macromolecular structures (such as myelin and cell membranes) go relatively 
undetected. However, this bound pool may be seen indirectly using magnetization transfer 
imaging. Magnetization transfer is often expressed as a ratio (magnetization transfer ratio 
(MTR)), which provides a semi-quantitative measure of the proportion of protons bound to 
macromolecular structures relative to those that are in free water. Combined MRI and 
histopathology studies in post mortem MS brains have demonstrated correlations between WM 
MTR and myelin content, and to a lesser degree, axonal and glial densities ( 
Table 2) (Schmierer et al., 2004). In the cortex myelin content is also significantly correlated with 
MTR (Schmierer et al., 2010; Chen et al., 2013). 
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Table 2: Pearson r correlations coefficients of MTR, DTI and qMT with histopathological features. Modified 
from (Schmierer et al., 2007b) and (Schmierer et al., 2004) and (Schmierer et al., 2007a). †Myelin and glial 
density estimated by light transmittance through stained tissues rather than absolute measures (thus the 
negative correlations). Axonal density measured as counts over a standardised stereological grid. MTR = 
magnetization transfer ratio. DTI = diffusion tensor imaging. FA = fractional anisotropy. MD = mean 
diffusivity. qMT = quantitative magnetisation transfer. fB = fraction of macromolecular protons. NS = non-
significant *p ≤ 0.01 **p ≤ 0.001  
Quantitative magnetisation transfer  
MTR is also reduced by oedema (Dousset et al., 1992), and is affected by sequence-dependent 
factors such as the saturation pulse frequency (Henkelman et al., 2001). Quantitative MT (qMT) 
measures (e.g. the fraction of macromolecular protons, fB) are absolute measures so may be less 
dependent on the MRI system used. Overall, no combined MRI-histopathological study has 
shown any greater sensitivity for myelin in comparison to MTR (Table 2). FB is thought to reflect 
protons in the macromolecular pool only, while MTR reflects both the macromolecular and 
bound pools. In-vivo and at post-mortem, the significantly lower lesional fB (43-46% of the 
surrounding NAWM fB) compared to the lesional MTR (69-75% of the surrounding NAWM MTR) 
is thought to reflect attenuation of the MTR by oedema and may suggest fB’s greater specificity 
for myelin (Schmierer et al., 2007a; Giacomini et al., 2009). However, although decreasing, the 
longer acquisition times and complex modelling necessary have thus far precluded widespread 
use in clinics or remyelination trials. 
  Histopathological feature 
  Myelin density† Axonal density Glial density† 
MRI feature 
MTR -0.84** 0.66** 0.13NS 
DTI: FA -0.79** 0.70** 0.50* 
DTI: MD 0.68** -0.66** -0.55* 
qMT: fB -0.80** 0.72** 0.41* 
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Myelin water fraction 
Multi-component T2 relaxometry exploits the distinct proton relaxation characteristics of water 
trapped in myelin bilayers (“myelin water”, with short T2 relaxation times), intracellular and 
extracellular water (medium T2 relaxation times) and CSF (long T2 relaxation times) (MacKay et 
al., 1994). Myelin water fraction (MWF) – the ratio of the short to the total water signal – 
correlates with myelin content (Laule et al., 2006), but again requires long acquisition times and 
suffers limited brain coverage. These concerns have, to some extent, been addressed with newer 
techniques such as 3D-GRASE (Prasloski et al., 2012), mcDESPOT (Deoni et al., 2008), FAST-T2 
(Vargas et al., 2015) and T2prep 3D SPIRAL (Nguyen et al., 2012), though acquisition times still 
exceed those of MTR and histopathological evidence of greater specificity or sensitivity 
compared to MTR are lacking. 
 
Non-MRI methods - Positron-emission tomography (PET) 
The limited specificity of MRI can to some extent be ameliorated with PET, which uses various 
radio-labelled tracers to target specific cells or tissues. In MS, PET has been used to explore 
changes in myelin content, inflammation and neuronal damage (though data in the latter is 
awaited). 
Multiple PET tracers have been used to study myelin, particularly the amyloid tracer 2-(4’-
methylaminophenyl)-6-hydroxybenzothiazole, also known as Pittsburgh Compound B ([11C]PIB) 
(Stankoff et al., 2011). [11C]PIB (and therefore myelin) concentration is lowest in black holes with 
ascending values seen in T2 lesions, perilesional WM and gadolinium-enhancing lesions, all of 
which show significantly lower uptake than in NAWM (Bodini et al., 2016). This pattern has been 
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replicated using 18F florbetapir which has a longer half-life (Carotenuto, 2018). [11C]PIB 
decreases (reflecting demyelination) and increases (reflecting remyelination) can be explored on 
a voxel-level with repeated scans. This has uncovered significant heterogeneity in the extent of 
remyelination between patients, heterogeneity within individual lesions (with some parts 
continuing to demyelinate and others remyelinating) and strong correlations between derived 
remyelination indices and clinical indices (for example EDSS (B = -0.67, p=0.006) (Bodini et al., 
2016).  [11C]PIB is not myelin-specific though – it is also used to detect fibrillary b-amyloid 
deposits in neurodegenerative conditions such as Alzheimer’s disease, blurring assessments of 
those with such comorbidities (particularly the elderly). 
For exploring innate inflammation, the most widely used target is the translocator protein (TSPO) 
which is found on the mitochondrial membranes of microglia, macrophages and astroglia. While 
not specific, it’s expression is principally driven by activation of microglia and macrophages. Using 
numerous tracers, significant heterogeneity has been identified in-vivo. For example, uptake of 
11C-PK11195 is (i) increased in lesions, the NAWM and grey matter of patients with SPMS, in-
keeping with pathological studies showing widespread microglial activation; and (ii) markedly 
increased in the perilesional NAWM of more than half of chronic T1 lesions in patients with SPMS 
consistent with the post-mortem findings of chronic active lesions (Prineas et al., 2001; 
Kutzelnigg et al., 2005; Rissanen et al., 2014). WM lesional and perilesional [18F]DPA-714 uptake 
correlated with severe disability worsening in the period preceding imaging, but has also 
highlighted that a far greater proportion of lesions exhibit active inflammation (37%) than is 
shown with gadolinium-enhanced MRI sequences (<2%) (Stankoff et al., 2018). Increased 11C-
OBR28 has been shown in cortical lesions, the extent of which – like WM lesions – correlated 
with clinical outcomes (Herranz et al., 2019). Limitations include many tracers’ inability to 
distinguishing microglial subtypes (and therefore discriminate their protective and 
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proinflammatory effects); and that microglial activation occurs in diseases other than MS 
including degenerative conditions, stroke and brain injury (Tronel et al., 2017). 
While PET offers significantly greater specificity and superior serialization of in-vivo 
pathophysiological changes compared to MRI, the comparatively lower resolution hampers 
visualization of lesions or small areas (Catana, 2017). Furthermore, the unknown effects of 
repeated exposure to ionizing radiation, the need to produce the radioisotopes near to the 
scanner (due to their short half-life) and the limited number of available PET scanners currently 
limit PET to the research setting (Preziosa et al., 2019). 
 
Heterogeneity in normal-appearing tissues.  
Normal-appearing grey matter (NAGM) 
MRI’s aforementioned poor detection of GM lesions (Kilsdonk et al., 2016) means that apparent 
NAGM abnormalities could reflect occult lesions. This problem is circumvented in 
histopathological studies. Extralesional cortical and thalamic GM show significant axonal loss 
compared to healthy controls (Cifelli et al., 2002; Choi et al., 2012; Bevan et al., 2018). Neuronal 
loss appears relatively independent of demyelination (Magliozzi et al., 2010): no differences in 
axonal density were seen between demyelinating cortical lesions and NAGM (Klaver et al., 2015). 
Cortical demyelination has typically been quantified in terms of demyelinating lesions, but 
reductions in NAGM myelin density are seen, in part reflecting areas of remyelination (Albert et 
al., 2007). 
However, the extent of NAGM damage is not uniform. Significantly greater neuronal loss is seen 
in the outermost cortical layers in some patients with SPMS, and the extent of cortical 
demyelinating lesions is also greatest in the outer cortical layers in both SPMS and PPMS (Choi et 
al., 2012). These abnormalities are associated, both in location and extent, with the degree of 
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meningeal inflammation, so a cytotoxic factor, released into the CSF by meningeal inflammation, 
has been postulated to be driving this outside-in cortical pathology (Magliozzi et al., 2010). The 
most striking form, meningeal lymphoid aggregates, have only been seen in SPMS, not PPMS 
(Magliozzi et al., 2007; Magliozzi et al., 2010). Such post-mortem studies are, by definition, biased 
towards those with end-stage MS, and due to the relatively young age at death of many 
participants, these two studies may be additionally biased towards those with more meningeal 
inflammation (which is associated with more rapid clinical disease progression and death (Howell 
et al., 2011)). Whether this outside-in gradient occurs earlier in disease, or is even detectable in-
vivo, prompted a search in-vivo using MRI. Using MTR, Samson and colleagues found that in both 
SPMS and RRMS the MTR was lowest (most abnormal) in comparison to healthy controls at the 
outer cortical surface with smaller MTR reductions visible within inner cortical layers (Samson et 
al., 2014). However, no such outside-in cortical gradient was seen in patients with PPMS despite 
post-mortem evidence of meningeal inflammation and a gradient of demyelination (Choi et al., 
2012). Whether this reflects a true absence of cortical gradients in PPMS – perhaps explained by 
the absence of meningeal lymphoid follicles found at post-mortem in PPMS (Magliozzi et al., 
2007) - or simply the methodology (for example smaller numbers of PPMS (19) versus SPMS (25) 
or RRMS (44) were examined), remains unclear. A true absence of these surface-based 
pathologies might suggest a key pathogenic difference between relapse-onset MS and PPMS. 
Normal-appearing white matter (NAWM) 
NAWM - regions free of lesions seen using conventional (PD/T2-weighted and FLAIR) MRI - are 
abnormal when assessed by a variety of techniques including MTR (Filippi and Rocca, 2005).  
However, like in GM, NAWM abnormalities are not uniform.  Perilesional tissue is abnormal, for 
up to 4mm from the T2-defined lesion edge (Vrenken et al., 2006). Moreover, if meningeal 
inflammation drives superficial cortical pathology via a soluble factor released into the CSF 
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(Magliozzi et al., 2010), then one might also expect to see gradients at other tissue-CSF 
boundaries, such as the periventricular white matter. Indeed, my colleagues at UCL’s NMR 
Research Unit had identified a periventricular gradient of MTR abnormality just prior to my 
arrival. In healthy controls, the MTR was highest adjacent to the lateral ventricles and decreased 
with increasing distance from them, while in patients with RRMS – and even more so in SPMS – 
the MTR was lowest adjacent to the lateral ventricles and increased with increasing distance from 
them (Liu et al., 2015). WM lesions are frequently seen in the periventricular region (Brownell 
and Hughes, 1962), so perilesional MTR reductions (Vrenken et al., 2006) or MRI-invisible lesions 
might confound a NAWM periventricular gradient. To circumvent perilesional MTR reductions, a 
2mm cuff around each lesion was also removed when generating the NAWM masks, and a 
sensitivity analysis excluding a 3mm cuff found virtually identical results (Liu et al., 2015). Indeed, 
the periventricular gradient was visible in both NAWM and lesional tissue. However, by definition 
MRI-invisible lesions could not be circumvented, and, because lesions accrue with time, the 
relatively long disease duration, even in the RRMS group (mean >11 years) may have meant a 
number of invisible lesions and thereby spuriously lower periventricular MTR. The Liu paper did 
not explore periventricular gradients in early relapse-onset MS or PPMS, nor did it examine the 
clinical correlations of periventricular gradients, their change over time or thir response to DMTs. 
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Aims and objectives 
The overall aims of my PhD were twofold. First, to examine the timing, evolution and clinical 
correlations of surface-based gradients in multiple sclerosis, and whether or not the 
periventricular gradient is influenced by peripheral immunodepletion; and second to explore the 
associations between DMT use in RRMS with subsequent conversion to SPMS. 
 
Project 1 
By looking for an abnormal periventricular MTR gradient in people who have recently had a CIS, 
we would be able to establish if it is seen from the earliest clinical stages of MS, whether it 
predicts subsequent disease activity, and - given that people usually have very few WM lesions 
immediately after a CIS - determine if it is closely associated with WM lesions. The identification 
of an early abnormal periventricular MTR gradient that is not directly related to lesion formation, 
but linked with clinical outcomes might suggest that there is a pathological process distinct to 
that underlying lesion formation that should be targeted from the earliest clinical stages of 
relapse-onset MS. Using previously acquired MTR data from a longitudinal study of people with 
a recent CIS, we aimed to (1) look for gradients in NAWM abnormalities around the lateral 
ventricles and, if present, to determine (2) whether or not they were associated with WM lesions, 
or (3) were associated with the subsequent risk of developing CDMS and disability. 
 
Project 2 
There is ongoing debate as to whether or not PPMS and SPMS are essentially the same disease, 
barring the preceding relapsing-remitting phase: the age at onset and rate of progression are 
similar (Kremenchutzky et al., 2006) and lesion morphology in relapse-onset and PPMS are 
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identical (Kuchling et al., 2014) but differences have been observed in both MRI and 
histopathological studies (Revesz et al., 1994; Correale et al., 2017). Post-mortem studies have 
revealed meningeal inflammation in both types of MS (Magliozzi et al., 2007; Choi et al., 2012) 
although the most structured form - lymphoid follicle-like aggregates - have only been observed 
in SPMS, not in PPMS (Magliozzi et al., 2007). The processes underlying abnormal cortical and 
periventricular MTR gradients remain unknown, but one possibility is that they are both linked 
with meningeal inflammation, perhaps through a CSF-mediated factor (Magliozzi et al., 2010). 
This raises seemingly conflicting possibilities that either lymphoid follicles are themselves not 
relevant to progression, or that the mechanisms leading to progression differ significantly 
between PPMS and SPMS. Using an early processing pipeline and smaller cohort, our group 
previously reported the absence of a statistically significant cortical MTR gradient in PPMS 
(Samson et al., 2014) supporting the latter hypothesis (but did not investigate periventricular 
gradients). If a common factor links cortical and periventricular MTR gradients, we would expect 
the latter to also be absent in PPMS. 
Using our recently optimised pipeline for WM and cortical GM segmentation (Pardini et al., 
2016), plus a larger cohort, we re-analysed healthy controls and patients with progressive MS to 
explore (i) whether periventricular and cortical gradients are seen in patients with PPMS 
compared to healthy controls; and if so, (ii) to explore whether either gradient correlates with 
disability; (iii) to compare the gradients and their evolution between patients with PPMS and 
SPMS; and (iv) to examine the relationship between periventricular and cortical gradient severity 
in both PPMS and SPMS. 
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Project 3 
Alemtuzumab is a potent immunomodulator licensed for RRMS, which stabilises MTR in the 
normal-appearing white matter (Button et al., 2013). It depletes peripheral mature lymphocytes 
(Coles et al., 2006) and substantially reduces the long-term risk of relapses (Tuohy et al., 2015). 
Alemtuzumab does not cross the blood-CSF barrier (Moreau et al., 1994) and should have no 
direct effect on isolated intrathecal pathological processes. If alemtuzumab were to affect the 
periventricular MTR gradient this would suggest the processes underlying it are influenced by the 
peripheral immune system. 
 
We therefore aimed to (i) examine the untreated evolution of the MTR gradient in RRMS; (ii) 
explore if alemtuzumab alters this; and (iii) determine if the pre-treatment MTR gradient predicts 
on-treatment relapses or change in disability. 
 
Project 4 
Using a recently-published validated definition of SPMS (Lorscheider et al., 2016) we aimed to 
compare the rate of SPMS conversion between different DMTs and an untreated cohort to 
determine whether individual DMTs are associated with a reduced rate of conversion from RRMS 
to SPMS. We then explored whether any additional advantage was conferred by initial treatment 
with fingolimod, natalizumab or alemtuzumab compared to glatiramer acetate or interferon 
beta, or treatment commencement or escalation within versus after 5 years of disease onset, in 
the rate of conversion to SPMS. 
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Chapter 2: Methods: Outside-in gradients 
of tissue abnormality 
Project 1: Periventricular gradients after a clinically isolated syndrome 
Performed in collaboration with Matteo Pardini (joint first author); plus Wallace Brownlee, 
Kryshani Fernando, Rebecca Samson, Ferran Prados Carrasco, Sebastien Ourselin, Claudia 
Gandini Wheeler-Kingshott, David Miller and Declan Chard. 
My role: conception and design of study; gathered existing scans and clinical information; planned 
and performed image processing pipeline (with Matteo Pardini); quality-assurance steps; 
analysed data (with assistance from Matteo Pardini); wrote manuscript and amended following 
co-author and journal reviews.  
 
Participants 
From a prospectively recruited CIS cohort (Fernando et al., 2005) we included data from 81 
people who had presented with a clinically isolated optic neuritis (ON), who had no previous 
history of neurological symptoms, were aged between 16 and 50 years at symptom onset, had 
3D fast spoiled gradient echo (FSPGR) as part of their baseline MRI assessments and MTR three 
months later. Participants were recruited from Moorfields Eye Hospital (London) by a single 
experienced neuro-ophthalmologist. They were evaluated clinically and with MRI a median of 1.4 
(range 0.1-3.5) months after ON onset (‘baseline’) and underwent a further scan (including 
magnetization transfer imaging) on the same scanner three months later (median 4.6; mean 4.8; 
	 	 60	
range 2.0-7.5 months after ON onset); patients were followed up clinically two and five years 
later (Brownlee et al., 2015) and had EDSS and paced serial addition test (PASAT, 3 second 
intervals (Cutter et al., 1999)) scores assessed at five years. This work therefore describes cross-
sectional MTR data (collected 4.6 months after symptom onset) with clinical data at 4.6 months 
plus two and five years after symptom onset. We also studied a group of 39 healthy controls with 
no known neurological disorder or clinical follow up. Demographic and clinical data are reported 
in Table 3.  
 
All participants gave written informed consent and the study was approved by the Joint Medical 
Ethics Committee of the Institute of Neurology and National Hospital for Neurology and 
Neurosurgery, and the Moorfields Eye Hospitals Ethics Committee.  
 
Clinical assessments 
MS was diagnosed on the basis of further relapses (clinically definite multiple sclerosis (CDMS, 
(Poser et al., 1983) and using the 2010 McDonald criteria (Polman et al., 2011).  
 
Magnetic resonance imaging 
All magnetic resonance studies were performed on a 1.5 Tesla (T) GE Signa Echospeed scanner 
(General Electric Medical Systems, Milwaukee, WI). The following sequences were acquired: (i) 
an FSPGR scan of the whole brain (124x1.5mm slices; matrix, 256x160, interpolated to a final in-
plane resolution of 1.1mm, TR= 10.9 ms, TE= 4.2 ms, TI= 450 ms) for volumetric measures; (ii) 
dual echo proton-density (PD)/T2 scans of the whole brain (46x3 mm contiguous axial-oblique 
slices parallel to the anterior/posterior commissural line, matrix 256x256, field of view (FOV) 
24x18 cm, repetition time (TR) =3200 ms, echo time (TE) =15/90 ms), for the evaluation of WM 
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lesions; (iii) T1-weighted pre- and post-gadolinium (0.1 mmol/kg body weight) spin echo 
sequences of the brain (46x3 mm contiguous axial-oblique slices parallel to the anterior/posterior 
commissural line, matrix 256x256, FOV 24x18 cm, TR=600 ms, TE=17 ms) to evaluate the 
presence of pathologically enhancing lesions; and (iv) MTR data using a dual-echo, spin-echo 
sequence of the whole brain (28x5mm contiguous, axial-oblique slices parallel to the 
anterior/posterior commissural line with an interleaved sequence described by Barker (TR=1720 
ms, TE=30/80ms, number of excitations 0.75, matrix 256x128, FOV 24x24cm, MT-weighted by 
the application of a pre-saturation pulse (Hamming apodized 3 lobe sinc pulse, duration 64ms, 
flip angle 1430°, and a peak amplitude of 14.6 μT giving a normal bandwidth of 62.5 Hz, applied 
1kHz from the water resonance (Barker et al., 1996))). MTR maps were calculated on a voxel-by-
voxel basis using the short echo data because of its higher signal to noise compared to the longer 
echo data. Proton density (PD) and T2-weighted images are included in this sequence, 
intrinsically registered to the MT data, and were used to facilitate registrations to native MT 
space as described below. The FSPGR scan was acquired at baseline (when magnetisation 
transfer imaging was not performed); all other scans and lesion counts used for this analysis were 
acquired three months later (when the FSPGR was not repeated (Fernando et al., 2005)). 
 
Image analysis 
MTR map calculation 
For each participant, MTR maps were calculated using the following equation: MTR (in 
percentage units (pu)) = ((MTRoff – MTRon) / MToff.) x 100). The interleaved nature of the MTR 
sequence used meant that co-registration of MTon and MToff data was not required. MTR values 
were extracted from each NAWM and lesion band using FSLstats 
(http://www.fmrib.ox.ac.uk/fsl/). 
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Tissue segmentation  
T1-hypointensities were outlined by WJB using a semi-automated edge-finding tool (JIM v6.0, 
Xinapse systems, Aldwincle, United Kingdom) on the 3D FSPGR images and these masks were 
used to perform lesion filling on the 3D FSPGR scans (Chard et al., 2010; Prados et al., 2016). After 
lesion filling the FSPGR scans were segmented into GM, WM and CSF probability maps using the 
new segmentation pipeline in Statistical Parametric Mapping 12 (SPM12; Wellcome Trust Centre 
for Neuroimaging, London, UK; www.fil.ion.ucl.ac.uk/). Brain parenchymal fraction (BPF) was 
calculated using SPM12-derived tissue segmentations for use as a covariate in the statistical 
models (Chard et al., 2010). 
 
Generation of NAWM masks 
WM lesions were identified on the dual echo PD/T2-weighted scans, and outlined by WJB using 
JIM v6.0 (Xinapse systems, Aldwincle, United Kingdom). This had been performed for a previous 
project (thus explaining why lesions were not marked on the PD/T2 scan interleaved with the MT 
sequence). Using NiftyReg (Modat et al., 2010; Modat et al., 2014) the T2-weighted image was 
linearly co-registered with the T2-weighted image embedded in the MT sequence, thus aligning 
the WM lesion masks with the MTR maps. NiftyReg implements a symmetric and inverse-
consistent registration ensuring that the results are unbiased towards the directionality of the 
registration process because the forward and backward transformations are optimised 
concurrently in an inverse-consistent manner. The symmetric full affine approach (Modat et al., 
2014) with 12 degrees of freedom is based on the asymmetric block-matching approach (Ourselin 
et al., 2001). 
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The PD and T2 images embedded in the MT sequence were used to generate a pseudo-T1 image, 
by subtracting the PD scans from the T2 images (Hickman et al., 2002). For each participant, the 
3D FSPGR scan was then linearly co-registered to the pseudo-T1 using NiftyReg (Modat et al., 
2014) and the transformation applied to the GM, WM and CSF tissue segmentation maps. In MTR 
space the GM, WM and CSF maps were binarised using a probabilistic threshold of > 90% (Samson 
et al., 2014). In MTR space, WM lesion masks were dilated by two voxels (to account for 
perilesional MTR abnormalities (Vrenken et al., 2006)), and the dilated lesion masks were 
subtracted from the thresholded WM tissue probability maps to produce NAWM masks. 
 
Segmentation of NAWM into concentric periventricular bands 
Given the voxel size of MT images (1x1x5 mm), to reduce the potential for partial volume effects 
between CSF and WM, all analyses were limited to two axial slices orthogonal to the wall of the 
lateral ventricles, i.e. a slice immediately above the insula, and the slice immediately below this. 
We used an automated method to reproducibly identify these slices in all participants: a position 
marker was placed in the lateral ventricles just superior to the insula on a MNI152 brain template 
(Grabner et al., 2006). The MNI152 brain template was registered to each participant’s native 
MTR space with a non-linear transformation as previously described (Muhlert et al., 2013) using 
NiftyReg (Modat et al., 2010). The position of the marker was checked and corrected as needed 
by one investigator and then the two axial slices were selected relative to this template marker. 
 
To identify the lateral ventricles we used a previously described approach (Liu et al., 2015). 
Briefly, a mask of the lateral ventricles was created in MNI152 space using the Wake Forest 
University School of Medicine PickAtlas toolbox (Maldjian et al., 2003) and then registered to 
each participant’s MTR native space using the previously computed transformation. The lateral 
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ventricle mask was then intersected with each participant's CSF mask on the two previously 
selected axial slices. These masks were checked and manually edited by one investigator to 
ensure anatomical accuracy, and then sequentially dilated in the axial plane by 1 voxel (1mm) 
using DilM (part of FSL software package (http://www.fmrib.ox.ac.uk/fsl/) producing concentric 
bands around the lateral ventricles (Figure 3). For this project, a periventricular band is therefore 
defined as a 1mm ring in the axial plane surrounding the lateral ventricles. These were 
intersected with the NAWM mask to generate bands of NAWM. We intersected the CSF masks 
with the rings and found that the first two bands contained CSF in over half of participants (first 
band 117/120 participants; second band 63/120), so these bands were discarded to limit partial 
volume effects from CSF in all patients. Residual CSF was identified in the first of these ten bands 
in ten people with ON and two controls and so these participants were excluded, leaving 71 
people with ON and 37 healthy controls. Bands of WM lesional tissue were derived by 
intersecting the bands with the lesion masks. As per previous work (Liu et al., 2015), the 
percentage of lesioned WM in each band were also computed (number of lesional voxels per 
band / total number of WM voxels per band).  
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Figure 3: A: Normal appearing white matter (NAWM) from two 5mm axial slices were extracted at (B) and 
immediately below (C) the level of the insula.  Bands of concentric MTR values from the normal-appearing 
white matter around the ventricles were then extracted (D and E). The first two bands were excluded to 
minimise partial volume effects. 
We also recalculated the mean NAWM and GM MTR (as previously reported (Fernando et al., 
2005)) for use as covariates in the statistical models. 
 
Statistical analyses 
Statistical analyses were performed using SPSS (IBM SPSS version 22 for Windows (SPSS, Inc., 
Chicago, IL, USA)). Demographic data are presented as mean (standard deviation) and MTR data 
as mean (standard error), while EDSS values are presented as median (range). In each participant, 
mean MTR values were calculated in the 1 mm bands in both axial slices, and then averaged 
across both slices, weighted by the number of voxels in each band. After discarding the first two 
bands (see above), we calculated periventricular MTR gradients over the next 5mm closest to the 
ventricles (i.e. NAWM MTR in band five – NAWM MTR in band one) and deep MTR gradients over 
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the subsequent 5mm (i.e. NAWM MTR in band ten – NAWM MTR in band six), dividing both by 
the number of intervals to give the MTR change in percentage units (pu) per mm. This division 
was consistent with previous work (Liu et al., 2015), and coincided with the point at which the 
MTR gradients in the ON and control groups converged.  
 
In the ON cohort, 58/71 patients were followed-up two and five years after their baseline MRI 
scan. These patients were subdivided into those who developed CDMS or McDonald MS within 
two years of their ON. We also examined those developing CDMS and McDonald MS within five 
years of their ON. To assess associations with gadolinium-enhancing lesions, the ON cohort was 
subdivided into those with or without enhancing lesions. To explore associations with WM 
lesions, the ON cohort was also subdivided into those who did or did not have T2 brain WM 
lesions and, in those with lesions, those who did or did not have periventricular lesions. 
Independent sample t-tests and analysis of variance (ANOVA) tests were used to compare clinical 
and MRI measures between groups. For the MTR gradient measures, the same comparisons were 
also performed using general linear models firstly correcting for BPF (to control for the possible 
effects of atrophy on periventricular MTR gradients), then correcting for mean NAWM and GM 
MTR (to ensure diffuse MTR changes were not driving MTR gradients).  Spearman correlation 
was used to explore the relationship between MTR gradients and both EDSS and PASAT scores. 
Factors predicting conversion to CDMS status were examined with multivariate binary logistic 
regression. Results were considered statistically significant at the p<0.05 level. 
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Project 2: Periventricular and cortical gradients in progressive 
multiple sclerosis 
Performed in collaboration with Azmain Chowdhury (joint first author), plus Baris Kanber, Ferran 
Prados Carrasco, Arman Eshaghi, Carole Sudre, Matteo Pardini, Rebecca Samson, Steven van de 
Pavert, Claudia Gandini Wheeler-Kingshott and Declan Chard. 
My role: conception and design of study; gathered existing scans and clinical information; planned 
and performed image processing pipeline (with Ferran Prados Carrasco); quality-assurance steps; 
analysed data (with assistance from Arman Eshaghi); wrote manuscript and amended following 
co-author and journal reviews.  
 
Subjects 
From an observational cohort (Samson et al., 2014) we analysed data from healthy controls and 
people with PPMS, SPMS or RRMS (as defined by the Lublin-Reingold criteria (Lublin and 
Reingold, 1996)) that had undergone MRI scanning with a protocol including the acquisition of 
volumetric T1-weighted images and MTR data. Some had repeat imaging performed 1-4 years 
later. All people in the MS groups additionally required an EDSS (Kurtzke, 1983) score at baseline. 
The study was approved by our local institutional ethics committee and written informed consent 
was provided by each participant. 
 
MRI 
Imaging was performed on a 3T Philips Achieva system (Philips Healthcare, Best, The 
Netherlands), and included: (i) Dual-echo PD / T2 weighted scans (1x1x3 mm3, TR = 3500 ms, TE 
= 19/85 ms) for lesion identification; (ii) T1-weighted scans (3D inversion-prepared (1x1x1 mm3, 
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T1=824 ms) fast field echo sequence (TR/TE = 6.9/3.1 ms, flip angle = 8°)) for volumetric measures 
and segmentation; and (iii) interleaved MTR data using a 3D-slab-selective fast field echo 
sequence with two echoes (1x1x1 mm3, TR = 6.4 ms, TE1/TE2 = 2.7/4.3 ms, flip angle = 9° with 
and without sinc-Gaussian shaped MT pulses of nominal flip angle 360°, offset frequency 1 kHz, 
duration 16 ms). All images were acquired sagittally with a field-of-view of 256x256x180mm3 
across the whole brain. 
 
Image analysis 
WM lesions were outlined on PD/T2-weighted images by SvdP using the semi-automated tool 
3D-slicer (Fedorov et al., 2012) and checked by DC. The resultant lesion masks were affine co-
registered to the T1-weighted images via pseudo-T1 images (as previously described (Hickman et 
al., 2002)) and transformed to T1-space using nearest-neighbour interpolation to enable lesion-
filling of the T1-weighted images (Prados et al., 2016). The MTon and MToff images were then 
registered to the T1-weighted volume using NiftyReg (Modat et al., 2014), and MTR maps (in pu), 
were calculated as follows: (((MToff – MTon) / MToff) x100). T1-weighted volumes were 
segmented into WM, GM and CSF using the geodesic information flows (GIF) algorithm (Cardoso 
et al., 2015). Lesions (plus a 2mm perilesional rim (Vrenken et al., 2006)) were subtracted from 
each participant’s WM mask, generating a NAWM mask. The NAWM and cortical GM (CGM) 
volumes were used as covariates in the periventricular and cortical models respectively. BPF was 
used as an alternative covariate in both periventricular and cortical gradient models in a 
sensitivity analysis to mirror a previous paper (Pardini et al., 2016). It was calculated as follows: 
(GM volume + WM volume) / (GM volume + WM volume + CSF volume). 
The NAWM mask was intersected with the MTR map, and segmented into 10 concentric bands 
using the normalised distance map derived from the normal to the Laplace equation isolines 
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(Pardini et al., 2016). Unlike in project 1 (performed before the updated method was optimised), 
this approach generates bands of varying thickness, which accounts for the differences in brain 
thickness within different brain regions plus the effects of atrophy: the relative position of a given 
band to the surface of the brain should therefore be maintained. Consistent with previous work 
using 3D MTR data, the innermost (periventricular) and outermost (pericortical) bands were 
excluded to mitigate partial volume effects (Liu et al., 2015). From the remaining 8 bands the 
periventricular NAWM gradient was calculated as follows: ((mean NAWM MTR band 3 – mean 
NAWM MTR band 1) / 2). Consistent with previous work, the CGM was also segmented into two 
bands using the Laplace method (Samson et al., 2014) but rather than using the absolute outer-
band MTR value (Samson et al., 2014) (which will be subject to inter-individual variations in whole 
brain MTR (Barker et al., 2005)), the cortical gradient was instead calculated as: (mean cortical 
GM MTR band 2 (outer) – mean cortical GM MTR band 1 (inner)). An alternative method for 
calculating the cortical gradient – applying the CGM mask to a 12-band segmentation, removing 
the outermost band, then calculating the cortical gradient over the 3 outermost bands – requires 
a lower probabilistic segmentation threshold (Pardini et al., 2016) to achieve similarly-sized 
bands, so increasing the chances of partial volume with adjacent WM and CSF, affecting results, 
and it also does not account for cortical folding as well as the present method. The mean NAWM 
and cortical GM MTR were also calculated in each participant for use as covariates in sensitivity 
analyses. Finally, to explore whether differences between current and previous (Samson et al., 
2014) results reflected the greater number of people studied, we restricted the groups to the 19 
people with PPMS and 35 healthy controls previously examined (Samson et al., 2014) and 
repeated the analyses.  
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Statistics 
MTR gradient values are presented as mean ± standard error, and all longitudinal differences 
were annualised to circumvent variable interscan intervals. We used general linear models to 
compare baseline gradients between groups and mixed-effects linear models to compare the 
rate of gradient change between disease subtypes. Consistent with previous work these models 
were adjusted for age and sex. Additionally, these models were also adjusted for either NAWM 
volume (periventricular gradient models) or cortical volume (cortical gradient models); and then 
repeated adjusting for BPF for comparison to previous work (Pardini et al., 2016).  To examine 
whether differences in gradients might be driven by more diffuse MTR changes we performed 
sensitivity analyses, additionally adjusting all periventricular gradient models for mean NAWM 
MTR, and all cortical gradient models for mean CGM MTR.  
Finally, we ran univariate general linear models comparing (i) baseline periventricular gradients 
with baseline cortical gradients; and (iii) baseline gradients with baseline disease duration, EDSS 
score and time from the last relapse. All analyses were performed in R (v3.3.1). Results were 
considered statistically significant at the p < 0.05 level.  
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Project 3: Periventricular gradient evolution following peripheral 
immunotherapy 
Performed in collaboration with Ferran Prados Carrasco (joint first author); plus Arman Eshaghi,  
Carole Sudre, Tom Button, Matteo Pardini, Rebecca Samson, Sebastien Ourselin, Claudia Gandini 
Wheeler-Kingshott, Joanne Jones, Alasdair Coles,  and Declan Chard. 
My role: conception and design of study; gathered existing scans and clinical information 
(including updating 13-year alemtuzumab data from research clinic); planned and performed 
image processing pipeline (with Ferran Prados Carrasco); quality-assurance steps; analysed data 
(with assistance from Arman Eshaghi); wrote manuscript and amended following co-author and 
journal reviews.  
 
Participants 
This study utilised the same early relapsing-remitting multiple sclerosis cohorts as Button et al., 
2013. Twenty alemtuzumab-treated patients from the CAMMS223 trial (ClinicalTrials.gov 
identifier: NCT0050778) were scanned immediately before treatment then annually for 3 years 
(scans performed between 2003-2007). Twenty-two people from a natural history cohort with 
annual imaging were scanned three times between 1998-2003 (Davies et al., 2005). In the 
alemtuzumab cohort, clinical follow-up (including Expanded Disability Status Scale (EDSS) scores 
(Kurtzke, 1983)) was undertaken every 3 months for 3 years then annually thereafter. 
 
Ethical approval was granted by the joint ethics committee for the Institute of Neurology and the 
National Hospital for Neurology and Neurosurgery, Queen Square, London (for the natural 
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history cohort) and by local review boards and ethics committees (for the CAMMS223 cohort). 
Written informed consent was obtained from all participants. 
 
Magnetic resonance imaging 
All images were acquired using the same 1.5 T Signa scanner (General Electric, Milwaukee, USA) 
at the Institute of Neurology, University College London using the same protocol (Davies et al., 
2005). The acquisition included (i) dual echo T2-weighted/PD images of the whole brain (50x3mm 
contiguous axial-oblique slices parallel to the anterior/posterior commissural line, matrix 
256x256, FOV 220x220mm, TR=3200ms) for lesion-identification and segmentation; (ii) T1-
weighted spin-echo whole-brain images (50x3mm contiguous axial-oblique slices parallel to the 
anterior/posterior commissural line, matrix 256x256, FOV 220x220mm, TR=600ms, echo 
time=17ms) for segmentation; and (iii) 2D interleaved dual-echo, spin echo magnetisation 
transfer imaging of the whole brain (28x5mm contiguous axial-oblique slices parallel to the 
anterior/posterior commissural line with an interleaved sequence (TR=1720ms, echo 
time=30/80ms, number of excitations 0.75, matrix 256x256, FOV 240x240mm, magnetisation 
transfer-weighted by the application of pre-saturation pulse (Hamming apodized 3 lobe sinc 
pulse, duration 64ms, flip angle 1430°, peak amplitude of 14.6mT giving a normal bandwidth of 
62.5Hz, applied 1 kHz from the water resonance)).  
The scanner was upgraded in April 2004; statistical analyses were adjusted to account for the 
small resultant MTR step-increase.  
 
Image analysis 
WM lesions were outlined on PD/T2-weighted images by TB using JIM v5.0 (Xinapse systems, 
Aldwincle, UK). The WM lesion mask was then resampled from PD/T2 to T1-weighted image 
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space using a transformation obtained by registering the pseudo-T1 image (generated from the 
PD/T2-weighted image (Hickman et al., 2002)) to the T1-weighted image. Lesion filled T1-
weighted images (Popescu et al., 2014; Prados et al., 2016) were segmented into WM, cortical 
grey matter (GM), deep GM and CSF using the GIF algorithm (Cardoso et al., 2015) and tissue 
masks were binarised with a 90% probabilistic threshold (Brown et al., 2017). These 
segmentations were also used to calculate brain parenchymal fraction, calculated as follows: (GM 
volume + WM volume) / (GM volume + WM volume + CSF volume). 
Lesions were dilated by 2 voxel layers to remove perilesional MTR abnormalities (Vrenken et al., 
2006), then subtracted from the WM segmentations to produce NAWM masks. MTR maps were 
calculated in T1-weighted image space on a voxel-by-voxel basis as follows: MTR (in pu) = (((MToff 
- MTon) / MToff) x100) using the short-echo data because of its higher signal-to-noise ratio. 
The whole brain was segmented into 12 concentric bands between the ventricular walls and pial 
surfaces using the normalised distance map derived from the Laplace equation isolines between 
the two surfaces (Yezzi and Prince, 2003; Pardini et al., 2016). The NAWM mask was 
superimposed over these bands (removing the deep GM (DGM) and cortical GM) then applied to 
the MTR maps, generating 12 bands of NAWM. Consistent with previous work using 2D MTR data 
(Brown et al., 2017), the first two (periventricular) bands were excluded to mitigate partial-
volume effects with CSF (Figure 4). 
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Figure 4: Brain segmentation into 12 concentric bands using the iterative application of the normalised 
central curve of the Laplace equation. The first 2 periventricular bands were excluded to mitigate partial 
volume effects, leaving 10 bands. Each band is represented by a different colour. 
 
Statistics 
Mean and standard error MTR (in pu) were calculated in each band, the periventricular NAWM 
(over the first 3 bands), the whole brain NAWM, the DGM and the cortical GM. Mean and 
standard error periventricular MTR gradients were calculated over the first three bands adjacent 
to the ventricles ((MTR in NAWM band 3 – MTR in NAWM band 1)/2) as previously described 
(Pardini et al., 2016). Higher periventricular gradients are more abnormal; while higher mean 
MTR values are less abnormal. 
Nested mixed-effects models adjusted for age, gender, prior relapse rate, BPF, scanner upgrade 
status and multiple comparisons compared the change in (i) periventricular NAWM MTR 
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gradients; and for comparison (ii) mean whole brain NAWM MTR and (iii) mean DGM MTR 
between the alemtuzumab and untreated groups. Further mixed-effects models adjusted for the 
same covariates compared the baseline (i) periventricular MTR gradient, (ii) mean whole brain 
NAWM MTR and (iii) mean DGM MTR between those who did or did not relapse following 
treatment with alemtuzumab. We used a 4-year cut-off (reflecting the time when half of those 
that relapsed had done so); and performed sensitivity analyses using different cut-offs. We 
previously reported the predictive value of the periventricular MTR gradient in untreated 
patients following a clinically-isolated ON (Brown et al., 2017), in which 3D MTR was used in more 
patients (n=71) compared to the present study. The present study necessarily excluded patients 
in the untreated cohort that began disease-modifying treatment before their finals scan. 
However, for completeness, we repeated our analyses in this smaller untreated cohort and 
report them seperately (p.Error! Bookmark not defined.). 
To determine whether or not changes in the periventricular MTR gradient were independent of 
lesional changes, we repeated each statistical model additionally adjusting for change in WM 
lesion number (first adjusting for change in whole brain lesion number; then adjusting for change 
in periventricular lesion number (calculated over the first 3 bands)). To explore whether changes 
in periventricular MTR gradient were distinct from more diffuse MTR changes, we additionally 
adjusted each MTR gradient model for change in periventricular NAWM MTR and whole brain 
NAWM MTR; and each mean whole brain NAWM MTR model for change in periventricular MTR 
gradient.   
Spearman rank statistics explored the correlations between (i) changes in whole brain NAWM 
MTR and periventricular MTR gradient (to further examine the relationship between the two 
metrics); and (ii) periventricular gradient and EDSS score. Statistics were performed in R (v3.3.1). 
Results were considered statistically significant at the p<0.05 level.   
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Chapter 3: Methods – The effect of 
disease-modifying therapies on 
conversion to secondary progressive 
multiple sclerosis 
Project 4  
Performed in collaboration with Alasdair Coles (joint first author); plus Dana Horakova, Eva 
Havrdova, Guillermo Izquierdo, Alexandre Prat, Marc Girard, Pierre Duquette, Maria Trojano, 
Alessandra Lugaresi, Roberto Bergamaschi, Pierre Grammond, Raed Alroughani, Raymond 
Hupperts, Pamela McCombe, Vincent Van Pesch, Patrizia Sola, Diana Ferraro, Francois 
Grand'Maison, Murat Terzi, Jeannette Lechner-Scott, Schlomo Flechter, Mark Slee, Vahid 
Shaygannejad, Eugenio Pucci, Franco Granella, Vilija Jokubaitis, Mark Willis, Claire Rice, Neil 
Scolding, Alastair Wilkins, Owen R Pearson, Tjalf Ziemssen, Michael Hutchinson, Katharine 
Harding, Joanne Jones, Christopher McGuigan, Helmut Butzkueven, Tomas Kalincik and Neil 
Robertson. 
My role: conception and design of study; analysis of data with assistance from Tomas Kalincik; 
wrote manuscript and amended following co-author and journal reviews. Contributed to data 
collection. 
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Ethical approval was granted by the Melbourne Health Human Research Ethics Committee and 
by each site’s institutional review board. All enrolled patients provided written or verbal consent, 
as per local regulations. 
 
Patients and inclusion criteria 
This international observational cohort study utilised prospectively-collected clinical data from 
three sources (all accessed in February 2017). Untreated patients were selected from the 
neuroinflammatory service database at the University Hospital of Wales, a tertiary referral centre 
in South-East Wales. Clinical data was initially collected as part of a cross-sectional study 
(Swingler and Compston, 1988) then through annual or semi-annual appointments. Treated 
patients were identified from MSBase, an observational cohort study collecting real-world data 
from patients with MS across 105 centers in 29 countries (Ingram et al., 2010). Additional 
alemtuzumab-treated patients were identified from five European non-MSBase centers using 
alemtuzumab before it was licensed (Bristol, Cardiff, Swansea, Dublin and Dresden (Kalincik et 
al., 2017a)). Within MSBase, glatiramer acetate or interferon beta, fingolimod and natalizumab 
had sufficient patient numbers with more than 4-years on-treatment follow-up (while 
teriflunomide and dimethyl-fumarate did not, so they were not included). The 4-year minimum 
follow-up period represented the longest follow-up period without excluding the majority of 
patients in MSBase treated with natalizumab or fingolimod. Data were subject to rigorous data-
quality procedures (see p.139). 
For inclusion, patients needed to be classified as RRMS (clinically definite MS (Poser et al., 1983)) 
at baseline, required the complete MSBase minimum dataset (sex, date of birth, date of clinical 
onset and dates of relapses (Butzkueven et al., 2006)), at least one EDSS score (Kurtzke, 1983) no 
more than 6 months before baseline and at least two EDSS scores after baseline (one to detect 
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disability progression and another to confirm the increase later (see definition below)). Patients 
stopping their initial therapy within 6 months were excluded (as some drugs require 6 months to 
exert their effect (Freedman et al., 2013)). The untreated cohort received no DMTs, even briefly. 
DMT dose, frequency and timing followed published protocols (He et al., 2015; Kalincik et al., 
2017a): alemtuzumab (12–24 mg intravenous once per day for 5 days [cycle 1] or for 3 days [cycle 
2 or more]); interferon-b-1a (30-250 μg subcutaneous or intramuscular injections administered 
between every other day to every other week); glatiramer acetate (20 mg subcutaneous injection 
once per day); fingolimod (0·5 mg oral once per day), and natalizumab (300 mg intravenously 
every 4 weeks). Given its administration schedule, quantifying the duration of alemtuzumab 
treatment effectiveness is challenging: first, the published period of reduced CD4 lymphocyte 
count (35 months/cycle (Hill-Cawthorne et al., 2012)) was used, and then a sensitivity analysis 
using the median period to re-treatment (7 years (Willis et al., 2016)) was performed. If patients 
received multiple DMTs, the first was used as the DMT under study (except when comparing 
early versus late escalation from interferon-b-1a or glatiramer acetate to fingolimod, 
alemtuzumab or natalizumab). Patients subsequently receiving different DMTs were excluded 
from analyses of single drugs versus untreated patients but were included in all other analyses. 
Patients receiving therapies at any time during the study period that were unlicensed were 
excluded (mitoxantrone, cladribine, rituximab, ocrelizumab, siponimod or autologous stem-cell 
transplantation). Although ocrelizumab and cladribine have subsequently been licensed, there 
were insufficient numbers meeting the minimum 4 years’ clinical follow-up criterion within 
MSBase to examine individually. 
No licensed therapies have shown greater reduction in relapse rates than natalizumab or 
alemtuzumab (Kalincik et al., 2017a). Patients receiving natalizumab or alemtuzumab who 
experienced relapses or disability-progression in this study were therefore already at the 
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therapeutic ceiling of treatment. This was replicated for patients receiving glatiramer acetate or 
interferon beta (in all analyses) by restricting inclusion to patients treated and followed-up 
before fingolimod, alemtuzumab or natalizumab became available, preventing the exclusion of 
patients who might have been prescribed these more potent therapies as first-line or escalation 
therapy during follow-up, and thereby preventing selection bias towards milder disease among 
the glatiramer acetate / interferon beta group. (During this period, mitoxantrone was 
occasionally employed as escalation therapy for particularly aggressive disease: to ensure the 
glatiramer acetate / interferon beta cohorts were not biased towards milder disease, sensitivity 
analyses including these patients were performed). Consistent with previous work, patients 
participating in clinical trials were excluded as their trial treatment assignation was not 
documented within MSBase, and trial EDSS frequencies often differ to clinical practice (Kalincik 
et al., 2017a). Patients with previous stem cell transplantation were also excluded.  
 
Study design 
To examine whether individual DMTs were associated with delayed or reduced conversion to 
SPMS, matching and analyses were repeated four times comparing untreated patients to those 
receiving initial treatment with (a) glatiramer acetate or interferon beta, (b) fingolimod, (c) 
natalizumab, or (d) alemtuzumab. In these analyses, the date of DMT commencement acted as 
the baseline date for treated patients. For untreated patients, the baseline date was the visit date 
when clinical and demographic parameters (calculated at each visit and quantified using the 
propensity score) most closely matched the corresponding baseline values of individual treated 
patients. 
Fingolimod (Cohen et al., 2010), alemtuzumab (Coles et al., 2008)  and natalizumab (Spelman et 
al., 2016) confer greater reductions in relapse rate than glatiramer acetate or interferon beta. To 
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examine whether they are associated with different effects on conversion to SPMS, patients 
receiving fingolimod, alemtuzumab or natalizumab as their initial DMT were matched and 
compared to patients initially treated with glatiramer acetate or interferon beta.  
To examine the association between timing of DMT commencement and conversion to SPMS, 
patients initially treated with glatiramer acetate or interferon beta within 5 years of disease onset 
were matched and compared with those initially treated after 5 years. For patients treated within 
5 years, the baseline was set at DMT commencement. For all patients treated after 5 years, the 
baseline was set at a visit within 5 years of symptom-onset, before therapy began, incorporating 
the period from baseline to treatment initiation into the follow-up. The date of this visit was 
identified by extracting the matching variables at each eligible visit within 5 years of symptom-
onset, then using a matching process to identify when these variables most closely matched 
those of a patient treated within 5 years.  By handling treatment exposure as a time-dependent 
variable, the analyses accounted for immortal time bias, including the untreated time from 
baseline to treatment initiation in the group treated after 5 years. This technique was repeated 
when comparing escalation from glatiramer acetate or interferon beta to fingolimod, 
alemtuzumab or natalizumab within or after 5 years of disease onset. 
 
Outcome 
The outcome in all analyses was conversion to SPMS based on an objective definition without 
functional scores (Lorscheider et al., 2016): patients required an EDSS increase (if the EDSS score 
was 5.5 or less, an increase of 1 point was required; if the EDSS score was over 5.5 an increase of 
0.5 points was required). This EDSS increase had to (i) occur in the absence of a relapse, (ii) be 
confirmed at subsequent appointments over at least 3 months; and (iii) reach an EDSS score of 4 
 or more. 
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Matching 
Using the MatchIt package (v2.4-22) the propensity of treatment was estimated using a 
multivariable logistic regression model using baseline age, sex, annualised-relapse rate in the 
year prior to baseline, EDSS score and disease duration. To minimise the difference in proportions 
of time on therapy during follow-up in the glatiramer acetate / interferon beta versus fingolimod 
/ alemtuzumab / natalizumab analysis, patients were additionally matched on the proportion of 
time on therapy during the median follow-up period (first 5.8 years). Patients in the early versus 
late escalation from glatiramer acetate / interferon beta to fingolimod / alemtuzumab / 
natalizumab analysis were also matched on disease duration at the time of starting glatiramer 
acetate or interferon beta plus the individual therapy they were escalated to. To increase 
matching precision (Rassen et al., 2012; Kalincik et al., 2017a), patients were matched in a 
variable matching ratio (10:1 to 1:1) by nearest neighbour matching using the optimal caliper (0.1 
standard deviations (SD) of the propensity score (Austin, 2011; Lunt, 2014)). Where treatment 
initiation was not used as the baseline (the late group in the early versus late glatiramer acetate 
or interferon beta and escalation analyses; and the untreated group in all untreated analyses), 
any visit could serve as baseline (to optimise matching). Consequently, multiple treatment 
periods from the same patient could be matched to different patients in the respective early or 
treated groups in these analyses.  To prevent these patients contributing disproportionately, the 
matching regression models for these analyses allowed replacement of these early or treated 
patients such that they too could also contribute multiple times to these analyses. Additionally, 
all subsequent models were weighted to account for the variable matching ratio (see below). 
Each patient’s follow-up was censored to the shortest of the two follow-up times from each set, 
resulting in identical follow-up durations between groups. Sets where either patient 
subsequently had less than two EDSS scores following baseline were excluded. 
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Statistics 
All analyses were performed using the survival package (v3.3.1) in R. Setwise weighted 
conditional proportional hazards models (Cox) clustered for matched patient sets examined the 
proportions of patients free from conversion to SPMS. All models were adjusted for EDSS 
frequency plus any variables showing residual imbalance following matching (as denoted by a 
standardised difference (quantified by Cohen’s d value) ≥ 0.2 (Cohen, 1988) (which indicates less 
than 92% overlap between the groups)). The weights were calculated as the inverse of the 
number of times a patient was included in an analysis to account for the variable matching ratio. 
The models comparing (i) glatiramer acetate or interferon beta with fingolimod, alemtuzumab or 
natalizumab, (ii) early versus late glatiramer acetate or interferon beta and (iii) early versus late 
escalation from glatiramer acetate or interferon beta to fingolimod, alemtuzumab or 
natalizumab were also adjusted for the proportion of time on therapy during the entire post-
baseline setwise-censored follow-up. The Schoenfeld’s global test was used to detect violation 
of the proportional hazards assumption (Schoenfeld, 1980); when violated, Weibull accelerated 
failure time regression models were used. To estimate the conditional hazard ratio, robust 
estimation of variance based on the Huber sandwich estimator was used. The Efron 
approximation was used to resolve tied survival times. Graphs were censored at the latest point 
that each group contained at least 10 patients or less than 10% of the original group, whichever 
came first. The percentage of patients that had converted to SPMS are presented at 5 years and 
the last year before censor in the text. Two-sided significance testing was used. Results were 
considered significant at the p<0.05 level. Because there was no adjustment for multiple 
comparisons, secondary analyses should be interpreted as exploratory. 
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Chapter 4: Results – Outside-In Gradients 
This chapter details results from the imaging studies (Projects 1-3), 
Project 1: Periventricular gradients after a clinically isolated syndrome 
This work was published in Brain, 2017: 
Brown JW*, Pardini M*, Brownlee WJ, Fernando K, Samson RS, Prados Carrasco F, et al. An 
abnormal periventricular magnetization transfer ratio gradient occurs early in multiple sclerosis. 
Brain : a journal of neurology 2017; 140(Pt 2): 387-98. *Joint First Author 
 
There were no significant demographic differences between the clinically isolated ON group and 
controls (Table 3). At the three-month scan, 55/71 (77.5%) of the ON group had WM lesions, 
46/71 (64.8%) had periventricular lesions and 22/71 (31.0%) had gadolinium-enhancing lesions. 
Thirteen patients were lost to follow-up. After two years, 18/58 (31%) had experienced a further 
clinical relapse and so developed CDMS while 40/58 (69%) had McDonald MS. Five years after 
ON, these figures had risen to 31/58 (53.5%) and 45/58 (77.6%) respectively. 
 
 
 Healthy 
Controls 
People with optic neuritis 
N N = 37 N = 71 
Mean age, years ± SD (range) 34.4 ± 4.8 (27-
47) 
33.5 ± 6.7 (20-48) 
Female : male  25 : 12 49 : 22 
Median baseline EDSS (range) - 1 (0-3) 
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Number with abnormal T2 scan 
(excluding symptomatic lesion) 
- 55 
Number with periventricular lesions - 46 
Number with Gd-enhancing lesions - 22 
Mean T2 lesion volume (ml) ± SD - 1.47 ± 3.32 
Mean brain parenchymal fraction ± SD 0.84 ± 0.04 0.85 ± 0.03 
Number attaining CDMS at time of MTR 
scan 
- 8 
Number attaining McDonald MS at time 
of MTR scan 
- 33 
Number with clinical follow-up at two 
and five years 
- 58 
Number converting to CDMS within two 
years of ON (of 58 with clinical follow up) 
- 18 
Number converting to McDonald MS 
within two years of ON (of 58 with 
clinical follow up) 
- 40 
Number converting to CDMS within five 
years of ON (of 58 with clinical follow up) 
- 31 
Number converting to McDonald MS 
within five years of ON (of 58 with 
clinical follow up) 
- 45 
Median (range) EDSS score at five year 
follow-up (assessed in 50/58) 
- 1 (0-8.5) 
Median (range) PASAT score at five years 
follow-up (assessed in 31/58) 
- 46.5 (17-59) 
Table 3: Baseline demographics. In the optic neuritis group, MTR scans were undertaken three months 
after first enrolment in the study, and so lesion measures from scans obtained at three months are shown. 
Volumetric brain scans were acquired at baseline but not three months. CDMS = clinically definite multiple 
sclerosis. EDSS = Expanded Disability Status Scale.  ON = optic neuritis. PASAT = paced serial addition test, 
3 second intervals. SD = standard deviation.   
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Table 4: Mean band MTR in healthy controls and patients with optic neuritis. Independent sample t-tests 
were used to compare the healthy control and whole optic neuritis groups; one-way ANOVA to compare 
the optic neuritis subgroups. pu = percentage units; ns = not significant. Bold P-values < 0.05. 
Band Mean ± SE MTR in pu Mean ± SE MTR in pu 
 Healthy controls 
(n=37) 
All Optic Neuritis 
(n=71) 
Optic Neuritis subgroups 
 Converted to 
CDMS <2y 
(n=18) 
Converted to 
CDMS 2-5y 
(n=13) 
Did not convert 
to CDMS 
(n=27) 
1 38.364 ± 0.138 37.670 ± 0.102 
p = 0.000 
37.371 ± 0.183 
p = 0.000 
37.831 ± 0.180 
p = 0.062 
37.805 ± 0.203 
p = 0.013 
2 38.334 ± 0.113 37.836 ± 0.085 
p = 0.001 
37.639 ± 0.166  
p = 0.001 
37.773 ± 0.205  
p = 0.020 
37.951 ± 0.156  
p = 0.043 
3 38.254 ± 0.095 37.912 ± 0.080 
p = 0.007 
37.862 ± 0.176  
p = ns 
37.946 ± 0.209  
p = ns 
37.903 ± 0.133  
p = ns 
4 38.293 ± 0.080 37.959 ± 0.075 
p = 0.003 
37.944 ± 0.158  
p = ns 
37.942 ± 0.190  
p = ns 
37.918 ± 0.132  
p = ns 
5 38.232 ± 0.080 37.936 ± 0.076 
p = 0.009 
37.901 ± 0.163 
p = ns 
37.916 ± 0.204 
p = ns 
37.859 ± 0.126 
p = ns 
6 38.109 ± 0.087 37.827± 0.077 
p = 0.017 
37.822 ± 0.162  
p = ns 
37.807 ± 0.209  
p = ns 
37.765 ± 0.129  
p = ns 
7 38.006 ± 0.083 37.751 ± 0.074 
p = 0.025 
37.751 ± 0.166  
p = ns 
37.772 ± 0.194  
p = ns 
37.706 ± 0.124  
p = ns 
8 38.024 ± 0.084 37.774 ± 0.073 
p = 0.027 
37.754 ± 0.174  
p = ns 
37.805 ± 0.192  
p = ns 
37.740 ± 0.115  
p = ns 
9 38.113 ± 0.084 37.864 ± 0.075 
p = 0.030 
37.805 ± 0.187 
p = ns 
37.942 ± 0.192 
p = ns 
37.822 ± 0.117 
p = ns 
10 38.187 ± 0.085 37.952 ± 0.078 
p = 0.044 
37.850 ± 0.191 
p = ns 
38.048 ± 0.198 
p = ns 
37.945 ± 0.123 
p = ns 
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Periventricular MTR gradients in ON compared with controls 
Table 4 and Figure 5 show the mean and standard error (SE) NAWM MTR per band in the ON and 
control groups. The mean MTR of each NAWM band was lower in the ON group than in healthy 
controls. In controls, mean MTR was highest in the bands nearest the ventricles and declined 
with distance from them. In contrast, in the ON group, mean MTR was lowest in the band nearest 
the ventricles, increased over the first 5mm and then paralleled control values. 
 
Over the first 5mm from the ventricles, we found significantly different MTR gradients between 
the ON and control groups (ON: mean +0.059 pu/mm ± 0.028; controls mean -0.033 pu/mm ± 
0.028, t=-2.62, p=0.010). This difference remained significant after adjustment for BPF (p=0.009). 
Conversely, the MTR gradient over the next five bands showed no significant difference between 
the groups (ON: +0.003 pu/mm ± 0.008, controls -0.009 pu/mm ± 0.012, p=0.541). 
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Figure 5: Normal-appearing white matter (NAWM) MTR of bands in healthy controls (HC - blue) and people 
with optic neuritis 4.6 months after symptom onset (ON - red). Mean ± 2 standard error (SE).  MTR is 
expressed as percentage units (pu). Band 1 is closest to the ventricular surface. 
 
 
Associations of periventricular MTR gradients with lesions 
In the ON group, over the first 5mm periventricular MTR gradients did not differ significantly 
between those with or without brain WM lesions seen on a T2-weighted scan from the same 
scanning session (+0.058 pu/mm ± 0.024 vs +0.063 pu/mm ± 0.043 respectively, p=0.918), Figure 
6. The periventricular MTR gradient in the ON group who did not have brain lesions showed a 
non-significant trend to be higher than healthy controls (+0.063 pu/mm ± 0.043 vs -0.033 pu/mm 
± 0.028 respectively, p=0.064).  
Periventricular bands 
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Figure 6: Normal appearing white matter (NAWM) MTR in healthy controls (HC - blue) and people with 
optic neuritis 4.6 months after symptom onset (ON), divided into those with (green) and without (yellow) 
lesions on their baseline scan. Mean ± 2 standard errors (SE) is shown. MTR is expressed as percentage 
units (pu). Band 1 is closest to the ventricular surface. 
 
The presence of periventricular lesions seen on a T2-weighted scan had no significant effect on 
the periventricular gradient (0.068 pu/mm ± 0.028 (with periventricular lesions) vs 0.043 pu/mm 
± 0.030 (without periventricular lesions), p=0.580, Figure 7). The mean gradient in those with and 
without gadolinium-enhancing lesions similarly did not differ significantly (0.067 pu/mm ± 0.040 
vs 0.055 pu/mm ± 0.025 respectively, p=0.794). 
 
 
Associations of periventricular MTR gradients with conversion to MS and disability  
Table 5 and Figure 8 show the gradients over the first and second 5mm of NAWM extending from 
the ventricles in the ON groups who did or did not develop CDMS within two years. 
Periventricular bands 
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Figure 7: Normal appearing white matter (NAWM) MTR in people with optic neuritis 4.6 months after 
symptom onset (ON) plus lesions, divided into those with (n=46, green circles) and without (n=9, yellow 
circles) periventricular lesions. Mean ± 2 standard error (SE). MTR is expressed as percentage units (pu). 
Band 1 is closest to the ventricular surface. 
Clinical classification at 2 years N 
MTR gradient 
mean ± SE (pu/mm) 
Periventricular 
(1 to 5 mm) 
Deep 
(6 to 10 mm) 
Healthy controls 37 -0.033 ± 0.028 -0.009 ± 0.012
Optic 
Neuritis 
Did not convert to CDMS 40 0.016 ± 0.029 0.020 ± 0.010 
Converted to CDMS 18 0.132 ± 0.041* -0.010 ± 0.019
Did not convert to McDonald MS 18 0.015 ± 0.048 0.021 ± 0.015 
Converted to McDonald MS 40 0.069 ± 0.028** 0.006 ± 0.011 
Table 5: Periventricular (1-5mm) and deep (6-10mm) MTR gradients in normal appearing white matter 
(NAWM) of people with optic neuritis (ON) and healthy controls (HC). Optic neuritis group divided 
according to conversion to clinically definite multiple sclerosis (CDMS) status within two years. *Converters 
vs. healthy controls p=0.001, converters vs. non-converters: p=0.020, non-converters vs. healthy controls 
p=0.221). Optic neuritis group also divided according to conversion to McDonald MS within two years. 
**converters vs healthy controls p=0.014; otherwise, no significant differences in gradients detected. 
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Figure 8: Normal appearing white matter (NAWM) MTR in healthy controls (HC - blue) and people with 
optic neuritis 4.6 months after symptom onset (ON), divided into those who did convert to clinically definite 
multiple sclerosis (CDMS) within two years (gold) and those that did not (green). Mean ± 2 standard errors 
(SE) is shown. MTR is expressed as percentage units (pu). Band 1 is closest to the ventricular surface. 
The periventricular MTR gradient in the group who developed CDMS within two years differed 
from healthy controls and the ON group who did not convert to CDMS within two years (Table 5; 
overall effect p=0.006; converters vs. healthy controls p=0.001, converters vs. non-converters 
p=0.020, non-converters vs. healthy controls p=0.221). The periventricular MTR gradient also 
differed between those who converted to CDMS within five years and healthy controls, while the 
difference between converters and non-converters did not reach significance; overall effect 
p=0.026; converters vs. healthy controls p=0.007, converters vs. non-converters p=0.123, non-
converters vs. healthy controls p=0.304). The differences between those who developed MS and 
HC remained significant when McDonald MRI criteria were used instead of CDMS (Table 5). The 
group effect on the periventricular MTR gradient did not materially change after including BPF in 
Periventricular bands 
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the statistical models. The group effect on the periventricular MTR gradient also remained 
significant after adjustment for mean NAWM MTR (p=0.014) and mean GM MTR (p=0.022). 
When both NAWM MTR and GM MTR were added, the model remained significant (p=0.021) as 
did differences in MTR gradients between converters and non-converters (p=0.037) and between 
converters and healthy controls (p=0.006). 
 
We also examined whether or not periventricular MTR gradients over 1-5mm had an effect on 
conversion to CDMS independent of the presence of lesions. A multivariate binary logistic 
regression showed that the MTR gradient over 1-5mm was independently associated with 
conversion to CDMS at two years (MTR gradient: odds ratio (OR) 61.708 p=0.023; presence of T2 
lesions OR 8.500 p=0.071). A similar pattern was seen when the MTR gradient was compared to 
periventricular T2 lesions (MTR gradient: OR 44.100 p=0.029; presence of periventricular T2 
lesions OR 5.84 p=0.040). However, the MTR gradient did not predict conversion to CDMS over 
five years. 
 
There was no significant difference in 6-10 mm MTR gradients between ON groups who did or 
did not develop CDMS at two or five years (p=0.124 and p=0.231 respectively). 
 
Unlike the periventricular MTR gradient, the mean MTR of band 1 or 5 in the ON group converting 
to CDMS within 2 years was not significantly higher than in those not converting to CDMS (see 
p.97). 
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Associations of MTR gradient, mean NAWM MTR and mean GM MTR with disability.  
A weak correlation was found between the MTR gradient over the first 5mm and EDSS status five 
years later (Spearman r=0.313, p=0.027; EDSS measured in 50/58 patients at this time point). No 
significant correlation was found between inner MTR gradient and PASAT score at five years 
(p=0.815), although this was only undertaken in 31/58 patients at this time point. 
No significant correlations were found between EDSS five years later and mean MTR in band 1 
(p=0.165) or band 5 (p=0.540), NAWM MTR (p=0.506) or GM MTR (p=0.109). 
 
Lesion measures 
The mean MTR of lesional voxels, like the NAWM MTR, was lowest at the ventricular margin and 
increased with distance from it (see Figure 9). The percentage of lesional WM per band is shown 
in Figure 10.  
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Figure 9: Mean MTR of white matter (WM) lesional voxels in patients with optic neuritis 4.6 months after 
symptom onset (ON). Mean ± 2 standard error (SE). MTR is expressed as percentage units (pu). Band 1 is 
closest to the ventricular surface. 
 
Periventricular bands 
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Figure 10: Percentage of lesional white matter (WM) per band in patients with optic neuritis 4.6 months 
after symptom onset (ON). Mean ± 2 standard error (SE). Band 1 is closest to the ventricular surface. 
 
  
Periventricular bands 
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Comparative results: capability of mean MTR in band 1 and band 5 for predicting conversion to 
CDMS and EDSS at 5 years 
 
Conversion to CDMS – band 1. 
In one-way ANOVA, the mean MTR of band 1 in the ON group who developed CDMS within two 
years was significantly smaller than in healthy controls, but was not significantly different when 
compared to the ON group who did not develop CDMS within two years (converters vs healthy 
controls p=0.000; converters vs non-converters p=0.077; non-converters vs healthy controls 
 People with optic neuritis Significance 
People with clinical 
follow-up 
People without 
clinical follow-up 
 
N N = 58 N = 13  
Mean age, years ± SD (range) 33.5 ± 6.4 (27-48) 33.6 ± 8.1 (21-46) p = 0.966 
female : male  40 : 18 9 : 4 p = 1.000 
Median baseline EDSS (range) 1 (0-3) 1 (0-2) p = 0.585 
Number with abnormal T2 scan 
(excluding symptomatic lesion) 
46 9 p = 0.471 
Number with periventricular lesions 40 6 p = 0.197 
Number with Gd-enhancing lesions 19 3 p = 0.741 
Mean brain parenchymal fraction ± SD 0.85 ± 0.04 0.85 ± 0.03 p = 0.388 
Mean inner MTR gradient ± SE 0.05 ± 0.02 0.09 ± 0.04 p = 0.378 
Table 6: Comparison of baseline clinical and radiological demographics in those with and without follow 
up at two and five years. 
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p=0.007). The results for conversion at five years were broadly similar (converters vs healthy 
controls p=0.000; converters vs non-converters p=0.301; non-converters vs healthy controls 
p=0.014). 
 
Conversion to CDMS – band 5. 
In one-way ANOVA, the mean MTR of band 5 in the ON group who developed CDMS within two 
years was not significantly smaller than in healthy controls or the ON group who did not develop 
CDMS within two years (converters vs healthy controls p=0.062; converters vs non-converters 
p=0.893; non-converters vs healthy controls p=0.012). The results at five years were broadly 
similar (converters vs healthy controls p=0.031; converters vs non-converters p=0.764; non-
converters vs healthy controls p=0.017). 
 
Disability 
We found no correlation between the mean MTR values in bands 1 and 5 with EDSS score at five 
years (p=0.165 and p=0.540 respectively).  
 
 
Effect of conversion to CDMS before MTR scan. 
As a confirmatory analysis we excluded those 8 ON subjects who converted to MS in the 3 month 
interval between the baseline clinical MRI and the MTR acquisition. Despite the reduced power, 
the pattern in group differences in periventricular MTR gradients was maintained: ON vs healthy 
controls (0.050 pu/mm ± 0.022 vs. -0.033 pu/mm ± 0.028, p=0.022); ON converting to CDMS 
within two years vs HC (0.114 pu/mm ±0.051 vs. -0.033 pu/mm ± 0.028, p=0.016); ON converting 
to CDMS within two years vs non-converters (0.114 pu/mm ± 0.051 vs. 0.016 pu/mm ± 0.028, 
p=0.102). 
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MTR gradient threshold calculations 
The range of periventricular MTR gradients found in those who developed CDMS within 2 years 
(-0.20 to 0.40 pu/mm) compared to those who did not (-0.41 to 0.62 pu/mm) - and in those who 
developed McDonald MS within two years (-0.41 to 0.40 pu/mm) compared to those who did not 
(-0.35 to 0.62 pu/mm) - overlapped substantially, and there was no clear cut off beyond which 
conversion from a CIS to MS was inevitable. The same pattern was seen when examining 
conversion versus no conversion at 5 years (CDMS: -0.41 to 0.40 pu/mm; -0.35 to 0.62 pu/mm) 
(McDonald MS: -0.41 to 0.40 pu/mm; -0.35 to 0.62 pu/mm).  
 
When we used the mean MTR gradient of the group who did not develop CDMS within 2 years 
as a cut-off (n=40), 13/18 (72%) of those converting to CDMS within 2 years had a greater MTR 
gradient; if a mean + 1 SD threshold is used, 7/18 (39%, expected by chance 16%); and greater 
than the mean + 2 SD 1/18 (6%, expected by chance 2%). In comparison, the proportion of 
controls exceeding these thresholds were: mean 14/37 (38%); mean + 1 SD 3/37 (8%); mean + 2 
SD 1/37 (3%). When we repeated this using the mean MTR gradient of controls as the threshold 
(n=37), 15/18 (83%) of those converting to CDMS within 2 years had a greater MTR gradient 
compared to 26/40 (65%) of those not converting within 2 years; if a mean + 1 SD threshold was 
used, respectively 9/18 (50%) and 9/40 (23%) exceeded the threshold, and greater than the mean 
+ 2 SD 4/18 (22%) and 1/40 (3%). 
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Project 2: Periventricular and cortical gradients in progressive 
multiple sclerosis 
This work was published in Multiple Sclerosis Journal, 2019: 
Brown JW*, Chowdhury A*, Kanber B, Prados F, Eshaghi A, Sudre C, et al. Magnetisation transfer 
ratio abnormalities in primary and secondary progressive multiple sclerosis. Multiple Sclerosis 
Journal. [Accepted; In Press] *Joint First Author 
 
Imaging was performed in 51 healthy controls (12 with follow-up imaging after median 2.1 (range 
1.5 – 2.7) years), 28 people with PPMS (14 with follow-up imaging after median 2.3 (range 1.2 – 
3.5) years) and 35 people with SPMS (15 with follow-up imaging after median 1.6 (range 1.1 – 
2.4) years). The control group were younger than either progressive group (Table 7), and the 
SPMS group had a greater proportion of females than the PPMS and control groups (all models 
were adjusted for age, gender and either NAWM volume or CGM volume).  
 
The MTR in each band was greater in healthy controls compared to those with PPMS and SPMS 
(Figure 11, Figure 12). The NAWM periventricular gradient was significantly shallower in healthy 
controls (0.122 ± 0.038 pu/band) compared to those with both PPMS (0.952 ± 0.185 pu/band, p 
< 0.0001) and SPMS (1.360 ± 0.143 pu/band, p < 0.0001), Table 8, Figure 13.  
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 Healthy controls 
People with progressive multiple 
sclerosis 
 N = 51 PPMS N = 28 
SPMS 
N = 35 
Mean age, years ± SD 41.7 ± 12.6 52.5 ± 9.3 53.9 ± 7.2 
Female : male  27 : 24 18 : 10 26 : 9 
Mean disease duration, y ± SD N/A 13.61 ± 7.39 22.6 ± 10.33 
Median (range) baseline EDSS N/A 6 (3 – 8) 6 (4 – 8.5) 
Number (%) with radiological 
follow-up 
12 (24%) 14 (50%) 15 (43%) 
Median (range) interval between 
MRI scans, years 
2.1 (1.5 – 2.7) 2.3 (1.2 – 3.5) 1.6 (1.1 – 2.4) 
Median (range) EDSS at follow-up N/A 6 (2.5 – 8) 6.5 (5 – 8.5) 
Table 7: Participant baseline demographics. SD=standard deviation. EDSS=Expanded Disability Status 
Scale; NA=not available. 
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Figure 11: Mean MTR per band for healthy controls (circles), people with primary progressive multiple 
sclerosis (PPMS – triangles) and people with secondary progressive multiple sclerosis (SPMS – squares) in 
normal-appearing white matter (NAWM). Error bars = 2 standard errors. MTR expressed in percentage 
units (pu). Band 1 is closest to the ventricular surface. Band 10 is closest to the cortical surface. 
Periventricular gradients measured in NAWM over bands 1-3, and cortical gradients measured in cortical 
GM over bands 8-10. 
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Figure 12: Mean MTR per band for healthy controls (circles), people with primary progressive multiple 
sclerosis (PPMS – triangles) and people with secondary progressive multiple sclerosis (SPMS – squares) in 
cortical grey matter (GM). Error bars = 2 standard errors. MTR expressed in percentage units (pu). Band 2 
is closest to the cortical surface. Cortical gradients measured in cortical GM over bands 1-2. 
 
 
  
	 	 105	
 Healthy Controls Progressive Multiple Sclerosis 
 All, N = 51 PPMS, N = 28 SPMS, N = 35 
Mean periventricular NAWM MTR gradient ± SE 
  -baseline (pu/band) 
  -annual change (pu/band/year) 
 
0.122 ± 0.038 
-0.011 ± 0.051 
 
0.952 ± 0.185 
0.090 ± 0.040 
 
1.360 ± 0.143 
0.021 ± 0.030 
Mean NAWM MTR ± SE 
  -baseline (pu) 
  -annual change (pu/year) 
 
39.779 ± 0.111 
-0.289 ± 0.150 
 
38.254 ± 0.281 
-0.231 ± 0.107 
 
38.282 ± 0.143 
-0.446 ± 0.099 
Mean NAWM volume ± SE 
  -baseline (cm3) 
  -annual change (cm3/year) 
 
460.091 ± 6.665 
-4.671 ± 3.973 
 
415.386 ± 10.490 
-1.248 ± 0.442 
 
383.094 ± 7.337 
-1.314 ± 0.541 
Mean cortical GM MTR gradient ± SE 
  -baseline (pu) 
  -annual change (pu/band/year) 
 
-2.860 ± 0.051 
0.090 ± 0.146 
 
-3.214 ± 0.103 
-0.018 ± 0.039 
 
-3.328 ± 0.101 
0.037 ± 0.009 
Mean cortical GM MTR ± SE 
  -baseline (pu) 
  -annual change (pu/year) 
 
32.183 ± 0.093 
-0.071 ± 0.239 
 
30.998 ± 0.206 
-0.238 ± 0.090 
 
30.556 ± 0.154 
-0.346 ± 0.097 
Mean CGM volume ± SE 
  -baseline (cm3) 
  -annual change (cm3/year) 
 
612.545 ± 7.463 
-5.490 ± 5.393 
 
570.030 ± 12.886 
-3.427 ± 1.071 
 
534.389 ± 8.917 
-1.363 ± 0.888 
Mean brain parenchymal fraction ± SE 
  -baseline 
  -annual change 
 
0.761 ± 0.001 
0.001 ± 0.001 
 
0.738 ± 0.004 
-0.001 ± 0.001 
 
0.726 ± 0.003 
-0.001 ± 0.001 
Mean T2 lesion number ± SE 
  -baseline 
  -annual change 
 
N/A 
N/A 
 
41.1 ± 5.8 
-3.3 ± 1.3 
 
43.2 ± 4.1 
-2 ± 1.5 
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Table 8: Imaging outcomes at baseline and annualised changes during follow-up in healthy controls, people with primary progressive multiple sclerosis (PPMS) 
and people with secondary progressive multiple sclerosis (SPMS). BPF=brain parenchymal fraction. GM=grey matter. NAWM=normal appearing white matter. 
SE=standard error. MTR is expressed as percentage units (pu). 
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Figure 13: Mean periventricular gradient in normal-appearing white matter (NAWM) in healthy controls, 
people with primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis 
(SPMS). Error bars = 2 standard errors. MTR gradients expressed in percentage units per band (pu/band). 
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These differences persisted when the models were additionally adjusted for mean NAWM MTR 
(p = 0.015  and p < 0.0001 respectively) and when the models were adjusted for BPF instead of 
NAWM volume (p < 0.001 and p = 0.003 respectively). No significant differences in periventricular 
gradient were found between people with PPMS and SPMS (p = 0.444), including after 
adjustment for mean NAWM MTR (p = 0.191) or when covarying for BPF instead of NAWM 
volume (p = 0.604). The cortical gradient was significantly shallower in healthy controls (-2.860 ± 
0.051 pu/band) compared with both PPMS (-3.214 ± 0.103 pu/band, p = 0.038) and SPMS (-3.328 
± 0.101 pu/band, p = 0.016), Figure 14. These differences lost significance when the models were 
additionally adjusted for mean cortical GM MTR (p = 0.570 and p = 0.589  respectively), and when 
the models covaried for BPF instead of cortical volume (p = 0.575 and p = 0.530 respectively). 
When the MS and healthy control groups were limited to those analysed previously (Samson et 
al., 2014) the results were consistent with those previously seen: a significant difference was 
seen between healthy controls and SPMS (p=0.030) but not PPMS (p = 0.150). No significant 
differences in cortical gradient were found between people with PPMS and SPMS (p = 0.372), 
including after adjustment for mean cortical MTR (p = 0.915).  
The baseline demographics and imaging outcomes (including model results) for people with 
RRMS are presented in Table 10 and Table 11. 
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Figure 14: Mean cortical gradient in cortical grey matter (GM) in healthy controls, people with primary 
progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS). Error bars = 2 
standard errors. MTR gradients expressed in percentage units per band (pu/band). 
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When all people with MS were grouped (RRMS, SPMS, PPMS), both the periventricular and 
cortical gradients showed very weak correlations with EDSS score (b 0.100, p=0.011; and b -
0.082, p=0.001 respectively) and disease duration (b 0.023, p=0.005; and b -0.015, p=0.004 
respectively) but not time from last relapse (b 0.021, p=0.357; and b -0.011, p=0.554). These 
associations did not materially change when additionally adjusted for clinical classification (Table 
9). Results for each disease subgroup are shown in Table 9.  A significant association was found 
between the periventricular gradient and cortical gradient (b -0.609, p<0.0001) which remained 
unchanged after additionally adjusting for disease group (Table 9).  
 
In those with radiological follow-up (Table 8), the annualised change in periventricular gradient 
was not significantly different between healthy controls -0.011 ± 0.051 pu/band/year) and 
people with either PPMS (0.090 ± 0.040 pu/band/year, p = 0.951) or SPMS (0.021 ± 0.030 
pu/band/year, p = 0.473). Including change in mean NAWM MTR in the model did not materially 
alter the results (p = 0.882 and p = 0.343, respectively). Similarly, no change in the annualised 
rate of change in cortical gradient was seen between healthy controls (0.090 ± 0.146 
pu/band/year) and people with either PPMS (-0.018 ± 0.039 pu/band/year, p = 0.553) or SPMS 
(0.037 ± 0.009 pu/band/year, p = 0.913). Including change in mean cortical GM MTR in the model 
did not materially alter the results (p = 0.964 and p = 0.350, respectively).
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 Coefficient  
(p-value) 
PPMS 
N = 28 
SPMS 
N = 35 
RRMS 
N = 56 
All MS patients 
 
 No adjustment for 
clinical classification 
Adjusted for clinical 
classification 
Periventricular NAWM MTR 
gradient 
Cortical GM MTR gradient -0.497 
P = 0.139 
-0.411 
P = 0.089 
-0.738 
P = 0.0001 
-0.609 
P < 0.0001 
-0.585 
P < 0.0001 
Periventricular NAWM MTR 
gradient 
Disease duration, years 
 
 
EDSS score 
 
 
Time from last relapse, years 
-0.024 
P = 0.325 
 
0.126 
P = 0.344 
 
N/A 
0.016 
P = 0.244 
 
-0.103 
P = 0.473 
 
0.027 
P = 0.417 
0.039 
P = 0.005 
 
0.127 
P = 0.039 
 
4.902 
P = 0.729 
0.023 
P = 0.005 
 
0.100 
P = 0.011 
 
0.021 
P = 0.357 
0.019 
P = 0.036 
 
0.096 
P = 0.065 
 
0.019 
P = 0.502 
Cortical GM MTR gradient Disease duration, years 
 
 
EDSS score 
 
 
Time from last relapse, years 
-0.0002 
P = 0.99 
 
-0.098 
P = 0.199 
 
N/A 
-0.022 
P = 0.024 
 
-0.076 
P = 0.470 
 
-0.002 
P = 0.943 
-0.008 
P = 0.392 
 
-0.067 
P = 0.112 
 
-0.389 
P = 0.975 
-0.015 
P = 0.004 
 
-0.082 
P = 0.001 
 
-0.011 
P = 0.554 
-0.012 
P = 0.041 
 
-0.073 
P = 0.033 
 
-0.191 
P = 0.422 
Table 9: Model results comparing gradients with (i) other gradients; and (ii) clinical associations 
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Baseline demographics of patients including those with RRMS 
 Healthy controls People with multiple sclerosis 
 N = 51 
PPMS 
N = 28 
SPMS 
N = 35 
RRMS 
N = 56 
Mean age, years ± SD 41.7 ± 12.6 52.5 ± 9.3 53.9 ± 7.2 42 ± 9.7 
Female : male  27 : 24 18 : 10 26 : 9 39 : 17 
Mean disease 
duration, years ± SD 
N/A 13.61 ± 7.39 22.6 ± 10.33 11.5 ± 8.1 
Median (range) EDSS 
at baseline  
N/A 6 (3 – 8) 6 (4 – 8.5) 2 (1 – 7) 
Number (%) with 
radiological follow-up 
12 (24%) 14 (50%) 15 (43%) 29 (52%) 
Median (range) 
interval between MRI 
scans, years 
2.1 (1.5 – 2.7) 2.3 (1.2 – 3.5) 1.6 (1.1 – 2.4) 1.8 (0.9 – 2.8) 
Median (range) EDSS 
at follow-up 
N/A 6 (2.5 – 8) 6.5 (5 – 8.5) 1.5 (1 – 6) 
Table 10: Participant baseline demographics. SD=standard deviation. EDSS=Expanded Disability Status 
Scale; N/A=not available. 
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 Comparison of progressive and relapsing multiple sclerosis: imaging outcomes 
 Healthy Controls Multiple Sclerosis 
 All (N = 51) PPMS (N = 28) SPMS (N = 35) RRMS (N = 56) 
Mean periventricular NAWM MTR gradient ± SE 
  -baseline (pu/band) 
  -annual change (pu/band/year) 
 
0.122 ± 0.038 
-0.011 ± 0.051 
 
0.952 ± 0.185 
0.090 ± 0.040 
 
1.360 ± 0.143 
0.021 ± 0.030 
 
1.031 ± 0.117 
0.046 ± 0.069 
Mean NAWM MTR ± SE 
  -baseline (pu) 
  -annual change (pu/year) 
 
39.779 ± 0.111  
-0.289 ± 0.150  
 
38.254 ± 0.281  
-0.231 ± 0.107 
 
38.282 ± 0.143  
-0.446 ± 0.099 
 
38.780 ± 0.142 
0.032 ± 0.139 
Mean NAWM volume ± SE 
  -baseline (cm3) 
  -annual change (cm3/year) 
 
460.091 ± 6.665 
-4.671 ± 3.973 
 
415.386 ± 10.490 
-1.248 ± 0.442 
 
383.094 ± 7.337 
-1.314 ± 0.541  
 
413. 295 ± 7.477 
-0.611 ± 0.515 
Mean cortical GM MTR gradient ± SE 
  -baseline (pu) 
  -annual change (pu/band/year) 
 
-2.860 ± 0.051 
0.090 ± 0.146 
 
-3.214 ± 0.103 
-0.018 ± 0.039 
 
-3.328 ± 0.101 
0.037 ± 0.009 
 
-3.072 ± 0.058 
0.047 ± 0.070 
Mean cortical GM MTR ± SE 
  -baseline (pu) 
  -annual change (pu/year) 
 
32.183 ± 0.093  
-0.071 ± 0.239 
 
30.998 ± 0.206  
-0.238 ± 0.090 
 
30.556 ± 0.154  
-0.346 ± 0.097 
 
31.509 ± 0.140 
-0.145 ± 0.148 
Mean CGM volume ± SE 
  -baseline (cm3) 
  -annual change (cm3/year) 
 
612.545 ± 7.463 
-5.490 ± 5.393 
 
570.030 ± 12.886 
-3.427 ± 1.071 
 
534.389 ± 8.917 
-1.363 ± 0.888 
 
570.364 ± 8.241 
-2.668 ± 0.741  
Mean brain parenchymal fraction ± SE 
  -baseline 
  -annual change 
 
0.761 ± 0.001 
0.001 ± 0.001 
 
0.738 ± 0.004 
-0.001 ± 0.001 
 
0.726 ± 0.003 
-0.001 ± 0.001 
 
0.743 ± 0.002 
-0.001 ± 0.000 
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 Mean T2 lesion number ± SE 
  -baseline 
  -annual change 
 
N/A 
N/A 
 
41.1 ± 5.8 
-3.3 ± 1.3 
 
43.2 ± 4.1 
-2 ± 1.5 
 
42.6 ± 4.1 
0.3 ± 0.8 
Table 11: Imaging outcomes at baseline and annualised changes during follow-up in healthy controls, people with primary progressive multiple sclerosis 
(PPMS), people with secondary progressive multiple sclerosis (SPMS) and people with relapsing-remitting multiple sclerosis (RRMS). BPF=brain parenchymal 
fraction. GM=grey matter. NAWM=normal appearing white matter. SE=standard error. MTR is expressed as percentage units (pu). 
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The NAWM periventricular gradient was significantly shallower in healthy controls (0.122 ± 0.038 
pu/band) compared to those with RRMS (1.031 ± 0.117 pu/band, p < 0.0001). This persisted when 
the model was additionally adjusted for mean NAWM MTR (p = 0.002) or when adjusted for BPF 
instead of NAWM volume (p = 0.034). The cortical gradient was significantly shallower in healthy 
controls (-2.860 ± 0.051 pu/band) compared to RRMS (-3.072 ± 0.058 pu/band, p = 0.030). These 
differences lost significance when the model was additionally adjusted for mean cortical GM MTR 
(p = 0.668) or when the model covaried for BPF instead of cortical volume (p = 0.975).   
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Project 3: Periventricular gradient evolution following peripheral 
immunotherapy 
This work was published in Multiple Sclerosis Journal, 2019: 
Brown JW*, Prados F*, Eshaghi A, Sudre C, Button T, Pardini M, et al. Periventricular 
magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab. 
Multiple Sclerosis Journal. [Accepted; In Press] *Joint First Author 
 
Seven patients in the natural history cohort received beta-interferon before the last scan so were 
excluded. One patient in the alemtuzumab cohort did not complete the imaging protocol so was 
excluded, leaving 34 for analysis (19 treated and 15 untreated patients). Baseline demographics 
were comparable between the groups (Table 12) except age (alemtuzumab group 32.8 years, 
untreated group 37.5 years) and prior annualised relapse rate (alemtuzumab group 2.73 
relapses/year, untreated group 1.72 relapses/year): all models were adjusted for these variables. 
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 Untreated Alemtuzumab-treated 
 
 
 
N=15 
All 
 
N=19 
With further 
relapse within 4 
years 
N=4 
Without further 
relapse within 4 
years 
N=15 
Mean age, years ± SD 37.5 ± 7 32.8 ± 9.5 29.9 ± 2.3 33.6 ± 7.7 
Female : male  10 : 5 13 : 6 3 : 1 10 : 5 
Mean disease duration, 
years ± SD 
1.69 ± 0.72 1.59 ± 0.77 2.03 ± 1.19 1.48 ± 0.62 
Mean annualised relapse 
rate ± SD 
1.72 ± 1.03 2.73 ± 1.28 2.92 ± 1.01 2.68 ± 1.38 
Median EDSS (range) 1 (0-4) 1.5 (0-3) 2.25 (0-2.5) 1.5 (0-3) 
Table 12: Participant baseline demographics. SD=standard deviation. EDSS=Expanded Disability Status 
Scale 
 
Evolution over time: alemtuzumab versus untreated groups 
The mean MTR in each band decreased (became more abnormal) in the untreated group with 
time but increased (became less abnormal) in the alemtuzumab group (Figure 15).  
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Figure 15: Normal appearing white matter (NAWM) MTR in untreated patients and patients treated with 
alemtuzumab. MTR is expressed as percentage units (pu). Band 1 is closest to the ventricles. 
 
The mean periventricular MTR gradient worsened (increased) in the untreated group by 0.030 ± 
0.025pu/band/year but improved (decreased) in the alemtuzumab group by -0.045 ± 
0.016pu/band/year (Table 8, Figure 16). The rate of change was significantly different between 
the groups (p=0.028) and did not materially change  after adjustment for change in whole-brain 
lesion number (p=0.037) or periventricular lesion number (p=0.050) but lost significance when 
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adjusted for change in periventricular NAWM MTR (p=0.124) or whole brain NAWM MTR 
(p=0.195). While the mean NAWM MTR, mean DGM MTR and mean cortical GM MTR decreased 
(becoming more abnormal) in the untreated group (-0.183 ± 0.030 pu/year; -0.394 ± 0.122 
pu/year and -0.261 ± 0.032 pu/year respectively), all stabilised or improved following 
alemtuzumab treatment with significant differences compared to untreated patients (0.279 ± 
0.062 pu/year, p=0.001; -0.011 ± 0.023 pu/year, p=0.001; and 0.052 ± 0.019, p = 0.0001 
respectively). These differences persisted after adjustment for change in whole-brain lesion 
number (p=0.006, p=0.003 and p=0.0002 respectively) and periventricular gradient (p=0.019, 
p=0.002 and p<0.0001 respectively). 
 
At baseline the periventricular MTR gradient correlated with mean whole brain NAWM MTR in 
both the alemtuzumab (r=-0.570, p=0.012) and untreated (r=-0.595, p=0.019) groups, but no 
correlation was found between the annualized change in these metrics in either the 
alemtuzumab (r=0.138, p=0.570) nor untreated (r=0.130, p=0.643) groups. 
 
Baseline predictive capabilities: those who relapsed versus those who did not (alemtuzumab 
only group) 
During clinical follow-up (median 13.5 (range 4.6-14.5) years), 8/19 patients treated with 
alemtuzumab relapsed (half within the first 4 years). The baseline MTR gradient was significantly 
more abnormal in those who relapsed within 4 years compared to those who did not (0.871 ± 
0.197pu/band versus 0.588 ± 0.054pu/band respectively, p=0.020), and remained significantly  
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 Untreated Alemtuzumab-treated  
p-value 
Alemtuzumab-treated  
p-value 
 All 
N=15 
All 
N=19 
Relapse within 4y 
N=4 
No relapse within 4y 
N=15 
Mean periventricular MTR gradient ± SE 
  -baseline (pu/band) 
  -annual change (pu/band/year) 
 
0.504 ± 0.068 
0.030 ± 0.025 
 
0.647 ± 0.062 
-0.045 ± 0.016 
 
0.044 
0.028 
 
0.871 ± 0.197 
-0.116 ± 0.060 
 
0.588 ± 0.054 
-0.026 ± 0.010 
 
0.020 
0.042 
Mean periventricular NAWM MTR ± SE 
  -baseline (pu) 
  -annual change (pu/year) 
 
33.518 ± 0.329 
-0.306 ± 0.119 
 
33.112 ± 0.339 
0.279 ± 0.062 
 
0.211 
0.008 
 
32.590 ± 0.994 
0.412 ± 0.227 
 
33.251 ± 0.353 
0.244 ± 0.053 
 
0.275 
0.559 
Mean whole brain NAWM MTR ± SE 
  -baseline (pu) 
  -annual change (pu/year) 
 
37.134 ± 0.166 
-0.183 ± 0.030 
 
37.076 ± 0.176 
0.208 ± 0.038 
 
0.831 
0.001 
 
36.951 ± 0.635 
0.275 ± 0.166 
 
37.109 ± 0.163 
0.190 ± 0.026 
 
0.931 
0.559 
Mean DGM MTR ± SE 
  -baseline (pu) 
  -annual change (pu/year) 
 
33.795 ± 0.137 
-0.394 ± 0.122 
 
33.770 ± 0.133 
-0.011 ± 0.023 
 
0.930 
0.001 
 
33.580 ± 0.202 
-0.028 ± 0.055 
 
33.909 ± 0.171 
-0.007 ± 0.027 
 
0.822 
0.872 
Mean CGM MTR ± SE 
  -baseline (pu) 
  -annual change (pu/year) 
 
31.802 ± 0.193 
-0.261 ± 0.032 
 
31.740 ± 0.137 
0.052 ± 0.019 
 
0.339 
0.0001 
 
31.495 ± 0.188 
0.038 ± 0.047 
 
31.917 ± 0.176 
0.056 ± 0.022 
 
0.410 
0.501 
Mean whole-brain T2 lesion number ± SE 
  -baseline 
  -annual change (lesions/year) 
 
16.400 ± 2.891 
0.867 ± 0.503 
 
25.579 ± 3.465 
-0.632 ± 0.480 
 
0.056 
0.010 
 
23.000 ± 6.621 
0.167 ± 0.319 
 
26.267 ± 4.110 
-0.844 ± 0.594 
 
0.568 
0.280 
Mean periventricular T2 lesion number ± SE 
  -baseline 
  -annual change (lesions/year) 
 
11.200 ± 2.154 
1.633 ± 0.557 
 
21.158 ± 3.209 
-0.736 ± 0.499 
 
0.011 
0.001 
 
17.250 ± 6.183 
-0.750 ± 1.250 
 
22.200 ± 3.771 
-0.733 ± 0.562 
 
0.799 
0.724 
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Mean brain parenchymal fraction ± SE 
  -baseline 
  -annual change 
 
0.713 ± 0.006 
-0.003 ± 0.000 
 
0.712 ± 0.003 
-0.003 ± 0.000 
 
0.453 
0.450 
 
0.715 ± 0.001 
-0.002 ± 0.000 
 
0.710 ± 0.003 
-0.003 ± 0.000 
 
0.187 
0.737 
Table 13: Imaging outcomes at baseline and annualised change during follow-up. SE = standard error. 
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Figure 16: Normal appearing white matter (NAWM) MTR periventricular gradient in the 
untreated group and those treated with alemtuzumab (Mean ± 2 x standard error). MTR 
gradient is expressed as percentage units per band (pu/band). 
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more abnormal after adjustment for baseline whole-brain lesion number (p=0.022), baseline 
periventricular lesion number (p=0.035), baseline periventricular NAWM MTR (p=0.034) or 
baseline mean whole brain NAWM MTR (p=0.003). These adjusted differences persisted when 
non-relapsers were compared to those relapsing within 2 or 3 years (n=3 for both, p=0.041) or 5 
years (n=5, p=0.014), but lost significance when comparing those who relapsed throughout 
follow-up (13.5 years, n=8, p=0.075). In contrast, no significant differences were found in baseline 
whole-brain lesion number (23.0 ± 6.6 versus 26.3 ± 4.1 respectively, p=0.568), baseline 
periventricular lesion number (17.3 ± 6.2 versus 22.2 ± 3.8  respectively, p=0.799), baseline brain 
parenchymal fraction (0.715 ± 0.001 versus 0.710 ± 0.003 respectively, p=0.187) or baseline 
mean whole brain NAWM MTR (36.951 ± 0.635pu versus 37.109 ± 0.163pu respectively, p=0.931) 
between those that relapsed within 4 years versus those that did not.  
 
Evolution over time: those who relapsed versus those who did not (alemtuzumab only group) 
The rate of change in MTR gradient was significantly different between those who relapsed 
within 4 years and those who did not (-0.116 ± 0.060pu/band/year versus -0.026 ± 
0.010pu/band/year respectively, p=0.042), and remained significant when change in whole brain 
lesion number (p=0.023), change in periventricular lesion number (p=0.035) or change in whole 
brain NAWM MTR (p=0.039) were added to the model. The rate of change in mean whole brain 
NAWM MTR was not significantly different between those who relapsed within 4 years and those 
who did not (0.275 ± 0.166pu/year versus 0.190 ± 0.026pu/year respectively, p=0.559), nor were 
the rates of change in whole-brain lesion number (0.17 ± 0.32/year versus -0.84 ± 0.59/year 
respectively, p=0.280), periventricular lesion number (-0.75 ± 1.25 /year versus -0.73 ± 0.56/year 
respectively, p=0.724) nor brain parenchymal fraction (-0.002 ± 0.000/year versus -0.003 ± 
0.000/year respectively, p=0.737). 
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The baseline median EDSS score (1.5, range 0-3) remained unchanged 13.5 years later (1.5, range 
0-6) in the alemtuzumab group. EDSS scores increased in the same 8/19 patients who relapsed 
during follow-up (occurring at the same time as the relapses). As no patients converted to SPMS 
during follow-up, the disability increases were therefore all attributed to the relapses, so further 
modelling was not performed. Neither the baseline MTR gradient nor mean whole brain NAWM 
MTR correlated with EDSS score at baseline (r=-0.002, p=0.994 and r=0.034, p=0.890 
respectively) or at follow-up (r=0.163, p=0.504 and r=-0.271, p=0.261 respectively). 
 
The predictive capability of the baseline periventricular gradient and its evolution with time in 
the untreated group is detailed below. 
 
Baseline predictive capabilities: those who relapsed versus those who did not (untreated group) 
During clinical follow-up (5 years), 10/15 untreated patients relapsed (all within the first 3 years). 
No difference was found in the baseline periventricular MTR gradient between those who 
relapsed compared to those who did not (0.462 ± 0.084pu/band versus 0.590 ± 0.120pu/band 
respectively, p=0.551), including after adjustment for baseline whole-brain lesion number 
(p=0.847), baseline periventricular lesion number (p=0.607) or baseline mean whole brain 
NAWM MTR (p=0.438). While a significant difference was found in baseline whole-brain lesion 
number (14.6 ± 2.8 versus 20 ± 6.9 respectively, p=0.043), and a trend was seen in baseline 
periventricular lesion number (10.2 ± 2.4 versus 13.2 ± 4.7 respectively, p=0.052), no differences 
were found in baseline brain parenchymal fraction (0.713 ± 0.008 versus 0.712 ± 0.007 
respectively, p=0.978) or baseline mean whole brain NAWM MTR (37.183 ± 0.216pu versus 
37.036 ± 0.275pu respectively, p=0.898) between those that relapsed versus those who did not.  
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Evolution over time: those who relapsed versus those who did not (untreated group) 
The rate of change in MTR gradient was significantly different between those who relapsed and 
those who did not (0.071 ± 0.026pu/band/year versus -0.052 ± 0.036pu/band/year respectively, 
p=0.001), and remained significant when change in whole brain lesion number (p=0.006), change 
in periventricular lesion number (p=0.005) or change in whole brain NAWM MTR (p=0.003) were 
added to the model. The rate of change in mean whole brain NAWM MTR was not significantly 
different between those who relapsed and those who did not (-0.185 ± 0.038pu/year versus -
0.181 ± 0.053pu/year respectively, p=0.850), nor were the rates of change in whole-brain lesion 
number (1 ± 0.7/year versus 0.7 ± 0.6/year respectively, p=0.415), periventricular lesion number 
(1.8 ± 0.8/year versus 1.4 ± 0.8/year respectively, p=0.561) nor brain parenchymal fraction (-
0.002 ± 0.001/year versus -0.005 ± 0.001/year respectively, p=0.273). 
 
Conclusions: outside-in gradients 
Outside-in MTR gradients of tissue damage were seen in periventricular and cortical regions at 
all stages of relapse-onset MS and primary-progressive MS. The periventricular MTR gradient was 
reversed by peripheral immunomodulation and independently predicted subsequent relapse 
activity on and off DMTs. The underlying process(es) appear at least partially distinct from those 
underlying lesion formation.  
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Chapter 5: Results – The effect of disease-
modifying therapies on conversion to 
secondary progressive multiple sclerosis  
Project 4.  
This chapter details the results from the observational study (Project 4). 
This work was published in JAMA, 2019: 
Brown JW*, Coles AJ*, Horakova D, Havrdova E, Izquierdo G, Prat A, et al. Association of initial 
disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. 
JAMA 2019; 321(2): 175-87. 
 
 
44,217 patients with multiple sclerosis (1,091 from the Welsh untreated cohort; 43,048 from 
MSBase; and 78 alemtuzumab-treated patients from non-MSBase centers) were assessed for 
eligibility (Figure 17). To avoid informed censoring bias, the glatiramer acetate / interferon beta 
groups were limited to those treated and followed-up before fingolimod, alemtuzumab or 
natalizumab became available for escalation (baseline year 1996-1998 (Table 14)). Following 
exclusion of ineligible patients (Figure 17), the matching process then matched 1,555 patients 
from 68 centers in 21 countries: 230 from the Welsh untreated cohort; 1,272 from MSBase and 
53 alemtuzumab-treated patients from non-MSBase centers (Table 14, Table 17, Table 18, Table 
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19, Table 20, Table 21, Table 22, Table 23 and Table 24). Propensity scores before and after 
matching are shown in Table 25. The assumption of proportionality was not met in 6/9 analyses 
(requiring Weibull accelerated failure time regression models). Differing follow-up duration with 
different drugs in the untreated comparisons (Figure 18) largely reflects the variable time from 
drug licensing.  
Compared with no treatment, treatment with each included therapy was associated with a 
significantly lower probability of converting to SPMS. For patients initially treated with glatiramer 
acetate or interferon beta (n=407), the hazard ratio (HR) was 0.71 (95% confidence interval (CI) 
0.61−0.81), p<0.001 in comparison to untreated patients (n=213); median censored follow-up 
7.6 (IQR 5.8-9.6) years); at 5 years 12% vs 27% respectively had converted, while at 11 years 47% 
vs 57% had converted (Figure 18). Fewer patients initially treated with fingolimod (n=85) 
converted compared to untreated patients (n=174) (HR 0.37 (95% CI 0.22−0.62), p<0.001; 
median censored follow-up 4.5 (IQR 4.3-5.1) years): at 5 years 7% vs 32% respectively had 
converted, while at 6 years 7% vs 39% had converted (Figure 18). Conversion to SPMS was also 
significantly lower for patients initially treated with natalizumab (n=82) compared to untreated 
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Table 14: Baseline Characteristics of Matched Patient Groups. EDSS, Expanded Disability Status Scale, range 0 (no disability due to MS) to 10 (death due to MS), 2 indicates 
minimal disability in 1 of 8 functional systems (but no impairment to walking); 3.5, moderate disability in 1 or 2 functional systems plus minimal disability in several others 
(but no impairment to walking); IQR, interquartile range; MS, multiple sclerosis. aStandardized difference quantified by the Cohen d value. Reproduced with permission from 
The American Medical Association (License number 4720830643128; granted 2nd December 2019) 
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Table 15: Baseline Characteristics of Matched Patient Groups. EDSS, Expanded Disability Status Scale, range 0 (no disability due to MS) to 10 (death due to 
MS), 2 indicates minimal disability in 1 of 8 functional systems (but no impairment to walking); 3.5, moderate disability in 1 or 2 functional systems plus 
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minimal disability in several others (but no impairment to walking); IQR, interquartile range; MS, multiple sclerosis. aStandardized difference quantified by 
the Cohen d value. bMedian disease duration at the time of commencing interferon beta or glatiramer acetate in the late group was 6.8 years (IQR, 5.7-
10.8). cMedian disease duration at the time of commencing fingolimod or alemtuzumab or natalizumab in the late group was 7.3 years (IQR, 6.1-10.4). 
Reproduced with permission from The American Medical Association (License number 4720830643128; granted 2nd December 2019) 
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Figure 17: MSBase Study Design of Patients with Multiple Sclerosis (MS). a When recorded, reasons for stopping included: 341 due to intolerance; 65, inconvenience; 42, 
pregnancy (or planned pregnancy); 65, inefficacy (relapses, EDSS progression, magnetic resonance imaging activity, or patient perception of lack of improvement); and 15, 
nonadherence. bIneligible treatments were defined as treatments not licensed for relapsing remitting MS at the time of the study period (mitoxantrone, cladribine, rituximab, 
ocrelizumab, siponimod, or autologous stem-cell transplant). DMT indicates disease-modifying therapy; EDSS, Expanded Disability Status Scale. Reproduced with permission 
from The American Medical Association (License number 4720830643128; granted 2nd December 2019) 
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Figure 18: Comparison of the Cumulative Hazard of Conversion to Secondary Progressive Multiple Sclerosis in Untreated Patients vs Matched Treated Patients Compared by Initial 
Treatment. HR indicates hazard ratio. Reproduced with permission from The American Medical Association (License number 4720830643128; granted 2nd December 2019) 
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Figure 19: Comparison of the Cumulative Hazard of Conversion to Secondary Progressive Multiple Sclerosis by Timing of Treatment. HR indicates hazard ratio. 
Reproduced with permission from The American Medical Association (License number 4720830643128; granted 2nd December 2019)  
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Figure 20: Comparison of Cumulative Hazard of Conversion to Secondary Progressive Multiple Sclerosis 
for Initial Treatment with Glatiramer Acetate or Interferon Beta vs Fingolimod, Alemtuzumab, or 
Natalizumab. HR indicates hazard ratio. Reproduced with permission from The American Medical 
Association (License number 4720830643128; granted 2nd December 2019). 
patients (n=164) (HR 0.61 (95% CI 0.43−0.86), p=0.005; median censored follow-up 4.9 (IQR 4.4-
5.8) years): at 5 years 19% vs 38% respectively had converted, while at 6 years 34% vs 48% had 
converted (Figure 18). The hazard ratio for converting to SPMS was significantly lower for 
patients initially treated with alemtuzumab (n=44) compared to untreated patients (n=92) (0.52 
(95%CI 0.32−0.85), p=0.009; median censored follow-up 7.4 (IQR 6.0-8.6) years): at 5 years 10% 
vs 25% respectively had converted, while at 8 years 21% vs 41% had converted (Figure 18).  
The probability of converting to SPMS was significantly lower for patients initially receiving 
glatiramer acetate or interferon beta within 5 years of disease onset (n=120) compared to 
matched patients treated with glatiramer acetate or interferon beta later (n=38) (HR 0.77 (95%CI 
0.61-0.98), p=0.03), median censored follow-up 13.4 (IQR 11-18.1) years. Five years after 
baseline 3% vs 6%, respectively, had converted to SPMS, while at 17 years 29% vs 47% had 
converted (Figure 19). Including patients escalated to mitoxantrone did not materially alter the 
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results (HR 0.82 (95%CI 0.67-1.00), p=0.05). The probability of converting to SPMS was 
significantly lower when initial treatment with glatiramer acetate or interferon beta was 
commenced within 5 years of disease onset (n=164) compared to untreated patients (n=104) (HR 
0.26 (95%CI 0.15-0.45), p<0.001) with the difference increasing proportionally throughout the 11 
years of follow-up (corresponding to 14 years disease duration (Figure 19)). In contrast, the 
significantly lower probability of conversion following initial treatment with glatiramer acetate 
or interferon beta commencing 5-10 years after disease onset (n=95) compared to untreated 
patients (n=158, HR 0.67 (95%CI 0.51-0.87), p=0.003) waned after 5 years of treatment (disease 
duration 11.8 years) and disappeared at 7.8 years (disease duration 14.6 years, Figure 19)). The 
probability of converting to SPMS was significantly lower for patients escalated from glatiramer 
acetate or interferon beta to fingolimod, alemtuzumab or natalizumab within 5 years of disease 
onset (n=307) compared to matched patients escalated later (n=331, HR 0.76 (95%CI 0.66-0.88), 
p<0.001; median censored follow-up 5.3 (IQR 4.6-6.1) years): at 5 years, 8% vs 14% respectively 
had converted while at 7 years, 14% vs 28% had converted (Figure 19). This difference persisted 
when the alternative (7-year) definition of alemtuzumab treatment duration was employed in a 
sensitivity analysis (HR 0.78 (95%CI 0.67-0.91), p=0.001). 
Patients initially receiving fingolimod, alemtuzumab or natalizumab (n=235) had a significantly 
lower risk of conversion to SPMS than matched patients initially receiving glatiramer acetate or 
interferon beta (n=380) (HR 0.66 (95% CI 0.44-0.99), p=0.046; median censored follow-up 5.8 
(IQR 4.7-8.0) years). At 5 years, 7% vs 12% respectively had converted, while at 9 years, 16% vs 
27% respectively had converted (Figure 20). This persisted in sensitivity analyses when the 
alternative (7-year) definition of alemtuzumab treatment duration was used (HR 0.60 (95%CI 
0.39-0.90), p=0.01); and when patients in the glatiramer acetate or interferon beta group 
escalated to mitoxantrone were included (HR 0.88 (95%CI 0.84-0.91), p<0.001). 
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Data quality procedure 
•Duplicate patient records were removed. 
•Centres with <10 patient records were excluded. 
•Patients with missing date of birth were excluded. 
•MS onset dates after the MSBase / University Hospital Wales / European Alemtuzumab centres 
data extract dates were removed. 
•Patients with missing date of the first clinical presentation of MS were excluded. 
•Patients with primary progressive or relapsing-progressive MS were excluded 
•The dates of MS onset and the first recorded MS course were aligned. 
•Patients with the age at onset outside the 0-100 range were excluded. 
•A logical sequence of the MS courses (i.e. clinically isolated syndrome, then relapsing-remitting 
MS, then secondary progressive MS) was assured. 
•Patients where conversion to secondary progressive MS occurred prior to commencing therapy 
(or being randomised for untreated patients) were excluded. 
•Visits with missing visit date or the recorded date before the clinical MS onset or after the date 
of MSBase data extract were removed. 
•EDSS scores outside the range of possible EDSS values were removed. 
•Duplicate visits were merged. 
•MS relapses with missing onset date or the recorded date after the date of MSBase data 
extractwere removed. 
•Duplicate MS relapses were merged. 
•Relapses occurring within 30 days of each other were merged. 
•Visits preceded by relapses were identified and time from the last relapse was calculated for 
each visit. 
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•Therapies were labelled as discontinued or continuing. 
•Therapies with erroneous date entries were removed (e.g. commencement date > termination 
date, commencement after the MSBase data extract date, commencement of disease modifying 
therapy before the year 1980). 
•MS disease modifying therapies were identified and labelled. 
•Duplicate treatment entries were removed. 
•Where multiple disease modifying therapies were recorded simultaneously, treatment end date 
of the previous therapy was imputed as the commencement date of the following therapy. 
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Baseline demographics for prematching cohorts, unmatched cohorts and matched cohorts 
 Initial ß-IFN / GA versus untreated 
Table 16: The untreated groups and late groups do not have prematching or unmatched data presented in the tables. This is deliberate – to achieve the closest 
match, each untreated or late patient had baseline set at the visit when clinical and demographic parameters most closely matched those of individual treated 
patients or early patients respectively (as described in the Methods section). For untreated patients this is usually not the first visit; and for late-treated patients 
it is a visit before treatment started. The mean age and disease durations of the matched patients are therefore significantly different to the corresponding 
values in the pre-matching and unmatched data (for example, the mean age in the matched untreated cohorts is 35-39; but the mean age if all permutations 
of each patient are averaged is 51; alternatively, using the first visit for each untreated patient gives an unrepresentatively low age). ß-IFN|GA = beta-
interferon or glatiramer acetate. EDSS: Expanded disability status scale. F|A|N = fingolimod, alemtuzumab or natalizumab. SPMS: secondary progressive 
multiple sclerosis. % in column headings: percentage of prematching patients. 
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 Initial Fingolimod versus untreated 
 
Table 17: The untreated groups and late groups do not have prematching or unmatched data presented in the tables. This is deliberate – to achieve the closest 
match, each untreated or late patient had baseline set at the visit when clinical and demographic parameters most closely matched those of individual treated 
patients or early patients respectively (as described in the Methods section). For untreated patients this is usually not the first visit; and for late-treated patients 
it is a visit before treatment started. The mean age and disease durations of the matched patients are therefore significantly different to the corresponding 
values in the pre-matching and unmatched data (for example, the mean age in the matched untreated cohorts is 35-39; but the mean age if all permutations 
of each patient are averaged is 51; alternatively, using the first visit for each untreated patient gives an unrepresentatively low age). ß-IFN|GA = beta-
interferon or glatiramer acetate. EDSS: Expanded disability status scale. F|A|N = fingolimod, alemtuzumab or natalizumab. SPMS: secondary progressive 
multiple sclerosis. % in column headings: percentage of prematching patients. 
 
  
	 	 143	
Initial Natalizumab versus untreated 
 
Table 18: The untreated groups and late groups do not have prematching or unmatched data presented in the tables. This is deliberate – to achieve the closest 
match, each untreated or late patient had baseline set at the visit when clinical and demographic parameters most closely matched those of individual treated 
patients or early patients respectively (as described in the Methods section). For untreated patients this is usually not the first visit; and for late-treated patients 
it is a visit before treatment started. The mean age and disease durations of the matched patients are therefore significantly different to the corresponding 
values in the pre-matching and unmatched data (for example, the mean age in the matched untreated cohorts is 35-39; but the mean age if all permutations 
of each patient are averaged is 51; alternatively, using the first visit for each untreated patient gives an unrepresentatively low age). ß-IFN|GA = beta-
interferon or glatiramer acetate. EDSS: Expanded disability status scale. F|A|N = fingolimod, alemtuzumab or natalizumab. SPMS: secondary progressive 
multiple sclerosis. % in column headings: percentage of prematching patients. 
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Initial Alemtuzumab versus untreated 
 
Table 19: The untreated groups and late groups do not have prematching or unmatched data presented in the tables. This is deliberate – to achieve the closest 
match, each untreated or late patient had baseline set at the visit when clinical and demographic parameters most closely matched those of individual treated 
patients or early patients respectively (as described in the Methods section). For untreated patients this is usually not the first visit; and for late-treated patients 
it is a visit before treatment started. The mean age and disease durations of the matched patients are therefore significantly different to the corresponding 
values in the pre-matching and unmatched data (for example, the mean age in the matched untreated cohorts is 35-39; but the mean age if all permutations 
of each patient are averaged is 51; alternatively, using the first visit for each untreated patient gives an unrepresentatively low age). ß-IFN|GA = beta-
interferon or glatiramer acetate. EDSS: Expanded disability status scale. F|A|N = fingolimod, alemtuzumab or natalizumab. SPMS: secondary progressive 
multiple sclerosis. % in column headings: percentage of prematching patients. 
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Initial ß-IFN / GA within 5 years versus initial ß-IFN / GA after 5 years 
 
Table 20: The untreated groups and late groups do not have prematching or unmatched data presented in the tables. This is deliberate – to achieve the closest 
match, each untreated or late patient had baseline set at the visit when clinical and demographic parameters most closely matched those of individual treated 
patients or early patients respectively (as described in the Methods section). For untreated patients this is usually not the first visit; and for late-treated patients 
it is a visit before treatment started. The mean age and disease durations of the matched patients are therefore significantly different to the corresponding 
values in the pre-matching and unmatched data (for example, the mean age in the matched untreated cohorts is 35-39; but the mean age if all permutations 
of each patient are averaged is 51; alternatively, using the first visit for each untreated patient gives an unrepresentatively low age). ß-IFN|GA = beta-
interferon or glatiramer acetate. EDSS: Expanded disability status scale. F|A|N = fingolimod, alemtuzumab or natalizumab. SPMS: secondary progressive 
multiple sclerosis. % in column headings: percentage of prematching patients. 
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Initial ß-IFN / GA within 5 years versus untreated 
 
Table 21: The untreated groups and late groups do not have prematching or unmatched data presented in the tables. This is deliberate – to achieve the closest 
match, each untreated or late patient had baseline set at the visit when clinical and demographic parameters most closely matched those of individual treated 
patients or early patients respectively (as described in the Methods section). For untreated patients this is usually not the first visit; and for late-treated patients 
it is a visit before treatment started. The mean age and disease durations of the matched patients are therefore significantly different to the corresponding 
values in the pre-matching and unmatched data (for example, the mean age in the matched untreated cohorts is 35-39; but the mean age if all permutations 
of each patient are averaged is 51; alternatively, using the first visit for each untreated patient gives an unrepresentatively low age). ß-IFN|GA = beta-
interferon or glatiramer acetate. EDSS: Expanded disability status scale. F|A|N = fingolimod, alemtuzumab or natalizumab. SPMS: secondary progressive 
multiple sclerosis. % in column headings: percentage of prematching patients. 
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Initial ß-IFN / GA 5-10 years versus untreated 
 
Table 22: The untreated groups and late groups do not have prematching or unmatched data presented in the tables. This is deliberate – to achieve the closest 
match, each untreated or late patient had baseline set at the visit when clinical and demographic parameters most closely matched those of individual treated 
patients or early patients respectively (as described in the Methods section). For untreated patients this is usually not the first visit; and for late-treated patients 
it is a visit before treatment started. The mean age and disease durations of the matched patients are therefore significantly different to the corresponding 
values in the pre-matching and unmatched data (for example, the mean age in the matched untreated cohorts is 35-39; but the mean age if all permutations 
of each patient are averaged is 51; alternatively, using the first visit for each untreated patient gives an unrepresentatively low age). ß-IFN|GA = beta-
interferon or glatiramer acetate. EDSS: Expanded disability status scale. F|A|N = fingolimod, alemtuzumab or natalizumab. SPMS: secondary progressive 
multiple sclerosis. % in column headings: percentage of prematching patients. 
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Escalation from ß-IFN/GA to F/A/N within 5 years versus escalation from ß-IFN / GA to F/A/N after 5 years 
 
Table 23: The untreated groups and late groups do not have prematching or unmatched data presented in the tables. This is deliberate – to achieve the closest 
match, each untreated or late patient had baseline set at the visit when clinical and demographic parameters most closely matched those of individual treated 
patients or early patients respectively (as described in the Methods section). For untreated patients this is usually not the first visit; and for late-treated patients 
it is a visit before treatment started. The mean age and disease durations of the matched patients are therefore significantly different to the corresponding 
values in the pre-matching and unmatched data (for example, the mean age in the matched untreated cohorts is 35-39; but the mean age if all permutations 
of each patient are averaged is 51; alternatively, using the first visit for each untreated patient gives an unrepresentatively low age). ß-IFN|GA = beta-
interferon or glatiramer acetate. EDSS: Expanded disability status scale. F|A|N = fingolimod, alemtuzumab or natalizumab. SPMS: secondary progressive 
multiple sclerosis. % in column headings: percentage of prematching patients. 
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Initial ß-IFN / GA versus initial F/A/N 
 
Table 24: ß-IFN|GA = beta-interferon or glatiramer acetate. EDSS: Expanded disability status scale. F|A|N = fingolimod, alemtuzumab or natalizumab. SPMS: 
secondary progressive multiple sclerosis. % in column headings: percentage of prematching patients. 
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Propensity scores before and after matching 
  
Table 25: Propensity scores before and after matching. ß-IFN|GA = beta-interferon or glatiramer acetate. F|A|N = fingolimod, alemtuzumab or natalizumab. 
	 	151	
Clinical characteristics of patients excluded through missing data.  
 
Table 26: Comparison of baseline demographics between patients excluded due to data missingness 
(<3 EDSS scores or <4 years of follow-up despite commencing the therapy more than 4 years data 
censor date) and those presented for matching.*minus untreated patients (as untreated patients 
have multiple potential baseline dates). †Baseline demographics presented at time of starting 
therapy. 
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Chapter 6: Discussion 
Project 1: Periventricular gradients after a clinically isolated 
syndrome 
In a previous study in people with established RRMS and SPMS, MS effects on NAWM MTR 
were found to increase close to the lateral ventricles (Liu et al., 2015). However, it could not 
be determined how early in the clinical course of MS this abnormal periventricular MTR 
gradient occurred, whether or not it was due to a mechanism independent of WM lesion 
formation, or if it was associated with subsequent disease activity. In the present study we 
found that an abnormal periventricular MTR gradient is present within five months of a 
clinically isolated ON, is not dependent on the presence of WM lesions and is associated with 
the subsequent risk of developing MS and disability. Both the periventricular NAWM MTR 
gradient and WM lesions independently predicted conversion to CDMS over two years. This 
raises the possibility that lesions and NAWM periventricular abnormalities in early MS may 
arise from different but nevertheless clinically relevant pathophysiological processes. 
 
In the ON group we looked for significant differences in the periventricular MTR gradients 
between those with and without WM lesions, those with and without periventricular WM 
lesions, and those with and without gadolinium-enhancing lesions, and found none. 
Consistent with previous work (Liu et al., 2015) MTR in lesions also showed periventricular 
gradients similar to those in NAWM. Collectively, this strongly suggests that abnormal 
gradients in NAWM MTR are not dependent on the presence of WM lesions. In keeping with 
	 	154	
previous results (Barkhof et al., 1997) periventricular lesions predicted conversion to CDMS 
over two years, and in a multivariate logistic regression the MTR gradient over 1-5mm also 
independently predicted conversion to CDMS over two years. The identification of an early 
abnormal periventricular MTR gradient that is not directly related to lesion formation, but 
linked with clinical outcomes suggests that there is a clinically relevant pathological process 
at least partially distinct to that underlying lesion formation. 
 
The pathological basis of the abnormal periventricular MTR gradient is uncertain. MTR 
correlates with myelin and axonal density, which are themselves correlated (Schmierer et al., 
2007a) and may also be reduced by tissue oedema and inflammation (Dousset et al., 1992; 
Gareau et al., 2000). There have been no histopathological studies looking for a gradient of 
pathology in extra-lesional periventricular WM. Several mechanisms could underlie the 
periventricular MTR changes seen, perhaps in combination, but without knowing the 
underlying pathological substrate we can only speculate which are responsible. These are 
discussed in a later section (p.165). 
 
Elucidating the responsible mechanism(s) may have significant implications for early MS 
treatment. For example, in established MS, neuropathological work has shown a cortical 
gradient in neuronal loss (Magliozzi et al., 2010) where an MTR gradient has also been 
identified (Samson et al., 2014). If a gradient in axonal loss were confirmed around the 
ventricles, one might infer that the in vivo periventricular MTR findings indicate a 
neurodegenerative process that should be targeted from the earliest clinical stages of MS. 
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There are a few study limitations worth noting. First, we used previously acquired MTR data 
with lower resolution (1x1x5mm) than that used in our recent study examining periventricular 
gradients in established MS (1x1x1mm, (Liu et al., 2015)) and given this, partial volume effects 
were a greater concern. To minimize these, we restricted our analysis to two axial slices 
perpendicular to the lateral ventricular wall (Figure 3), so avoiding oblique CSF-WM 
boundaries within periventricular voxels, and through plane smoothing of periventricular 
MTR gradients (recalling that these were seen over the first 5 mm around the ventricles, and 
the axial slices were 5 mm thick). Despite this, the first two periventricular bands still 
contained CSF in the majority of participants, and so these bands were also excluded from 
subsequent analyses. Noting that the periventricular MTR gradient seen in previous work was 
steepest close to the ventricles (Liu et al., 2015), it is likely that excluding these bands will 
have significantly reduced our sensitivity to gradients. In 10/81 participants with ON and 2/39 
healthy controls, there was still CSF in the third band so these participants were also excluded 
from the analyses, further reducing the power of the study to detect periventricular 
gradients. While we were very careful to avoid partial volume effects between CSF and WM, 
partial volume between periventricular bands will tend to smooth MTR gradients, and so 
reduce sensitivity to disease effects. Similarly, restricting our analysis to two axial slices, while 
limiting the risk of MTR gradients being smoothed through plane, substantially reduced the 
volume of each band studied when compared to our previous study using 1x1x1mm MTR 
data; this too is likely to have reduced sensitivity to disease effects. To allow for brain atrophy, 
which could exacerbate this further, we included BPF as a covariate when looking for 
differences in MTR gradients between clinical subgroups, and found no material difference in 
the results. To provide context with established MTR metrics and confirm that the difference 
in MTR gradient between converters and non-converters was not simply driven by diffuse 
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tissue differences, we added NAWM and GM MTR as covariates and the MTR gradient 
remained a significant factor. 
 
By five years, about ~55% of the ON group developed CDMS, while at the time of their MTR 
scan only ~10% had done so (Table 3). The pattern of group differences in periventricular MTR 
gradient were still apparent, albeit with less statistical significance, following exclusion of 
those converting before the MTR scan (see p.Error! Bookmark not defined.). As such, we 
think it is unlikely that the apparent predictive power of the periventricular MTR gradient for 
conversion to CDMS within 5 years is simply due to such a gradient being present in those 
who had already developed CDMS by the time of their MTR scan. Thirteen of the 71 people 
with ON studied at baseline did not have clinical follow-up. There were no significant 
differences in any baseline demographic features between those who were or were not 
followed up (see p.Error! Bookmark not defined.), so we believe this is unlikely to have biased 
our results in favour of detecting differences in periventricular MTR gradients between 
groups, but it may have reduced our sensitivity to them. 
 
While we have assessed cross-sectional differences in MTR measures between the HC and 
ON groups, it would be of considerable interest to see how these differences evolve with 
time, and whether or not these changes relate more closely to clinical outcomes. Some 
longitudinal MTR data is available for the present cohorts (HC n = 18, ON n = 44), but the 
resolution of the 2D MTR scans (1 x 1 x 5mm) means that it is not possible to accurately align 
the same axial slices over time. When we looked for changes in periventricular MTR gradients 
over time without registering scans, we found no significant change over 5 years. 
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It is well recognised that a substantial number of people with MS may have significant 
cognitive deficits (Langdon, 2011).  However, only about half (31/58) of those followed-up at 
5 years underwent cognitive testing, of whom only 12 had developed clinically definite MS. 
Given this, it is perhaps unsurprising that we did not find a correlation between 
periventricular MTR gradients and cognitive impairment in this cohort, and this might be 
better examined in a group of people with progressive MS who are more likely to have 
cognitive impairment (Langdon, 2011). 
 
The parent cohort’s principal presenting CIS was ON, and for consistency we excluded three 
non-ON participants who would otherwise have been eligible for our study. In some cohorts, 
ON appears to carry a lower risk of conversion to CDMS when compared with other 
presentations (Tintore et al., 2015) and it would be of interest to see if periventricular 
gradients differ dependent on the type of CIS. 
 
In our assessment of the lesional periventricular gradient, we account for increasing band size 
by presenting the percentage of lesioned WM per band (Figure 10). However, this might not 
fully exclude an effect from band volume due to the periventricular predilection for lesions. 
Future work should list the volume per band.  
 
While inner periventricular MTR gradients independently contributed to the prediction of 
conversion to CDMS and McDonald MS, there was substantial overlap in the range of values 
between groups (see p.99) and no clear threshold was found beyond which conversion to MS 
by 5 years was inevitable. As such the methods employed here for measuring periventricular 
MTR gradients are unlikely to be useful in clinical practice. It remains unclear whether 
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methodological optimisation will improve this capability, or whether – like lesional metrics – 
accurate individual prognostication using gradients is not possible.  However, this does not 
negate the clinical relevance of the pathological processes underlying abnormal MTR 
gradients, which - independent of those leading to WM lesion formation - may be a potential 
target for treatments. 
 
In conclusion, our findings show that an abnormal periventricular MTR gradient occurs soon 
after a CIS and is associated with subsequent conversion to MS and disability. The abnormal 
periventricular MTR gradient was not significantly affected by the presence of WM lesions, 
and therefore seems likely to arise from an at least partly independent mechanism. 
Histopathological studies are warranted to elucidate the nature of these MTR gradients.   
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Project 2: Periventricular and cortical gradients in progressive 
multiple sclerosis 
We identified both periventricular and cortical MTR gradients in PPMS and replicated our 
previous findings of cortical and periventricular gradients in SPMS (Samson et al., 2014; Liu et 
al., 2015). The cortical and periventricular gradients did not differ significantly between the 
PPMS and SPMS groups. In the few subjects with longitudinal imaging, when compared with 
healthy controls, no significant changes in these gradients were observed over a median 
period of 2 years. When all people with MS were combined, significant associations were seen 
between periventricular and cortical gradient severity; and both gradients increased with 
increasing disability and disease duration.  
 
The present results suggest that the processes underlying cortical and periventricular MTR 
gradients may be similar in PPMS and SPMS. The finding of a cortical gradient in PPMS in the 
present study but not previously (Samson et al., 2014) appears to reflect the larger cohort (28 
here versus 19 previously with PPMS; 51 versus 35 healthy controls). However, while the 
optimized processing pipeline better accounts for cortical folding, its ability to distinguish 
cortical gradients from whole cortical MTR effects is severely limited because cortical 
gradients are calculated from the only 2 cortical bands of MTR, which may explain why all 
cortical models lost significance when additionally covaried for mean CGM MTR.  
 
The pathological substrate and pathogenic processes underlying these MTR gradients remain 
unknown, but are discussed in a later section (p.165). 
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The presence of a significant association between cortical and periventricular gradients in the 
RRMS group (n=56) but not the PPMS (n=28) or SPMS (n=35) groups may also reflect the 
smaller sample sizes, particularly given the significant association seen at the whole-group 
level when additionally covarying for clinical classification.  The apparent absence of a change 
in gradients over time should also be interpreted with caution, given that only a small subset 
of the cohorts had serial MTR studies (12/51 healthy controls, 14/28 with PPMS and 15/35 
with SPMS), and follow-up was limited to 1.6-2.3 years (Table 7). The correlations seen 
between disease duration and gradient severity were very weak (Table 9) though this and 
previous cross-sectional works have shown a steeper periventricular gradient in SPMS 
compared with RRMS (Liu et al., 2015) collectively suggesting that gradients do worsen over 
time. Associations of cortical and periventricular MTR gradients with disability, as measured 
by EDSS scores, were also very modest. Only in SPMS did cortical MTR gradients weakly 
correlate with EDSS scores. Furthermore, spinal cord pathology was not assessed, which may 
be of greater clinical relevance in PP than SPMS (Losseff et al., 1996); and EDSS scores 
exceeding 3.5 essentially reflect impaired mobility and do not capture cognitive or memory 
impairments (Paul, 2016), both of which may be associated with cortical pathology (Calabrese 
et al., 2011). Further work using larger cohorts and spinal cord examination is needed to 
explore these issues. 
 
In conclusion, as with SPMS, periventricular and cortical gradients are present in PPMS, and 
do not appear to differ substantially between these subtypes of progressive MS. 
Histopathological examination of the substrates underlying these gradients may provide 
useful insights into the processes leading to them.  
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Project 3: Periventricular gradient evolution following peripheral 
immunotherapy 
The number of participants in this study is small, and larger studies are required to 
corroborate these preliminary findings. Notwithstanding this, we found that, untreated, the 
abnormal periventricular MTR gradient in RRMS increased over time. In contrast, in those 
patients who received alemtuzumab this gradient decreased (becoming less abnormal), and 
this was not explained by effects on WM lesion accrual nor brain atrophy. As alemtuzumab is 
undetectable in the CSF after treatment (Moreau et al., 1994) and has no apparent effect on 
oligoclonal bands (Hill-Cawthorne et al., 2012), a direct intrathecal action is unlikely to explain 
this result. The biological implications of these findings are discussed on p.175.  
 
The baseline periventricular MTR gradient was significantly more abnormal in those patients 
who relapsed within 4 years of receiving alemtuzumab compared to those who did not 
relapse, while no such differences in baseline lesion number, brain parenchymal fraction nor 
whole brain NAWM MTR were found. 
 
Limitations 
Our study has limitations. The number of participants is too small for definitive conclusions: 
caution is required when interpreting the results with small subgroups and larger cohorts are 
needed to verify our findings. Such work might also examine the effect of other DMTs on the 
gradient’s evolution and predictive capabilities: insufficient numbers of patients imaged with 
the same protocol precluded this here.  
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Baseline differences (particularly in relapse rate) reflect the opposing treatment strategies 
(high efficacy therapy versus no treatment). This may account for the higher baseline 
periventricular gradient seen in the alemtuzumab group. Despite this, and the adjustment for 
baseline relapse rate in all models, a significantly different rate of change in gradient was still 
observed between the groups. The untreated group were older than the alemtuzumab group, 
though again significant differences were seen despite adjusting models for baseline age. 
While a significant difference in periventricular gradient evolution was seen between 
untreated patients who relapsed versus those who did not, no difference in baseline gradient 
was seen (p.Error! Bookmark not defined.). Given such a difference was seen in a larger 
untreated cohort (Brown et al., 2017), we suggest that this most likely reflects this cohort’s 
smaller size and exclusion of those untreated patients that started a DMT before their final 
scan (further diminishing the cohort size and biasing the untreated group that relapsed to a 
milder clinical phenotype).  
 
No longitudinal healthy control or non-MS neurological disease data was obtained using this 
protocol, so the natural effects of age on the periventricular MTR gradient, nor its disease 
specificity, can be determined. This also means that we cannot establish if the effects 
alemtuzumab exerts on the periventricular MTR gradient are specific to MS. The baseline 
relapse rate in the untreated cohort is high compared with patients currently receiving no 
DMTs in clinical practice, reflecting the low DMT uptake rates in the United Kingdom at the 
time of recruitment. To minimize partial volume effects we applied a stringent probabilistic 
segmentation threshold and removed the two bands closest to the CSF, where periventricular 
disease effects are maximal. Despite this – and the sample size, and adjustment for atrophy 
and lesional measures – a treatment effect was still observed. The lack of gadolinium 
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administration prevented us examining the effects of enhancing lesions at baseline, though 
in a larger study we found no difference in periventricular gradient between those with and 
without enhancing lesions (Brown et al., 2017).  
 
The baseline periventricular MTR gradient partially correlated with baseline mean whole 
brain NAWM MTR (r=-0.57-0.59), although given that the MTR gradient is derived from bands 
of NAWM MTR this is unsurprising. While both improved following treatment with 
alemtuzumab, their rate of change was not correlated. We could not distinguish independent 
changes in the periventricular gradient from changes in NAWM MTR, though we did find this 
when examining predictors of post-treatment relapses in the alemtuzumab group. Given the 
independent differences between these metrics in a larger study (Brown et al., 2017), we 
suspect this reflects the small sample size here. The 3mm-thick T1 slices provide less accurate 
tissue segmentations than with scans used for volumetric measures (typically obtained at 1 x 
1 x 1 mm resolution), and this will affect small structures (such as DGM) more than larger 
ones; this precluded examination of the effect of alemtuzumab on DGM periventricular and 
cortical MTR gradients. Despite any resultant noise, statistically significant changes in NAWM 
MTR gradient were still seen between the groups. It is unlikely that an improvement in the 
periventricular MTR gradient represents a ceiling effect (i.e. less abnormal regions have less 
scope for improvement) as the final post-alemtuzumab MTR in each band was still 
considerably lower than that seen in healthy controls (<38pu versus >40pu respectively 
(Pardini et al., 2016)). 
 
In conclusion, we have shown that the abnormal periventricular MTR gradient in multiple 
sclerosis increases with time but appears to be reversed following treatment with 
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alemtuzumab. The periventricular MTR gradient may predict therapeutic response. Larger 
corroboratory studies are now needed. The cause of the periventricular MTR gradient 
remains unknown, but growing evidence of its clinical relevance, responsiveness to 
treatment, and therefore its potential use as a trial outcome measure, make it increasingly 
important to understand the processes underlying it.  
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Integration of projects 1-3 into a rapidly-evolving picture of 
outside-in tissue abnormalities in MS 
The work detailed in this thesis forms a small part of a growing delineation of outside-in tissue 
abnormalities within multiple sclerosis. Much work has been published contemporaneous to 
this PhD, so this section of the discussion will provide an updated summary and set our 
findings into the wider characterisation of outside-in tissue abnormalities, and what may 
underlie them. The evidence for outside-in gradients - neuropathological and imaging - will 
be summarised in WM and GM before potential causes and clinical relevance are discussed. 
 
Normal-appearing white matter 
The NAWM is not normal, yet abnormalities are not uniform.  First, perilesional tissue is 
abnormal on MTR, for up to 4mm from the T2-defined lesion edge (Vrenken et al., 2006). 
Second, in healthy controls WM MTR is highest adjacent to the lateral ventricles and 
decreases with distance from them; in all types of MS, NAWM MTR is lowest (most abnormal) 
at the ventricular edge and increases over the first ~5 mm before mirroring, at lower levels, 
patterns seen in healthy controls (Liu et al., 2015; Brown et al., 2017; Brown et al., 2019a). 
This periventricular MTR gradient surrounds supratentorial and infratentorial ventricles 
(Pardini et al., 2016) and has been replicated with DTI, most markedly in patients with 
oligoclonal bands (Pardini et al., 2019). 
 
The periventricular NAWM MTR gradient appears independent of lesions: the severity is the 
same in those with and without WM or enhancing lesions and remains visible after excluding 
up to 3mm of perilesional tissue to mitigate subtle MTR abnormalities; gradients and lesions 
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have differing distributions (gradients surround the fourth ventricle (despite low lesion 
density around the fourth ventricle)); and gradients occur within lesional tissues (Pardini et 
al., 2016; Brown et al., 2017; Pardini et al., 2019). Outside-in MTR gradients are also seen in 
cervical cord WM (Kearney et al., 2014). Taken together this suggests at least partially distinct 
mechanisms underlying lesion formation and those causing outside-in gradients).  
 
Neither MTR nor DTI can distinguish myelin or neuronal loss and the pathologic substrate 
underlying periventricular WM gradients remains unexplored. Despite the low resolution, a 
PET study has found a periventricular gradient of microglial activation in NAWM and GM 
(Poirion et al., 2017). 
 
Normal-appearing grey matter (NAGM) 
Extralesional cortical and thalamic GM show significant axonal loss compared to healthy 
controls (Cifelli et al., 2002; Choi et al., 2012; Bevan et al., 2018). Neuronal loss appears 
relatively independent of demyelination (Magliozzi et al., 2010): no differences in axonal 
density were seen between demyelinating cortical lesions and NAGM (Klaver et al., 2015). 
Cortical demyelination has typically been quantified in terms of demyelinating lesions, but 
extralesional reductions in myelin density are seen (Bevan et al., 2018), in part reflecting areas 
of remyelination (Albert et al., 2007). 
 
Significantly greater neuronal loss in the outermost cortical layers is seen in some patients 
with SPMS (Magliozzi et al., 2010) and PPMS (Choi et al., 2012) that is related to the level of 
immune cell infiltration in the meninges. In SPMS an accompanying gradient of microglial 
activation is seen (Magliozzi et al., 2010), though this has not been examined in PPMS.  
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Preliminary neuropathology studies in patients with progressive MS  have recently found a 
thalamic “outside-in” gradient of neuronal loss and microglial activation, maximal close to the 
ependyma (Magliozzi et al., 2018a). This gradient, present in lesional and normal-appearing 
thalamic tissues, was most marked in cases where meningeal B-cell follicles were found in 
other brain regions. This finding may mirror the “pial-in” pattern of subpial cortical injury, 
providing further evidence that intrathecal, compartmentalized inflammation is a major 
driver of cortical and subcortical GM MS damage (Magliozzi et al., 2010). 
 
Notwithstanding the limited sensitivity to GM lesions, mean GM MTR is decreased in all 
disease stages, including after a CIS (Fernando et al., 2005). Outside-in gradients in GM MTR 
are seen in all types of MS, both in the cortex (where the MTR is lowest (most abnormal) in 
comparison to healthy controls at the outer cortical surface (Samson et al., 2014; Brown et 
al., 2019a)), and the deep GM (where the MTR is lowest at the inner ventricular surface 
(Pardini et al., 2016)). A corresponding gradient of thalamic atrophy, maximal at the CSF 
boundary and lessening with increasing distance from it, is visible at the earliest stage of 
paediatric MS (Fadda et al., 2019) and is MS-specific (since it was not seen in children with 
monophasic demyelination). T2*, which inversely correlates with myelin and iron content, 
has also shown outside-in cortical gradients, visible from the first relapse (Mainero et al., 
2015).  
 
Both periventricular and cortical MTR gradients are more severe in SPMS compared to RRMS 
(Samson et al., 2014; Liu et al., 2015) and worsen with increasing disease duration (Brown et 
al., 2019a).  
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What causes outside-in gradients? 
The cause of periventricular and cortical gradients – and whether or not they reflect the same 
processes – remains unclear. The correlations between the severity of (i) periventricular and 
cortical MTR gradients; (ii) periventricular DTI gradients and cortical lesion loads; and (iii) 
periventricular lesion loads and cortical atrophy may suggest a common cause (Jehna et al., 
2015; Brown et al., 2019a; Pardini et al., 2019). A spatially consistent feature could therefore 
be CSF.  CSF from patients with MS (or a CIS) causes axonal damage and neuronal death in-
vitro (Alcazar et al., 2000; Vidaurre et al., 2014), and when sampled at the time of a relapse 
induces oligodendrocyte apoptosis (Menard et al., 1998). 
 
CSF: intrathecal inflammation 
Meningeal inflammation, lymphoid-like tissue formation and choroid plexus trafficking have 
all been invoked in the genesis of intrathecal inflammation; their surface-based effects on 
brain parenchyma must be mediated via CSF, as few if any immune cells are found in the 
surface layers. 
 
Intrathecal inflammation: meningeal inflammation 
While most pronounced in progressive disease, meningeal inflammation is seen 
histopathologically at all stages of relapse-onset and progressive MS (Magliozzi et al., 2007; 
Lucchinetti et al., 2011; Choi et al., 2012).  Such ‘compartmentalised inflammation’ may 
attract and retain further inflammatory cells, facilitating a pro-inflammatory 
microenvironment within this relatively sequestered compartment (Krumbholz et al., 2006; 
Meinl et al., 2008).  Although lesions and surface-based gradients appear to reflect distinct 
mechanisms, identical antigen-experienced B-cell clones are found in meningeal aggregates 
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and WM perivascular spaces in progressive MS (Lovato et al., 2011), suggesting a common 
origin and possibly a unifying cause of GM and WM lesions. 
A strong correlation has recently been found between a common molecular pattern of 
intrathecal (CSF) inflammation able to predict cortical pathology (R2 = 0.88), both at disease 
onset (where it correlated with cortical lesion number) and at post-mortem (where it 
correlated with the presence of meningeal inflammation and the percentage of demyelinated 
cortex). Magliozzi and colleagues found increased expression of proinflammatory cytokines 
(IFNγ, TNF, IL2 and IL22) and molecules promoting sustained B-cell activity and lymphoid 
neogenesis (CXCL13, CXCL10, LTα, IL6 and IL10) in the post-mortem meninges and 
correspondent CSF of SPMS patients with increased meningeal inflammation and GM 
demyelination (Magliozzi et al., 2018b). Their data corroborate the hypothesis that meningeal 
inflammation, diffuse or organized in lymphoid-like structures, in one of the main sources of 
CSF inflammatory mediators (Gardner et al., 2013). Similar molecular patterns were identified 
in the CSF of naïve patients with recent-onset MS, and multivariate models including seven 
such cytokines explained 88% and 89% of the variance in cortical lesion number and volume 
respectively. Interestingly, this specific profile is MS-specific, not present in the other 
neurological diseases examined (inflammatory and non-inflammatory) and incorporates both 
inflammatory and non-inflammatory components which may explain the fact that in other 
conditions characterised by meningeal and CSF inflammation, subpial cortical demyelination 
was never observed (Magliozzi et al., 2018b).  
Studies of MS animal models also support a key role of meningeal inflammation in cortical 
demyelination and axonal loss. In experimental autoimmune encephalomyelitis (EAE), 
pathogenic T-cells enter the CSF, are re-stimulated by meningeal antigen-presenting cells, 
undergo clonal expansion and produce cytokines, in turn promoting T-cell infiltration across 
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pial vessels, parenchymal invasion in the (CSF-adjacent) cord WM and the clinical onset of 
disease (Bartholomaus et al., 2009; Kivisakk et al., 2009; Reboldi et al., 2009). This pattern has 
been reproduced in cortical biopsies of patients presenting with an atypical CIS (Lucchinetti 
et al., 2011). Periventricular and pericisternal leucocyte invasion is seen in the earliest stages 
of both EAE and peripheral (adjuvant-induced) inflammation (Schmitt et al., 2012). The 
limitations of animal models are well-rehearsed: these animals do not have MS, only a model 
of inflammatory demyelination. Caution should therefore be exercised in translating animal 
findings to humans. However, injection of a combination of TNF and IFNg into the 
subarachnoid space overlying the cortical GM can give rise to similar subpial pathology in rats 
with circulating anti-myelin antibodies (Gardner et al., 2013).  
 
Until recently, MRI detection of meningeal inflammation relied on surrogates (principally 
cortical lesions) with poor sensitivity and very low inter-rater reliability (Geurts et al., 2011; 
Seewann et al., 2012). However, postcontrast T2 FLAIR has recently identified changes that 
may represent leptomeningeal enhancement in up to half of patients with MS, with the 
greatest frequency in those with SPMS, older age, longer disease duration and higher EDSS 
scores  (Absinta et al., 2015; Eisele et al., 2015; Zivadinov et al., 2017). Although only two 
patients proceeded to post-mortem examination (both with PPMS), areas of leptomeningeal 
enhancement on T2 FLAIR corresponded to regions of cortical demyelination, and meningeal 
inflammation (Absinta et al., 2015). However, leptomeningeal enhancement is not specific for 
meningeal inflammation as subarachnoid veins, dural venous sinuses and basal meninges all 
enhance on postcontrast T2 FLAIR (Zurawski et al., 2017). A small recent study at 7T found 
that LME correlated with cortical GM atrophy but not with neocortical lesions (Ighani et al., 
2019). Notwithstanding MRI’s limited ability to detect GM lesions, this finding may suggest 
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that meningeal inflammation is more involved in MS neurodegenerative inflammatory 
processes, rather than focal lesion development. 
     
Intrathecal inflammation: lymphoid tissues 
The most striking form of meningeal inflammation – lymphoid tissue formation – is seen in 
about 40% of patients with SPMS at post-mortem (Magliozzi et al., 2007), but has recently 
been reported in similar proportions of patients who died following their first MS 
presentation (Bevan et al., 2018). Lymphoid-like tissues are topographically related to subpial 
cortical demyelinating lesions, but also occur alongside areas of reduced myelin density 
suggesting either partial demyelination or remyelination (Magliozzi et al., 2010; Bevan et al., 
2018). In particular, the presence of lymphoid-like structures in the meninges of SPMS is 
closely associated with graded damage: elevated neuronal and astrocyte loss accompanied 
by increased microglia density have been measured close to the CSF/pia surface and decrease 
in the inner cortical layers close to the WM (Magliozzi et al., 2010). The partial destruction of 
the glia limitans formed by the astrocyte end-feet on the pial surface may probably favour 
the diffusion of soluble cytotoxic, myelinotoxic and inflammatory factors from the circulating 
CSF towards the superficial cortical layers directly causing neurodegeneration or indirectly so 
(by activating resident microglia) (Calabrese et al., 2015).  
Further neuropathology studies seeking meningeal aggregates in PPMS cases - as well as 
exploring the substrates underlying gradients in periventricular brain regions - are now sorely 
needed. The absence of organized lymphoid-like structures in PPMS might reflect the lower 
numbers of tissue blocks examined from a smaller number of patients at post-mortem or that 
aggregates are not required for surface-based gradients in tissue damage to occur. Given 
aggregates typically occur in sulci, the lack of difference between mean sulcal and gyral 
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cortical MTR favours the latter explanation (Samson et al., 2013). Up to now, lymphoid 
follicles have not been found in the spinal cord either despite a clear correlation between the 
severity of NAWM axonal loss and the degree of both NAWM microglial/macrophage 
activation and the density of meningeal T-cells (Androdias et al., 2010). 
  
Intrathecal inflammation: choroid plexus 
An alternative (or perhaps additional) route for inflammatory cells to enter the CSF is via the 
choroid plexus. The concentration of the tight-junction protein claudin-3 (responsible for 
maintaining the blood-CSF barrier) is significantly lower in patients with MS than in healthy 
controls (Kooij et al., 2014). 
 
CSF: oxidative stress 
The finding of elevated proinflammatory CSF cytokines suggested that cytokine-induced 
synaptic hyperexcitability, glutamate-dependent neurotoxicity or direct cytokine induced 
death receptor signalling caused neuronal death and dysfunction, again pointing to an 
inflammatory origin (Rossi et al., 2012; Rossi et al., 2014). Elevated ceramide levels, which 
impair mitochondrial function, decrease neuronal energy production and increase reactive 
oxygen species and free radical production, culminating in neuronal damage, have been 
found in MS CSF (Vidaurre et al., 2014). In patients with progressive (but not relapsing-
remitting) MS, ceramides additionally accentuate this process by decreasing glucose 
bioavailability, culminating in ‘virtual hypoglycosis’ in these patients’ CSF which too leads to 
neurotoxicity (Wentling et al., 2019). Ceramides are sphingolipids, and the elevated levels 
found in the CSF, particularly C24, are thought to reflect white matter destruction or exosome 
release from membranes of mature oligodendrocytes (Wentling et al., 2019).  
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Factors beyond the CSF 
The periventricular venous watershed predisposes the region to hypoperfusion and hypoxia, 
and from the earliest clinical stage of MS, periventricular hypoperfusion is greater in MS than 
in healthy controls (Andeweg, 1996; Dewar et al., 2003; Varga et al., 2009; Beggs, 2013). Such 
a watershed has not been demonstrated in the well-perfused cortex though. 
Granular ependymitis is seen in some patients with MS at post-mortem, and is associated 
with 11% of (largely chronic or burnt-out) periventricular lesions (Adams et al., 1987). A 
resultant soluble factor released into the CSF could conceivably cause both periventricular 
and cortical damage. The structural integrity of the cortical glia limitans is compromised in 
progressive MS (Magliozzi et al., 2010), thus allowing greater diffusion of molecules into the 
underlying grey matter, but a similar compromise of the ependymal layer has yet to be 
investigated.  
WM lesions nearly always form around veins, and the high venular density around the lateral 
ventricles likely accounts for WM lesions’ periventricular predilection (Brownell and Hughes, 
1962; Adams et al., 1987; Narayanan et al., 1997; Evangelou et al., 2000). Lesions themselves 
are unlikely to directly explain the WM periventricular MTR gradient: lesions plus a two voxel-
layer NAWM perilesional cuff were excluded in all projects (Liu et al., 2015; Brown et al., 2017; 
Brown et al., 2019a; Brown et al., 2019c), and extending this to a four voxel-layer cuff led to 
almost identical results (Liu et al., 2015). Further, the periventricular gradient is visible in 
NAWM, deep GM and in lesional tissue itself and appeared similar in those with and without 
T2-visible or enhancing lesions (Liu et al., 2015; Pardini et al., 2016; Brown et al., 2017).  
A tract-mediated effect of lesions may also contribute to periventricular (but not cortical) 
gradients: adjacent to the lateral ventricles run multiple WM tracts (e.g. those in the corpus 
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callosum, and so it may be expected that the remote effects of axonal transection in lesions 
(Trapp et al., 1998) will be more apparent in regions with high compared with low densities 
of parallel tracts. Again, as periventricular MTR gradients did not significantly differ between 
CIS patents who did and those who did not have additional brain lesions this is unlikely to 
explain periventricular gradients (Brown et al., 2017). 
 
Clinical relevance of surface-based gradients in MS 
WM lesions have established diagnostic and prognostic utility. Following a CIS, the presence 
of characteristic T2-hyperintense WM lesions can fulfil the diagnosis of McDonald RRMS 
(Thompson et al., 2017) and predict the likelihood of a further relapse (Fisniku et al., 2008). 
Infratentorial lesions independently predict moderate disability (hazard ratio 6.3) (Minneboo 
et al., 2004) while baseline enhancing lesions (and new supratentorial lesions within 1 year) 
independently predict cognitive impairment (Brownlee et al., 2019). 
 
Outside-in gradients occur early in MS (Samson et al., 2016; Brown et al., 2017; Fadda et al., 
2019). They may have clinical utility (though at present require offline image processing and 
require corroboration in larger cohorts using the optimised processing pipeline before 
considering use in trials or even clinical practice). The periventricular NAWM MTR gradient is 
seen within 5 months of a CIS and independently predicts a further relapse within 2 years (OR 
61.7, p=0.02), dwarfing the predictive effect of T2 lesions (OR 8.5, p=0.07, (Brown et al., 
2017)). Furthermore, unlike any other radiological markers (Wattjes, 2015), it independently 
predicts on-treatment relapses following alemtuzumab (Brown et al., 2019c), though larger 
studies are mandatory to corroborate this. Surface-based gradients in the cortex (Mainero et 
al., 2015; Brown et al., 2019a), periventricular WM (Brown et al., 2017; Brown et al., 2019a) 
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and spinal cord WM (Kearney et al., 2014) all modestly correlate with disability. Pathological 
studies noted the most aggressive disease-course during life was associated with gradients of 
cortical neuronal loss and the most marked meningeal inflammation at post-mortem, and a 
pro-inflammatory CSF pattern which was detectable early in disease (Magliozzi et al., 2007; 
Magliozzi et al., 2018b). 
 
Insights from treatment effects on surface-based pathology 
Interpretation of the improvement in periventricular MTR gradients following alemtuzumab 
is speculative, as their underlying pathogenesis remains unknown (Brown et al., 2019c).  
Axonal regeneration has not been reported to any substantial degree in the adult human 
brain, so an improvement in periventricular MTR gradients following alemtuzumab is 
therefore more likely to reflect resolution of periventricular inflammation, facilitation of 
remyelination or both. While identical antigen-experienced B-cell clones are found in 
meningeal aggregates and perilesional spaces in progressive multiple sclerosis (suggesting a 
common peripheral origin (Lovato et al., 2011)), the periventricular MTR gradient seen in both 
NAWM and lesional tissue is, at least partially, independent of WM lesion formation (Brown 
et al., 2017). Further, the distribution of WM lesions differs from that of the MTR gradient 
(Pardini et al., 2016), suggesting there are two overlapping processes; one linked with lesion 
formation and another influencing the intensity of pathology within them. Alemtuzumab 
exerts its effects by depleting mature lymphocytes outside the BBB, not by entering the brain 
parenchyma (Moreau et al., 1994), yet it effects a substantial reduction in new WM lesion 
formation. It is plausible that alemtuzumab also modulates lymphocyte populations entering 
the CSF space, so the subsequent amelioration of periventricular MTR gradients might reflect 
a reduction in intrathecal inflammation.  The apparent ability to predict treatment response 
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might therefore reflect the degree of intrathecal inflammation, and - given the MTR gradient 
showed continued improvement two years after the last dose of alemtuzumab - aggressive 
peripheral immunodepletion may have an enduring effect on it. Alemtuzumab may 
additionally facilitate endogenous repair through the production of a beneficial factor 
(neurotrophins, for example, are increased following alemtuzumab (Jones et al., 2010)).  
 
Trials of intrathecal rituximab (an anti-CD20 B-cell depleting immunotherapy) in progressive 
MS have found only transient improvements in intrathecal B-cell numbers, markers of CNS—
tissue embedded B-cells (sCD21) and cytokines released by lymphoid follicles (including CXCL-
13) – despite sustained peripheral B-cell depletion - and no material improvements in clinical 
outcomes (Komori et al., 2016; Bergman et al., 2018; Bhargava et al., 2019). One trial used 
leptomeningeal enhancement as a surrogate for meningeal inflammation which remained 
unaffected by two courses of intrathecal rituximab (Bhargava et al., 2019). The disappointing 
results may in part reflect the methodology - small sample sizes (n=8-23), short follow-up (6-
24 months) and small numbers of treatments (2-3 cycles) – or the participants’ prolonged 
disease duration (19-24 years), noting that in the relapsing phase early treatment is 
associated with better clinical outcomes (for example (Brown et al., 2019b)). Alternatively, 
intrathecal rituximab may not be a viable strategy for reducing meningeal inflammation. 
Lower CSF-complement levels and insufficient antibody-mediated natural killer cell-mediated 
cytotoxicity may mean that intrathecal rituximab cannot deplete intrathecal B-cells 
sufficiently. The high levels of B-cell survival factors (BAFF for example (Magliozzi et al., 2004)) 
in areas of meningeal inflammation might also prevent sufficient B-cell depletion by 
rituximab. Or, the persistence of other cell populations may continue to drive tissue damage 
and thus disability. The lack of standardised biomarkers of meningeal inflammation hamper 
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such studies. However, longer and larger studies on patients with shorter disease duration 
comparing the effect of intravenous rituximab (B-cell depleting), intrathecal rituximab (B-cell 
depleting), intravenous natalizumab (T-cell depleting) and intravenous alemtuzumab (B and 
T-cell depleting) on putative imaging biomarkers of meningeal inflammation (periventricular 
gradients, subpial lesion numbers and leptomeningeal enhancement) and on molecular 
biomarkers (e.g. CSF CXCL13) might help illuminate the effect of currently available therapies. 
 
In addition, a recent phase IIb trial of GNbAC1 (an agent targeting a component of the human 
endogenous retrovirus type W, linked with inflammation and inhibition of remyelination) has 
interpreted improvements in periventricular MTR gradients as possible remyelination (Curtin 
et al., 2012; Hartung et al., 2017), though this may, in part or whole, be an anti-inflammatory 
effect. 
 
There is now a clear imperative to understand the cellular substrates and molecular 
mechanisms underlying periventricular MTR gradients and to explore the effects of different 
therapies on them. 
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Project 4: The effect of disease-modifying therapies on conversion 
to secondary progressive multiple sclerosis 
In this observational cohort study that used prospectively-collected clinical data, initial 
treatment with fingolimod, alemtuzumab or natalizumab was associated with a significantly 
lower risk of conversion to SPMS compared to initial treatment with glatiramer acetate or 
interferon beta. The risk of conversion was significantly lower for early compared to late 
treatment: either in the case of starting glatiramer acetate or interferon beta within 5 years 
of disease onset versus later commencement, or when escalating from glatiramer acetate or 
interferon beta to fingolimod, alemtuzumab or natalizumab within 5 years of disease onset 
versus later escalation.  
 
These results suggest that initial treatment with glatiramer acetate or interferon beta is 
associated with reduced conversion to SPMS compared to untreated patients. There is no 
consensus in the literature. Intention-to-treat analysis of the study conducted by the IFNb 
Multiple Sclerosis Study Group found no difference in conversion rates between interferon 
and placebo 16 years later, though many placebo-treated patients subsequently received 
DMTs (Ebers et al., 2010). Six of seven observational studies reported favourable associations 
between glatiramer acetate or interferon beta and SPMS conversion, both individually 
(Trojano et al., 2007; Goodin et al., 2011; Patrucco et al., 2012; Drulovic et al., 2013; Tedeholm 
et al., 2013; Bergamaschi et al., 2016) and in a meta-analysis (Signori et al., 2016). The 
remaining observational study from British Columbia – the only one to circumvent immortal 
time bias (Suissa, 2008) through treating interferon exposure as a time-dependent variable 
(ensuring time before interferon treatment contributed to the untreated follow-up time) – 
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found no relationship between interferon exposure and SPMS conversion (Zhang et al., 2015). 
These observational studies – all published before an objective SPMS definition became 
available – have highly heterogeneous methods including variable (or inaccessible) SPMS 
definitions, inconsistent exclusion of relapse-related disability-increases; and variable 
strategies for mitigating indication bias (arising from non-random treatment exposure), 
attrition bias (reflecting between-group differences in follow-up duration), detection bias 
(from differing EDSS frequency during follow-up) and immortal-time bias.  In observational 
study designs, propensity score-based estimators better reflect true differences than 
nonexperimental estimators, such as multivariable regression or latent variable selection 
models, providing an overlap exists between the compared groups (Dehejia RH, 1999). In this 
analysis, matching with a caliper was employed, which is more robust in scenarios with 
restricted sample size and strong treatment-selection processes than unrestricted propensity 
score-based methods such as inverse probability of treatment weighting or optimal full 
matching (Austin, 2011; Lunt, 2014). All models were adjusted for EDSS frequency to mitigate 
detection bias and setwise censoring of follow-up duration was used to mitigate attrition bias. 
To address the issue of immortal-time bias (Suissa, 2008) disease-modifying therapy was 
treated as a time-dependent variable. The risk of SPMS conversion increases with disease 
duration (Weinshenker et al., 1989), which should be considered in evaluations of SPMS 
conversion rates in different treatment scenarios (Table 14, Figure 18). For instance, 
subgroups with longer disease duration at baseline (e.g. here natalizumab) are expected to 
be associated with a relatively greater SPMS conversion rate than those with shorter disease 
duration at baseline (e.g. here alemtuzumab or fingolimod).  
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This study has several limitations. First, given its observational design, the study is unable to 
ascribe causality and cannot distinguish between prevention and delay of conversion to 
SPMS. The longest comparison however showed a favourable association of early (versus 
later) glatiramer acetate or interferon beta, enduring to the end of follow-up 17 years after 
baseline (median disease duration 20 years; Figure 19). Second, the absence of EDSS 
functional score subcomponents precluded using the SPMS definition with the highest 
combination of sensitivity, specificity and accuracy; the definition used in this study, requiring 
total EDSS only, has previously been shown to be associated with a 1% loss of accuracy and 
6% reduction in sensitivity (Lorscheider et al., 2016).  Third, the differing baseline 
demographics of each DMT cohort (Table 14) required differing matched untreated cohorts 
with differing follow-up durations; their relative therapeutic effects should therefore not be 
compared between analyses (Figure 18). A particular problem with the fingolimod/untreated 
comparison was the inability to eliminate informed censoring bias because fingolimod-
treated patients subsequently escalated to monoclonal antibody treatment (due to on-
treatment disease activity) were excluded (Figure 18). Such informed censoring does not 
affect the comparison between untreated patients and monoclonal antibodies (as patients 
cannot be escalated from these highly-effective therapies (Kalincik et al., 2017a)) nor the 
untreated comparisons with glatiramer acetate or interferon beta (where the inclusion 
criteria ensured more potent therapies were not generally available during the studied 
epoch). Fourth, the glatiramer acetate or interferon beta cohorts therefore came from an 
earlier period, leading to 10-11 years median difference in the baseline dates of the glatiramer 
acetate or interferon beta versus untreated analyses, and 13 years median difference in the 
glatiramer acetate or interferon beta versus fingolimod, alemtuzumab or natalizumab 
analysis. It is possible that unmeasured changes in care between time epochs - more specialist 
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nurses, better symptomatic management, lower thresholds for escalating therapy for 
example - may have contributed to differences in SPMS conversion rates in these particular 
analyses.  However, all other analyses (with contemporaneous groups (≤5 years difference, 
Table 14)) also support early and aggressive DMT use. The ability to match contemporaneous 
untreated patients to those commencing fingolimod, alemtuzumab or natalizumab (Table 14) 
took advantage of the United Kingdom’s lower DMT uptake rates. The generalisability of the 
untreated group to other geographic regions cannot be guaranteed. Fifth, a large number of 
patients were excluded due to ineligibility (Figure 17). At least 65 patients were excluded 
through stopping their DMT within 6 months due to inefficacy. Though a modest number, 
their exclusion may have biased the remaining patients presented for matching towards a 
relatively milder disease. Those excluded due to missing data were slightly older with higher 
baseline EDSS scores (Table 26). While the exclusion criteria have made the results more 
robust, the resultant unmatched cohorts are, by definition, unrepresentative of the whole 
unfiltered cohort. Despite the stringent matching criteria 63-97% of treated eligible patients 
were successfully matched, and beyond lower baseline relapse rates, the matched cohorts 
(Table 14) are similar to those in the original placebo-controlled phase III trials of these 
therapies (Group, 1993; Comi et al., 2001; Polman et al., 2006).  Sixth, some factors were 
unavailable across all cohorts (for example smoking status; lesion number or brain volume on 
MRI; drug adherence; or the presence of oligoclonal bands in cerebrospinal fluid), precluding 
their inclusion in matching models. If these variables differed systematically between the 
compared groups, and are associated with the risk of SPMS conversion, then they might have 
acted as confounders. Through the use of an objective SPMS definition, any positive bias of 
outcomes by the clinician instigating the intervention or escalation should have been 
mitigated.  Seventh, the assessment of disability (and therefore SPMS conversion) relied on 
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the EDSS. Although the most widely-used disability measure, it has high inter-rater variability 
at lower scores, limited sensitivity to cognitive impairment and – at scores over 3.5 – is largely 
determined by ambulation (Meyer-Moock et al., 2014). To mitigate inter-rater variability, this 
published definition of SPMS requires EDSS step 4 attainment and confirmation of EDSS 
increases on two occasions, at least 3 months apart. Eighth, the numbers of patients available 
in some analyses was quite small. Despite this, clinically and statistically significant differences 
between the groups were observed. Ninth, while relatively few patients contribute to the 
final periods of follow-up in Figure 18 and Figure 19, the groups universally diverge long 
before this and the statistics are heavily weighted towards the left of each figure. Tenth, while 
death due to non-MS causes may represent a competing risk, we were unable to include this 
in the presented models due to incomplete reporting. Eleventh, this study did not assess the 
risks associated with DMTs, and so the association between initial fingolimod, alemtuzumab 
or natalizumab use and lower risk of SPMS conversion – which is consistent with these 
therapies’ greater effect on relapse rates and disability metrics (Coles et al., 2008; Cohen et 
al., 2010; Spelman et al., 2016) - must be considered in light of their greater risks, 
administration and monitoring schedules, and initial costs during the DMT selection process. 
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Chapter 7: Conclusions 
Outside-in gradients in lesional and normal-appearing tissues are seen in all types of MS and 
may have some predictive capabilities. The underlying process(es) appear at least partially 
distinct from those underlying lesion formation. We now need to know the molecular and 
histopathological substrates underlying MRI-visible periventricular gradients, in particular 
whether or not it is pathologically equivalent to the neurodegenerative gradient already seen 
in cortical GM. Additionally, to explore whether they are requisite for outside-in gradients, 
lymphoid-like aggregates should be sought in the brains of patients with PPMS, and in the 
spinal cord of all patients with MS (in both settings MRI and histopathological evidence of 
gradients are seen). Demonstrating subpial pathology following subarachnoid cytokine 
injection in non-EAE animal models might support the aetiological role of inflammation and 
may provide a chronic model to study the effects of therapeutics.  
 
At present, meningeal inflammation represents the best explanation for cortical gradients.  
As this does not explain gradients seen in WM lesions and periventricular tissues, a CSF-
mediated process – secondary to meningeal inflammation or primarily degenerative - would 
offer a plausible link. The precise unifying CSF factor is as yet unidentified. Potential biomarker 
candidates - cortical lesions, leptomeningeal enhancement, gradients and CSF profiling – 
require optimisation, standardisation, comparison (including with existing outcome 
measures) and a systematic examination of their response to therapies. 
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Among patients with RRMS, initial treatment with fingolimod, natalizumab or alemtuzumab 
was associated with a lower risk of conversion to SPMS compared to initial treatment with 
glatiramer acetate or interferon beta over a median 5.8 years of follow-up.  Lower conversion 
to SPMS was also associated with earlier DMT commencement or escalation compared to 
later commencement or escalation.  These findings, considered along with these therapies’ 
risks, may help inform decisions about DMT selection. But other critical questions surrounding 
DMT use remain unanswered. How early to commence DMTs; whether to ‘treat-to-target’ 
(suppressing both clinical evidence of inflammation (e.g. relapses) and paraclinical evidence 
(e.g. silent MRI lesions). I hope to explore both questions using observational data as a post-
doctoral researcher. Whether early intensive therapy is more effective than escalation 
therapy; how to sequence DMTs; and whether (and when) to stop DMTs are critical yet 
unresolved questions: clinical trials and international observational studies will be key. 
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